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(Under the direction of Ronald Swanstrom) 
With over 37 million people living with HIV-1, and over one million new infections 
occurring each year, HIV-1 continues to be a significant public health burden. Current therapies 
that eliminate viral replication are not curative and require life-long adherence, placing 
substantial economic, social, and physical burdens on people living with HIV-1. The 
implementation of an HIV-1 cure is hampered by mechanisms of HIV-1 persistence. In this 
dissertation, I examine two such mechanisms of persistence – compartmentalization and 
reservoir formation – through the analysis of genetic diversity. The genotypic and phenotypic 
properties of HIV-1 in the male genital tract (Chapter 2) and the central nervous system (Chapter 
3) are examined using sensitive methodologies such as next generation sequencing with Primer 
ID and ddPCR-based single genome amplification. The results obtained further elucidate the 
factors influencing the establishment of compartmentalized lineages and shed light on the 
sources of HIV-1 observed in the cerebrospinal fluid.  
Currently a cure is not possible due to the presence of a long-lived reservoir of latently 
infected cells. Understanding the mechanisms behind reservoir formation could facilitate the 
design of therapeutic approaches to limit the size of the reservoir. To this end, we analyzed the 
formation of the long-lived HIV-1 DNA reservoir and the replication-competent reservoir in the 
same set of ART-treated participants. Results demonstrated that the majority of both the largely 
defective HIV-1 DNA and replication-competent reservoirs were seeded in the year before ART 
iv 
initiation, suggesting a common mechanism of formation. Furthermore, the results suggest that 
strategies to block reservoir formation employed near the time of ART initiation would 
substantially reduce the size of the reservoir, thereby lowering the barrier to an HIV-1 cure.  
Overall, the results presented here advance our understanding of HIV-1 
compartmentalization and reservoir formation. This work examines HIV-1 diversity in multiple 
anatomic regions, introduces tissue-derived insights into HIV-1 replication in the central nervous 
system and further elucidates the mechanisms behind the establishment of the long-lived 
reservoir. By advancing our understanding of mechanisms of HIV-1 persistence, we continue to 
make progress toward a cure.  
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OVERVIEW OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
Origin of the pandemic 
Human immunodeficiency virus (HIV) is a lentivirus belonging to the Retroviridae 
family and is the causative agent of acquired immunodeficiency syndrome (AIDS). The virus 
was first identified in 1983 (1, 2) two years after the Centers for Disease Control reported an 
unusual increase in the number of cases of Kaposi’s sarcoma and Pneumocystis pneumoniae in 
men from New York and California (3). A second, distinct human retrovirus was identified in 
1986, which displayed genetic similarity to, but distinct antigenicity from the first described 
human immunodeficiency virus (4, 5). Phylogenetic analyses have since revealed two types of 
HIV, termed HIV-1 and HIV-2, which arose as the result of separate cross-species transmission 
events. HIV-1, which is genetically most similar to simian immunodeficiency virus isolated from 
chimpanzees (6), is more pathogenic, with an increased transmission rate compared to that of 
HIV-2, and is responsible for the global HIV pandemic.  
HIV-1 is further subdivided into four groups (Group M, N, O, and P). The major group 
(Group M) has infected over 37 million people worldwide. Within Group M, there are distinct 
subtypes and circulating recombinant forms, each with their own geographic distribution. 
Subtype B is prevalent in Europe and North America, while subtype C infections occur primarily 
in sub-Saharan Africa. While HIV-1 has caused a global pandemic, the burden of infection is 
highest among young women in sub-Saharan Africa.  
 2 
Genome organization 
The HIV-1 genome is comprised of a single strand of positive-sense RNA, approximately 
9.7 kilobases in length. The genome contains ten genes (gag, pro, pol, env, vpr, vpu, vif, nef, tat 
and rev) which encode fifteen proteins, including the structural proteins present in the Gag and 
Env polyproteins, enzymes reverse transcriptase, protease and integrase, and the accessory 
proteins Vif, Tat, and Nef. The coding regions are flanked on either side by long terminal 
repeats, in which the transcription start site is found.  
 
Replication strategy 
The lifecycle of HIV-1 can be broken down into three main parts: viral entry, replication, 
and virion assembly. In order for HIV-1 to enter a cell, the envelope (Env) protein spike must 
bind to the CD4 receptor on the cell surface (7). The Env protein spike is a heavily glycosylated 
trimer composed of heterodimers of gp120 and gp41 domains. gp120 contains variable regions 
(denoted V1 through V5), separated by constant domains C1 through C5. Binding of CD4 
induces a conformational change in gp120 that exposes the V3 loop and the bridging sheet which 
facilitates coreceptor binding. HIV-1 primarily utilizes the seven-transmembrane G protein-
coupled receptor CCR5 as a coreceptor (8, 9), though mutations in Env can enable the virus to 
utilize CXCR4 in some circumstances (10, 11). Coreceptor binding exposes the gp41 fusion 
peptide which consequently inserts into the host cell membrane. Upon membrane fusion, each 
gp41 domain in the trimer folds at a hinge region resulting in the formation of the six-helix 
bundle. This structure forms a pore in the host cell membrane, allowing the RNA-containing 
capsid to be delivered into the cytoplasm.  
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The exact location of the uncoating and reverse transcription steps are still being 
elucidated. Historically, these processes were thought to occur in the cytoplasm. However, recent 
work has challenged these assertions with evidence to suggest that uncoating and at least some 
reverse transcription occur inside the nucleus (12).  Reverse transcription is primed by the Lys3 
tRNA primer that is packaged inside the virion, along with reverse transcriptase (13). Two 
strand-transfers occur during the process of reverse transcription, each representing an 
opportunity for template switching (14-16). Following reverse transcription, the newly-
synthesized proviral DNA is shuttled into the nucleus through nuclear pores. The virally-encoded 
integrase facilitates insertion of the viral DNA into the host genome at which point the cell is 
irreversibly infected (17). Viral transcription is tightly regulated, with specific mRNA products 
being produced at different points in the infection. Initially, only completely spliced mRNAs are 
produced which encode the proteins Tat and Rev are produced (18). Accumulation of Rev allows 
unspliced and partially spliced mRNAs to exit the nucleus through the interaction of Rev and the 
RRE (Rev Response Element) located in an intron in env (19, 20). These partially spliced 
transcripts encode Env, and the accessory genes Vif, Vpr, and Vpu.  
Viral mRNA transcripts are translated after transport to the cytoplasm, with Env being 
translated in the rough endoplasmic reticulum. Concurrent with translation, Env travels through 
the cellular secretory pathway at which point it is glycosylated, assembled into trimers, and the 
cellular protease furin cleaves the Env into gp120 and gp41 subunits (21), (reviewed in (22)). 
Gag and the Gag-Pro-Pol polyprotein coordinate the assembly of viral products necessary for the 
formation of an infectious virion through protein-protein and protein-RNA interactions. At a 
minimum, two copies of single-stranded, positive-sense genomic RNA, cellular Lys3 tRNA, 
Env, the Gag polyprotein, and the viral enzymes integrase, reverse transcriptase and protease are 
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required for infectivity (23). Dimerized genomic viral RNA is shuttled to the site of virion 
assembly near the plasma membrane through direct interactions with the nucleocapsid domain of 
Gag (24, 25). Budding of the immature virion is accomplished through the activity of the host 
endosomal sorting complexes required for transport (ESCRT) machinery (26). Either during or 
after budding, the packaged protease cleaves the subunits of Gag in an orderly, step-wise fashion 
(27-29). The newly cleaved CA/capsid protein forms a conical core surrounding the genomic 
RNA, representing the final step in virion maturation. The mature virion is now able to infect a 
new cell.  
 
Immune Response 
The earliest innate immune responses to HIV-1 infection in the human host appear in 
conjunction with the first detectable viral RNA in the plasma. These early modulators of immune 
function include acute-phase proteins, cytokines and chemokines. While some cytokines 
produced during acute infection are antiviral, the pro-inflammatory environment created by this 
cytokine cascade can contribute to viral replication as well as bystander killing of CD4+ T cells, 
thereby mediating pathology (30). As viremia increases, the first HIV-specific CD8+ T cell 
responses arise, approximately one month after initial infection. These CD8+ T cell responses 
are specific for Env and Nef, rather than more conserved viral proteins, and they likely 
contribute to the decline in peak viremia (31, 32). Following the CD8+ T cell-mediated decline 
in viremia, escape mutants are observed as HIV-1 evolves under the pressure of the adaptive 
immune response; as a result, cellular immune response specificity shifts. In some individuals, 
cellular immune responses shift towards conserved regions of the genome that are less 
permissive to escape mutations. Over the course of primary infection, most individuals develop 
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antibodies capable of neutralizing autologous virus (33-35). These neutralizing antibodies drive 
the evolution of escape mutants with re-arranged glycan shields that occlude antibody binding 
sites (34). Some individuals develop broadly neutralizing antibodies over the course of untreated 
infection, typically directed towards highly conserved regions of the envelope glycoprotein such 
as the CD4 binding site or the membrane proximal external region, develop (36, 37). Such 
antibodies can neutralize both autologous and heterologous virus. The design of an immunogen 
capable of eliciting these types of antibody responses is an active field of research (38).  
   
Clinical course of untreated HIV-1 infection 
HIV-1 is primarily transmitted through sexual contact, though it can also be transmitted 
through the blood-borne route (39) (primarily through intravenous drug use (40, 41)) as well as 
by mother-to-child transmission, either in the perinatal period (42-44) or through breastfeeding 
(45). The clinical course of untreated HIV-1 infection can be broken down into three phases: 
acute infection, chronic infection, and AIDS. Serological studies of individuals at various time 
points during the course of infection have revealed an ordered pattern to the appearance of 
markers of infection, ultimately culminating in the detection of HIV-specific antibodies. As such, 
acute infection can be broken down into discrete stages based on the presence/absence of these 
biological markers (46). During acute infection, HIV-1 RNA levels in the blood rise rapidly 
eventually reaching a peak as a high as 105 or 106 copies/mL before the adaptive immune system 
begins to control viral replication. Following the initial viral peak, the viral load begins to drop 
as the result of CD8+ T cell-mediated killing of infected cells (31), eventually reaching a steady 
state where viral replication and cell death are in homeostasis, known as the “set-point” (47). The 
viral set-point has clinical and prognostic value as well as implications for subsequent 
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transmission. A higher viral set-point has been correlated with a shorter time to the development 
of an AIDS-defining illness (48, 49), and an increase in the likelihood that an infected individual 
will transmit the virus (50, 51). There is a wide person-to-person variation in viral set-point, a 
portion of which can be explained by the presence of protective HLA alleles which allow for the 
presentation of conserved viral antigens with limited mutational capacity to CD8+ T cells (52, 
53).  
The establishment of a viral set-point marks the transition from the acute phase of 
infection into the chronic phase. During the chronic phase, viral load remains relatively stable, 
while CD4+ T cell counts begin to decline. In both HIV and SIV infection, the greatest loss of 
CD4+ T cells occurs in the gut associated lymphoid tissue (54-57), which harbors over 40% of 
all lymphocytes (58). The diminution of CD4+ T cells occurs due to the combination of the death 
of infected cells (59), as well as bystander killing (reviewed in (60)). Damage to the 
gastrointestinal tract can lead to microbial translocation which fuels persistent immune activation 
(61-63). This chronic inflammatory environment eventually leads to the premature senescence of 
T cell responses, which, combined with a reduction in CD4+ T cells, further increases immune 
dysfunction putting individuals at an increased risk of acquiring AIDS-defining illnesses. 
Without antiretroviral therapy, chronic infection lasts an average of ten years, at which point 
CD4+ T cell counts decline more rapidly, viremia increases, and the individual progresses to 
AIDS.  
   
Success and limitations of antiretroviral therapy (ART) 
The identification of compounds capable of halting HIV-1 replication (collectively 
known as antiretroviral therapy, or ART), transformed HIV-1 into a manageable, chronic illness 
 7 
rather than a progressive, ultimately fatal disease. Currently, there are six major classes of 
antiviral drugs, with each class targeting a different step in the viral life cycle. Three of these 
classes inhibit the activity of viral enzymes, including reverse transcriptase inhibitors (both non-
nucleoside and nucleoside), integrase strand-transfer inhibitors, and protease inhibitors. Other 
classes of therapeutics focus on restricting viral fusion or entry into a host cell. ART is most 
effective at suppressing viral replication when multiple antiviral compounds, usually from 
different classes, are used in combination. A typical first-line regimen may consist of two 
nucleoside reverse transcriptase inhibitors with an integrase strand transfer inhibitor, a protease 
inhibitor, or a non-nucleoside reverse transcriptase inhibitor. With the advent of antiretroviral 
therapy, individuals living with HIV-1 can enjoy lifespans similar to those of their HIV-negative 
counterparts (64, 65).  
While ART is able to halt viral replication, there are a few limitations. First, drug-
resistant HIV-1 variants can arise. Such mutations can occur in the presence of an insufficient 
concentration of ART, such as might occur when an individual is not completely adherent to 
their regimen, or, less frequently, in anatomical regions where drug penetration is sub-optimal. 
Drug resistance mutations are detrimental to individuals as well as populations as they can 
reduce the efficacy of first-line ART regimens. Studies of ART-naïve individuals have 
demonstrated the presence of minor drug-resistant variants, suggesting such variants can be 
transmitted (66). The second limitation of ART is that it is not curative. As such, individuals 
must adhere to their ART regimens for life. ART prevents new rounds of infection, but does not 
eliminate cells that are already infected. Infected cells are killed by viral cytopathic effects or by 
the immune system when viral antigens are expressed. However, as discussed in subsequent 
sections, HIV-1 can exist in a transcriptionally silent, or latent, form. Cells harboring latent HIV-
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1 are not eliminated by the immune system as they do not express viral antigens, nor are they 
killed by viral cytopathic effects as little to no HIV-1 transcripts are produced. Finally, prolonged 
ART use has been associated with multiple side-effects including increased risk of 
cardiovascular disease, loss of bone density, and renal dysfunction (67, 68), (reviewed in (69)). 




Definition and significance of compartmentalization 
HIV-1 particles and infected cells have been identified in a number of anatomical 
locations, including the peripheral blood, lymphoid tissues, central nervous system, and both the 
male and female genital tracts. Some anatomical locations, such as the central nervous system 
and parts of the male genital tract, are protected by specialized barriers that restrict the 
movement of cells, and the diffusion of small molecules. Inflammatory conditions can 
permeabilize these barriers, allowing for more complete exchange of cells from the periphery. 
During these periods of permeability, HIV-1 can enter these “immune privileged” sites. 
Subsequent viral replication within anatomical compartments that are not in regular exchange 
with the periphery can lead to the development of viral lineages that are genetically distinct, or 
compartmentalized.  
Though not always the case, compartmentalization is often the result of the virus adapting 
to replicating in an environment that contains different target cells than that of the peripheral 
blood or lymphoid tissues. For example, compartmentalized HIV-1 populations derived from the 
cerebrospinal fluid (CSF) can be adapted to entering cells that express low densities of CD4 on 
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the cell surface (such as macrophages). This phenotypic change has been thought to arise as the 
result of the virus being sequestered in an anatomical region that contains a greatly reduced 
density of CD4+ T cells as compared to the peripheral blood or lymphoid tissues, thus forcing 
the adaptation to replication in a different cell type. Less frequently, macrophage-tropic HIV-1 
has been identified in the male genital tract as well (70, 71).  
The identification of anatomically distinct sites of HIV-1 replication has important 
implications for the field of cure research. Studies examining the concentrations of ART in 
various tissues and compartments have shown incomplete penetrance and subclinical 
concentrations in several tissues, most notably the CNS and lymph nodes (72, 73). Sustained, 
independent replication in an anatomical region with poor ART penetrance could lead to the 
development of compartment-specific drug resistance mutations. In such cases, region-specific 
interventions would be required for an effective cure. Therefore, understanding the mechanisms 
behind the establishment and maintenance of compartmentalized HIV-1 lineages is an important 
goal. In the following sections, the two anatomical locations of relevance to my work will be 
discussed: the male genital tract and the central nervous system. 
 
HIV-1 in the Male Genital Tract 
 
Insights gained from the study of semen HIV-1 viral load 
The majority of new HIV-1 infections occur as the result of sexual transmission (74). 
Understanding the properties of HIV-1 shed in semen, and the factors that influence the amount 
of viral RNA present in semen have been important avenues of research. Following mucosal 
exposure, the virus replicates locally within the genital tract before disseminating into one of the 
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draining lymph nodes then initiating a systemic infection. Throughout infection, HIV-1 RNA is 
detectable in the semen of most HIV-positive men who are not on suppressive ART (75-77), 
however viral RNA levels (a surrogate for released virus particles) are generally highest in acute 
infection as well as end-stage disease. Semen viral loads correlate with blood plasma viral loads, 
though they are typically about one log lower. Several factors have been shown to influence the 
amount of HIV-1 present in semen, including decreased CD4+ T cell counts (78, 79), stage of 
disease (79, 80), and the presence of inflammatory processes such as co-infection with other viral 
(81, 82) or bacterial infections . Elucidating these factors has been important as the amount of 
HIV-1 present in the semen impacts the likelihood that transmission will occur (83).  
 
HIV-1 and STI co-infections 
Co-infection with HIV-1 and other sexually transmitted diseases (STIs) is common (84). 
Infection with STIs such as gonorrhea, chlamydia, and herpes simplex virus can augment both 
HIV-1 acquisition (85-87) and transmission potential in infected individuals. In HIV-negative 
individuals, infection with an STI can increase the probability of HIV-1 acquisition. Ulcerative 
STIs can damage the mucosal barrier, facilitating the dissemination of HIV-1 into the submucosa 
where CD4+ T cells reside. Additionally, the presence of an infectious agent in the genital tract 
can recruit CD4+ T cells from the periphery into the genital tract thereby increasing the number 
of target cells susceptible to HIV-1 infection. In untreated HIV-1 infection, STI co-infection has 
been linked with increased blood and semen viral loads (88), faster disease progression, and an 
increased probability of transmitting HIV-1 to a partner. In treated HIV-1 infection, STI co-
infection has been postulated as a determinant of discordant viral shedding in the genital tract, as 
discussed below.  
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Evidence for local HIV-1 replication in the male genital tract 
Understanding the source of HIV-1 that is shed in the semen has been an ongoing 
research endeavor since the virus was first identified in seminal secretions. Early on, 
discrepancies were identified between blood and semen viral loads and viral phenotypes which 
spurred the notion that HIV-1 in the male genital tract can be biologically distinct from HIV-1 in 
the periphery. Primary among these observations was the characterization of HIV-1 in the semen 
that was phylogenetically distinct from that of blood-derived variants (89-91). Importantly, not 
all semen-derived virus is distinct from that of the periphery, as evidenced by longitudinal 
studies. As such, the viral populations present in the male genital tract are dynamic, changing 
with the microenvironment.  
Studies using non-human primate models of simian immunodeficiency virus (SIV) have 
been helpful in elucidating the potential sources of HIV-1 in the semen. Semen is a complex 
biological fluid, containing secretions from multiple organs within the male genital tract. In order 
to determine the extent to which various semen-producing organs can be infected with SIV, 
target cells and SIV DNA were quantified in multiple genital tract tissues in SIV-infected 
macaques. SIV DNA (92) and RNA (93) has been detected in the testis, epididymis, seminal 
vesicles and prostate of infected macaques. Phylogenetic analyses revealed that the SIV DNA 
from each organ within the genital tract clustered separately from the blood. Similar results have 
been obtained in studies of HIV-1 infection. HIV-1 DNA isolated from non-sperm cells can be 
distinct from HIV-1 RNA in the seminal plasma, as well as the blood (94). Observations such as 
these support the notion that HIV-1 in the male genital tract can replicate independently from 
HIV-1 in the periphery. It is important to note that the majority of these studies have utilized 
bulk PCR and cloning prior to sequencing, both of which can contribute to the generation of 
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recombinant species not observed in vivo. Single-genome amplification (SGA), and the advent of 
next-generation sequencing technologies coupled with template tracking strategies such as 
Primer ID, have been able to circumvent the pitfalls of early studies.  
Longitudinal studies of HIV-1 isolated from the semen of antiretroviral therapy-naïve 
men have provided insights into the potential mechanisms that contribute to the establishment 
and maintenance of compartmentalization in the genital tract. Stage of infection and the presence 
of inflammatory conditions such as viral or bacterial co-infection have been proposed as drivers 
of HIV-1 compartmentalization. In acutely infected macaques, blood and semen viral 
populations are mixed in the period before peak viremia, but following the peak, viral 
populations in the semen can become genetically distinct from variants circulating in the plasma 
(95). Longitudinal analyses of population dynamics between the blood and semen of individuals 
with acute infection have also identified varying degrees of compartmentalization, though 
contrary to macaque studies, these compartmentalized lineages did not persist over time (96). 
Similar discordance has been observed in chronically infected individuals as well (97, 98). Taken 
together, it does not appear that stage of disease influences the likelihood that compartmentalized 
lineages will form or persist.  
We (97) and others (99) have examined the hypothesis that local inflammation due to the 
presence of a concurrent sexually transmitted infection could influence the establishment and 
maintenance of compartmentalized lineages in the male genital tract. The results of these studies 
have demonstrated that concurrent STIs do not impact the prevalence of compartmentalization in 
the male genital tract. However, since next generation sequencing technologies have become 
available, it is important to re-examine this question in the context of an increased sampling 
depth which corresponds to an increased ability to detect minor populations present at low 
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frequencies. In Chapter Two, compartmentalization in the male genital tract is examined using 
deep sequencing with Primer ID.  
 
Determinants of viral shedding on ART 
Antiretroviral therapy is able to effectively suppress viral replication and reduce viral 
RNA present in the blood and semen to undetectable levels by standard clinical tests with a limit 
of detection of 40 copies of viral RNA/mL. However, multiple studies have noted the presence 
of HIV-1 RNA in semen when blood plasma levels are below the limit of detection (100-104). 
The phenomenon of discordant viral shedding is concerning, as blood plasma viral loads are 
generally used in medical settings to evaluate the efficacy of an individual’s ART regimen, and 
suppression in the blood is regarded as representative of suppression throughout the body. For 
the most part, this is an accurate proxy, as extensive studies of tissue and blood-derived variants 
from individuals on ART have failed to demonstrate ongoing viral replication (105-107). The 
detection of HIV-1 RNA in semen despite suppressed blood viral loads is reminiscent of CNS 
escape, in which HIV-1 is detectable in the CSF despite low or undetectable blood viral loads. 
However, unlike the CNS, discordant viral shedding in the male genital tract poses an increased 
risk of HIV-1 transmission. As such, work must be done to understand the drivers of viral 
shedding on ART.  
It has been well-described that multiple tissues within the genital tract harbor HIV-1 
DNA. Though a small percentage of these cells is likely to harbor replication-competent virus, it 
has been postulated that the activation of these cells, perhaps as the result of encountering their 
cognate antigen, could reactivate the virus and promote viral shedding that is sequestered to the 
genital tract. Indeed, multiple studies noting discordant shedding have observed the phenomenon 
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in the context of increased immune activation as determined by the reactivation and shedding of 
other latent viral infections such as Epstein-Barr virus (81) and cytomegalovirus (82, 108). In 
addition to local immune activation, HIV-1 in the male genital tract may be more susceptible to 
reactivation as the result of incomplete drug penetrance into the tissues. Semen concentrations of 
antiretroviral drugs differ from concentrations observed in the blood (109). The magnitude of 
this difference varies depending on the class of drug, with protease inhibitors having the lowest 
concentration in semen relative to blood, and nucleoside analogues the highest concentrations 
(reviewed in (110)). This effect is largely explained by the different protein-binding capacities of 
the various classes of antiretrovirals (111, 112). 
In much the same way that the determinants of the establishment of compartmentalized 
lineages in the genital tract remain unknown, so do the determinants of discordant shedding in 
the context of antiretroviral therapy. Studies comparing blood and non-sperm cell-derived HIV-1 
DNA to RNA shed in the semen will help elucidate the source of this virus. Of utmost 
importance is the evaluation of the infectivity of virus shed in the presence of ART, an issue that 
has yet to be systematically studied.  
 
HIV-1 in the Central Nervous System 
 
HIV-1 entry into the CNS 
HIV-1 has been detected in the CSF of individuals in all stages of infection though the 
mechanisms by which the virus enters may vary. In homeostatic conditions, viral entry into the 
CNS is largely precluded by the blood-brain and blood-CSF barriers. During acute HIV-1 
infection, individuals experience a massive cytokine storm which leads to a breakdown of these 
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barriers allowing free virions to cross into the CNS (113, 114). Detection of HIV-1 nucleic acids 
in the CSF (115) and brain (116) have been observed in the weeks following infection. Virions 
may most often cross an intact BBB when infected T cells cross the barrier during routine 
immune surveillance (117). This method of entry, known as the Trojan horse method (although 
originally assigned to putatively infected monocytes), is the most likely method of HIV-1 entry 
into the CNS during chronic infection, once the integrity of the BBB has been re-established.  
  
Immune surveillance in the central nervous system 
The central nervous system (CNS) has historically been described as an immune 
privileged site. This definition arose as the result of xenograft experiments in which it was noted 
that allogenic grafts placed within the brain failed to elicit an immune response unless the 
periphery had already been exposed to the antigen (118). As such, the immune system appeared 
to have a limited ability to respond to CNS-derived antigens. This idea was further supported by 
the lack of lymphatic drainage from the CNS, the absence of antigen-presenting cells within the 
CNS, and the decreased expression of both MHC class I and class II on the surface of CNS cells.  
Though the presence of the blood-brain and blood-cerebrospinal fluid barriers (BBB, 
BCSFB) limits the free diffusion of small molecules into the CNS, peripheral immune cells 
regularly patrol the CSF. The CSF of a healthy individual contains between 175,000 and 500,000 
leukocytes, approximately 75% of which are CD4+ T cells (119). The majority of CD4+ T cells 
in the CSF display a memory phenotype (120). When properly licensed, these cells can cross the 
glia limitans and invade the parenchyma in response to antigenic stimulation. In order to limit the 
bystander effects of a massive inflammatory response to a CNS antigen, multiple mechanisms 
unique to the CNS are in place to limit the inflammatory nature of immune responses. Antigen 
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presentation by microglia stimulate T cells to produce IFN-g, rather than IL-2 and limit the 
ability of T cells to proliferate (121). Gangliosides present in the plasma membrane of CNS cells 
suppress NF-kB activity, further reducing the production of IL-2. In this manner, T cells can 
respond to CNS infections without inducing massive amounts of inflammation.  
Regional differences in susceptibility and immune responses to CNS infections have been 
observed (122, 123), which are in part attributable to the heterogeneous distribution of various 
cell types within the brain (124, 125). For example, in in vivo experiments utilizing Ifnarfl/fl 
Gfap-Cre+ mice, astrocytes derived from the cerebellum respond faster to interferon stimulation 
compared to cerebral cortex astrocytes (126). Additionally, the uneven distribution of microglia 
(124, 125, 127), the resident innate immune cells present in the brain, may play a role in the 
development of region-specific responses. As described above, there is a delicate balance 
between pro- and anti-inflammatory responses that must be carefully maintained to ensure that 
local immune responses do not lead to the destruction of non-renewable cells. In light of this, 
regional differences in immune responses may play a role in preventing neuronal death by 
limiting inflammation.   
 
Compartmentalization in the CNS 
Much of our understanding of HIV-1 in the CNS comes from the study of HIV-1 present 
in the CSF, as it is much more readily sampled than the brain. HIV-1 sequences derived from the 
CSF are genetically distinct, or compartmentalized, from HIV-1 present in the periphery in 
between 20 – 50% of individuals (128, 129). As such, not only is HIV-1 able to enter the CNS, 
but it is also capable of sustained, independent replication as well. The existence of 
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compartmentalized virus within the CNS has several implications both for patient health and the 
possibility of an HIV-1 cure.  
There is an important distinction between compartmentalization and clonal amplification. 
Clonal amplification is denoted by the presence of a group of low-diversity, or identical, 
sequences. Such sequences can arise as the result of proliferation of an infected cell, or through a 
single cell producing large quantities of virions, potentially as the result of TCR-mediated 
activation of the cell. In contrast to the presence of a genetically diverse, compartmentalized 
lineage, clonal amplification does not represent sustained, independent viral replication. Clonal 
amplification is often discussed as a form of compartmentalization, as these viral amplification 
events can be observed in one anatomical compartment, such as the CNS, and not in the 
periphery. However, clonal amplification and sustained, independent viral replication represent 
two distinct biological phenomena. True compartmentalization in an anatomical compartment 
such as the CNS involves a genetic bottleneck followed by replication with little exchange with 
the periphery. In some cases, selective adaptation to replication in an environment with an 
altered cellular milieu can also drive the emergence of compartmentalized lineages.  
There are many obstacles to achieving independent viral replication within the CNS. 
HIV-1 primarily enters and replicates in activated CD4+ T cells, which have a high density of 
CD4 on their surfaces. This high density is thought to be required as the HIV-1 Env protein binds 
CD4 with low affinity and therefore may associate and dissociate multiple times during the entry 
process (130). Furthermore, T cell-tropic HIV-1 may require multiple bound CD4 molecules in 
order to initiate the conformational change required for co-receptor binding. While CD4+ T cells 
are present in the CSF, they are not normally found in the parenchyma in healthy individuals. 
Entry assays using HIV-1 envelopes derived from compartmentalized lineages have 
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demonstrated that most variants undergoing independent replication within the CNS have the 
ability to enter cells that express low densities of CD4, such as macrophages (131-135). In 
contrast, clonally amplified CSF-derived variants not observed in the periphery are generally 
found to be T cell-tropic (115, 136). This observation is consistent with an infected T cell 
migrating into the CNS in response to antigenic stimulation.  
One implication of CNS compartmentalization is the idea that the CNS could serve as a 
viral reservoir during ART. In support of this hypothesis, HIV-1 (137-143) and SIV DNA (144, 
145) have been detected in the brain at multiple stages of infection. Quantitative viral outgrowth 
assays performed on brain tissue-derived cells from macaques infected with SIV have detected 
replication-competent virus isolated from macrophages in the brain in the presence (146, 147) 
and absence (148, 149) of suppressive ART, providing evidence that macrophages in the central 
nervous system can serve as a viral reservoir. In vitro work has demonstrated that HIV-1 can be 
recovered from latently infected macrophages and microglia following stimulation with latency 
reversing agents (150). An independent viral reservoir within the CNS, located primarily in 
latently infected macrophages/microglia presents multiple challenges for a cure. ART 
penetration into the CNS is variable (151), as a result of the BBB, which can translate into the 
development of region-specific drug resistant HIV-1 variants (152, 153). It may therefore be 
necessary to develop specific therapeutics to target reservoir cells in the CNS. Additionally, 
macrophages and microglia have substantially different cellular metabolisms than T cells (154), 
which has the potential to alter the efficacy of latency reversing agents that have been designed 
to target T cells, further supporting the need for CNS-specific therapies.  
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Limitations of CSF sampling 
While the CSF is the most readily accessible CNS-derived fluid, there are important 
limitations to consider when using it to gain insight into processes occurring within the 
parenchyma. CSF is an actively secreted fluid, produced by selective ion flux across epithelial 
cells of the choroid plexus, creating an osmotic pressure gradient that drives the movement of 
water into the lumen (reviewed in (155)). Adult humans have between 150 to 200 mL of CSF 
circulating at any time, and around 600 mL are produced each day. As a result, the entire volume 
of CSF, including its contents, turns over three to four times daily. This rapid turnover is 
essential to the maintenance of healthy neurons, as the CSF drains metabolic waste produced in 
the parenchyma. However, this turnover presents challenges for the accurate sampling of HIV-1 
variants produced by infected cells residing in the brain over time.   
Understanding the origins of CSF-derived HIV-1 is important in evaluating the utility of 
CSF monitoring as a proxy for viral replication in the parenchyma. To date, very few studies 
have directly compared CSF-derived HIV-1 to brain tissue-derived variants. The studies that 
have performed this analysis have been severely limited by the technical difficulties of 
amplifying HIV-1 from the brain and thus have relied on extensive culturing of tissue-derived 
variants prior to sequencing (156). Prolonged culturing leads to the development of viral 
adaptations to tissue culture conditions, which can interfere with the study of viral variants 
present in vivo. Given the numerous clinical consequences of HIV-1 in the CNS, and the 
potential to serve as a viral reservoir, it is important that we elucidate the origins of HIV-1 in the 
CSF, a topic that will be explored in Chapter Three.  
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HIV-associated CNS disorders 
The presence of HIV-1 in the CNS has been associated with the development of 
neurocognitive disorders. The most severe of these, HIV-associated dementia (HAD), is largely 
only observed in untreated individuals with late-stage disease. The clinical manifestation of 
HAD is accompanied by multiple physical alterations within the brain, most notably diffuse 
white pallor (indicative of demyelination (157, 158)), immune cell infiltrates, and multi-
nucleated giant cells (159, 160). Population studies conducted in Africa suggest that between 25 
to 30% of antiretroviral therapy-naïve individuals will develop HAD (161, 162).  
With the increasing availability of ART, the prevalence of HAD has been significantly 
reduced. However, the proportion of HIV-positive individuals who experience some form of 
HIV-associated neurocognitive impairment has remained the same (163) (reviewed in (164)). In 
the ART era, the most common forms of HIV-associated neurocognitive impairment include 
asymptomatic neurocognitive impairment (ANI), and mild/moderate neurocognitive impairment 
(MND), both of which fall under the more broad category of HIV-associated neurocognitive 
disorders (HAND). Clinical presentation of HAND is varied, with symptoms including changes 
in motor skills, gait, as well as speech and memory disturbances (165, 166). The etiology of 
HAND is largely unknown. Physical changes to the brain, such as decreased brain volume (167) 
and increased immune activation have been observed in the months following infection. Since 
HIV-1 cannot infect neurons, the neurological dysfunctions observed with HAND/HAD must 
arise as the result of indirect effects that damage neurons. Increased and sustained immune 
activation has been observed in the CNS, despite suppressive ART (168, 169) which has been 
postulated to contribute to neuronal loss. Indirect viral cytopathic effects have also been 
investigated. The viral proteins Tat, Rev, and Env are cytopathic and could contribute to 
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neuronal dysfunction (170, 171). Given the lack of a reliable biomarker to indicate an 
individual’s susceptibility to developing HAND, or to progression of neurocognitive impairment, 
it is crucial that we continue to increase our understanding of the causes and consequences of 
HIV-1 infection in the CNS.  
 
Other neurovirulent viruses  
It has long been appreciated that viral infections, and the associated host immune 
response, can lead to neurological complications. For example, Guillain-Barre syndrome has 
been observed as a post-infection consequence of both viral and bacterial infections. The CNS 
pathology and neuronal damage associated with HIV-1 infection is largely attributed to increased 
inflammation and leukocyte recruitment, as the virus does not infect neurons. However, studies 
of other neurovirulent viruses have revealed that both direct and indirect effects of CNS viral 
invasion can mediate pathologic processes.  
Flaviviruses such as West Nile virus (WNV) and Zika virus (ZIKV) are highly relevant 
neurotropic pathogens whose emergence in the past several decades has spurred research into the 
factors mediating CNS pathology. Both WNV and ZIKV generally cause asymptomatic or mild 
clinical cases. However, WNV-related neurological symptoms are observed in 1 of 150 people 
infected (172), and ZIKV infection has been associated with meningoencephalitis (173), acute 
myelitis (174), and encephalitis (175) in adults and microcephaly in developing fetuses (176, 
177). Data from mouse models of flavivirus infections have shown that both WNV and ZIKV 
directly infect neurons (178, 179). Both innate and adaptive immune responses are critical for 
controlling viral dissemination to and replication in the central nervous system (126, 180-183). 
Flaviviral infection of the CNS is abrogated via CD8+ T cells recruited through chemokine 
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gradients that mediate viral clearance (184). Deficiencies in T cell chemokine receptors, such as 
CCR5, have been shown to inhibit lymphocyte trafficking to the CNS, and are associated with 
worse outcomes (185).  
Viral persistence in the CNS, with or without clearance in the periphery, has been 
observed in ZIKV (186, 187) infections. The mechanism surrounding ZIKV persistence in 
discrete anatomical sites such as the CNS is not well-understood, though it has been suggested 
that the relative lack of a humoral immune response in the CNS may contribute to the 
phenomenon (186). Ultimately, while the mechanisms of entry and types of infected cells may be 
different, the insights gained from studies of other neurotropic viruses have the potential to shed 
light on our understanding of immune responses in the CNS. 
 
THE LATENT HIV-1 RESERVOIR 
 
The latent reservoir is a major barrier to a cure 
HIV-1 persists in the presence of effective ART in a transcriptionally silent state, referred 
to as viral latency (188, 189). While the majority of infected cells die, either by viral cytopathic 
effects or host immune responses, a minority of CD4+ T cells survive and transition into a long-
lived memory phenotype. The percent of resting CD4+ T cells that carry integrated HIV-1 DNA 
is less than 0.05%, and even fewer cells carry replication-competent HIV-1 (190). However, 
despite the low frequency of latently infected cells, viremia rapidly and reproducibly emerges 
when individuals discontinue their ART regimens (191, 192). The decay rate of the latent 
reservoir in the presence of ART is exceedingly slow, with an estimated half-life of 44 months 
(193, 194). Therefore, ART alone is insufficient to cure HIV-1.  
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Defective HIV-1 DNA dominates the latent reservoir 
Discrepancies between the burden of HIV-1 DNA and the amount of replication-
competent virus present in individuals on suppressive ART suggest that a portion of HIV-1 DNA 
reservoir is defective, and therefore incapable of producing infectious virions. Seminal work by 
Ho and colleagues has demonstrated that defective proviral genomes comprise the majority 
(>95%) of the total HIV-1 reservoir (195). Defects observed included large internal deletions, 
hypermutation leading to premature stop codons, and packaging signal defects (196). Such 
defects arise during the process of reverse transcription, through a combination of host antiviral 
effects (such as APOBEC3) and missteps in the strand transfers that must occur in order for the 
full viral RNA to be reverse transcribed.  
While defective genomes cannot produce infections virions, a growing body of work 
suggests that cells infected with defective HIV-1 DNA contribute to the morbidity associated 
with HIV-1 infection. Chronic inflammation can persist, despite the elimination of viral 
replication with effective antiretroviral therapy (197, 198). Recent work has described a role for 
defective proviral genomes in maintaining this state of immune activation/chronic inflammation 
that is often observed in treated HIV-1 infection. While defective proviral genomes cannot 
produce infectious virions, they can make viral proteins (199, 200). Infected cells producing 
these proteins can be recognized by CD8+ T cells (201, 202). In this regard, defective genomes 
may represent an important driver of persistent immune activation, contributing to substantial 
morbidity. In summary, while not directly contributing to viral recrudescence upon ART 
discontinuation, the presence of defective viral genomes can negatively impact patient health.  
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Composition and location 
HIV-1 primarily infects activated CD4+ T cells. Infection of resting CD4+ T cells 
generally results in a non-productive infection, as the reduced cellular metabolism of resting cells 
presents a barrier to the successful completion of reverse transcription. However, a minority of 
infected, activated CD4+ T cells transition into a memory phenotype, with a half-life of several 
months, thereby forming the latent reservoir. Integrated HIV-1 DNA has been identified in 
multiple CD4+ T cell memory subsets, with the highest concentrations observed in central 
memory (CD45RA-,CCR7+, CD27+) and transitional memory (CD45RA-, CCR7-, CD27+) 
(203). The search for the specific cell type and anatomical location of latently infected cells has 
been an intensely studied avenue of research. Work by Estes and colleagues recently attempted 
to define both the location and approximate number of SIV-infected cells throughout the entire 
body both before and after ART (204). The results of this study demonstrated that lymphoid 
tissues (primarily lymph nodes and gut-associated lymphoid tissue) contained the highest 
proportion of infected cells in both naïve and ART-treated rhesus macaques. Analyses of 
different T cell subsets from individuals on ART have described a higher burden of intact 
proviral DNA in Th1 polarized CD4+ T cells (205) as well as effector memory cells (206). 
Results from studies such as the ones described above indicate that the majority of latently 
infected cells reside within tissues. As such, it is increasingly important to investigate properties 
of tissue-derived HIV-1 as well as ensuring novel ART methodologies (long-acting formulations, 
depots, rings) maintain sufficient drug concentrations within tissues.
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Methods to study the reservoir 
Multiple studies have shown that the burden of HIV-1 DNA has clinical implications 
(207-212). However, since the majority of viral DNA is defective, methods that quantify total 
HIV-1 DNA, such as PCR-based assays, generally overestimate the size of the reservoir (213). 
On the other hand, quantitative viral outgrowth assays (QVOA), which quantify replication-
competent virus, underestimate the size of the reservoir, as not all inducible, replication-
competent viruses reactivate following a single round of stimulation (195). This divide between 
the replication-competent and the total DNA reservoir has spurred a line of investigation aimed 
at separating out the defective and replication-competent reservoirs based largely on the notion 
that there is little of value to be gained by studying defective proviruses. Given the ease with 
which we can examine the total DNA reservoir, compared to the labor-intensive approaches to 
studying the replication-competent reservoir, the field as a whole would benefit from 
demonstrated ways in which the total DNA reservoir can serve as a proxy for the replication-
competent reservoir.  
 
Mechanism of formation 
Since the long-lived reservoir is the major barrier to achieving an HIV-1 cure, 
understanding the temporal dynamics and physiological mechanisms that govern its formation 
will enable us to create targeted interventions to limit its formation. A smaller reservoir would 
translate to a reduced barrier to a cure. This would be helpful, as with the exception of the Berlin 
(214) and London (215) patients, an HIV-1 cure has not been achieved largely due to the size 
and self-renewing properties of the reservoir, discussed below. Given the difficulties associated 
with attaining a sterilizing cure (elimination of all HIV-1-infected cells from an individual) cure 
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strategies are increasingly aiming at sustained clinical remission, whereby an individual can 
discontinue antiretroviral therapy and remain without detectable viremia indefinitely. Strategies 
that limit the size of the reservoir would facilitate these endeavors.  
The presence of an HIV-1 reservoir has been documented to exist in humans (216-218) 
and non-human primate models of SIV infection (219) who initiated antiretroviral therapy during 
acute infection. Work by Whitney and colleagues demonstrated that replication-competent SIV 
proviruses exist in a transcriptionally silent state even before plasma viremia can be detected 
(219). This observation appeared to mirror previous studies examining reservoir formation in 
acutely infected individuals (220) that had concluded the reservoir forms early and continuously 
throughout untreated infection. However, phylogenetic studies examining the genetic 
relationship between reservoir viruses and pre-ART RNA variants noted a skewing in the 
proportion of replication-competent (221) and HIV-1 DNA (222, 223) genomes that were most 
closely related to RNA variants circulating near the time of ART initiation. Importantly, these 
studies have identified reservoir variants that date to early infection, though the limited 
frequency with which such variants are identified suggest that the long-lived, on-ART reservoir 
is not seeded continuously throughout untreated infection.  
The differential stability of latently infected cells in the presence and absence of 
antiretroviral therapy suggests a change in the half-life of infected cells that occurs around the 
time that antiretroviral therapy is initiated. In this view, the reservoir pre-ART is formed 
continuously, thereby accounting for the identification of reservoir variants dating to acute 
infection, but this portion of the reservoir decays rapidly. There is ongoing controversy in the 
field as to whether there is a difference in the decay rate of intact and defective proviral 
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genomes. While this question is best answered in the context of longitudinal studies, it is 
discussed in detail in Chapter Four.  
 
Maintenance 
The discrepancy between the half-life of memory CD4+ T cells and the decay rate of the 
HIV-1 reservoir suggests the reservoir is maintained or replenished. One mechanism by which 
the reservoir might be maintained is through ongoing viral replication during antiretroviral 
therapy (224). This idea has been thoroughly examined and there is overwhelming evidence 
against ongoing viral replication in the presence of ART (105, 106). Instead, a number of 
observations suggest that the reservoir is maintained through proliferation of infected cells. Chief 
among these observations is the finding that a significant and increasing portion of reservoir 
sequences are genetically identical (225-227), which would be expected if an infected cell 
proliferated in response to either intrinsic or extrinsic stimuli. Integration site analysis has shown 
that HIV-1 integration into cancer genes can stimulate cellular proliferation, thereby contributing 
to the maintenance of the long-lived reservoir (228, 229), however this mechanism does not 
appear to be important for most of the cells that undergo proliferation of this type. In addition, 
proliferation can occur without triggering viral reactivation, thereby preventing immune 
clearance (230). Altogether, there are three main drivers of cellular proliferation that contribute 
to the stability of the latent reservoir: homeostatic proliferation in response to cytokines, antigen-
driven proliferation (231), and HIV-1 integration site-driven proliferation. The self-renewing 
capacity of the latent reservoir is a significant barrier to a cure, and the ongoing proliferation of 
infected cells can obscure efforts to reduce reservoir size (232). Given the difficulties associated 
with eliminating latently infected cells, it is increasingly important to explore methods aimed at 
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blocking reservoir formation that are informed by an enhanced understanding of the mechanisms 
by which the reservoir forms.  
 
OBJECTIVES AND SIGNIFICANCE OF DISSERTATION 
The overarching goal of the work discussed in this dissertation is to use viral diversity to 
examine important aspects of HIV-1 biology. Compartmentalization and the latent reservoir both 
present significant challenges to the design and implementation of an HIV-1 cure, and as such, 
they will be the topics discussed in the subsequent chapters. Chapters Two and Three deal with 
HIV-1 compartmentalization in the male genital tract and central nervous system, respectively. 
Chapter Four examines the formation of the long-lived HIV-1 DNA reservoir.  
In Chapter Two, I re-examine the relationship between HIV-1 and STI co-infections as it 
relates to the formation and maintenance of compartmentalized lineages in the male genital tract. 
This work builds upon previous work in the field by examining these questions in the context of 
a Primer ID deep sequencing strategy. This strategy allows for the accurate determination of the 
number of HIV-1 templates sequenced while reducing PCR and sequencing-based errors. Results 
demonstrated that STI-associated inflammation did not influence the establishment or 
maintenance of compartmentalized HIV-1 lineages in the male genital tract. Furthermore, we 
observed a large percent of clonal sequences in both the blood and seminal plasma, a 
phenomenon that had not previously been discussed in the context of chronic infection. 
In Chapter Three, the origins of HIV-1 in the cerebrospinal fluid are examined. There 
have been very few studies that have attempted to determine to what extent the virus present in 
the CSF represents the overall diversity of HIV-1 in the brain. Using a droplet digital PCR-based 
single genome amplification strategy, HIV-1 env sequences are obtained from multiple regions 
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of the brain and compared to HIV-1 RNA sequences derived from the blood and cerebrospinal 
fluid. Additionally, the burden of HIV-1 DNA in various regions of the brain is assessed. This 
work provides insight into the complex nature of HIV-1 in the central nervous system.  
In Chapter Four, another fundamental aspect of HIV-1 biology is examined in the context 
of viral diversity – the formation of the long-lived HIV-1 DNA reservoir. This work was done in 
collaboration with Carolyn Williamson’s lab at the University of Cape Town and the Center for 
the AIDS Programme of Research in South Africa (CAPRISA). Our collaborators performed 
longitudinal sequencing of plasma HIV-1 RNA over the course of an average of 4 years of 
untreated HIV-1 infection. These pre-ART RNA sequences were used to phylogenetically date 
reservoir sequences that we obtained after individuals had been on suppressive antiretroviral 
therapy for 5 years. Using viral evolution that occurs prior to ART, we show that the majority of 
HIV-1 DNA reservoir sequences are most closely related to viral variants circulating in the year 
before ART initiation. Furthermore, in a subset of participants, we perform a head-to-head 
comparison of the timing of the formation of the HIV-1 DNA and replication-competent 
reservoirs. Our results show that both the replication-competent, and the largely defective HIV-1 
DNA reservoirs are seeded at similar times. Previous work had examined the formation of the 
DNA reservoir (222) and the replication-competent reservoir (221). The work presented in 
Chapter Four extends these previous studies by examining the formation of both reservoirs in the 
same set of participants. In doing so, this work enhances our understanding of the mechanisms of 
reservoir formation and suggests that strategies aimed at blocking memory T cell formation 
around the time of ART initiation might significantly reduce the size of the reservoir.
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CHAPTER II. DEEP SEQUENCING REVEALS COMPARTMENTALIZED 




The goal of this project was to determine whether inflammation associated with the 
presence of a concurrent sexually transmitted infection (STI) would influence the establishment 
and persistence of compartmentalized HIV-1 lineages present in the male genital tract.  
  
AUTHOR SUMMARY 
The driving force behind the establishment of compartmentalized lineages in the male 
genital tract has not been elucidated. Unlike the central nervous system, in which the ratio of T 
cells to macrophages serves as an evolutionary pressure for the virus to evolve the ability to enter 
cells with a low density of CD4 and thus drive the emergence of compartmentalized lineages, no 
such factors have been identified in the male genital tract. We therefore tested the hypothesis that 
STI-associated urethritis would recruit CD4+ T cells into the genital tract. These cells could 
themselves be infected, or they could serve to amplify viral variants within the genital tract. 
Either scenario would result in the mixing of viral populations present in the periphery and the 
 
1 This chapter previously appeared as an article in the Journal of Virology. The original citation is as follows: O.D. 
Council, S. Zhou, C.D. McCann, I. Hoffman, G. Tegha, D. Kamwendo, M. Matoga, S.L. Kosakovsky Pond, M.S. 
Cohen and R. Swanstrom. Deep sequencing reveals compartmentalized HIV-1 in the semen of men with and 
without STI-associated urethritis. J Virol, 2020. DOI: 10.1128/JV.00151-20. Author contributions are as follows: 
conceived and designed the experiments: ODC, SZ, CDM, IH, GT, DK, MM, SLKP, MSC, RS; performed the 
experiments: ODC, SZ, CDM; analyzed the data: ODC, SZ, SLKP; wrote the paper: ODC, RS.  
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genital tract, thus resulting in an equilibrated population. Conversely, in the absence of STI-
associated inflammation, viral populations in the genital tract and the periphery would remain 
separate, leading to independent replication and thus a compartmentalized viral population 
within the genital tract. To test this hypothesis, we performed Primer ID deep sequencing on 
paired blood and semen samples from HIV+ men before and after antibiotic treatment of a 
concurrent STI. As a control, we also sequenced paired blood and semen samples from HIV+ 
men without a concurrent STI. Overall, we observed varying degrees of compartmentalization in 
6/24 (25%) of participants. In men with urethritis, compartmentalized lineage were observed in 
the genital tract of 6/19 (31.5%) men, as compared to 1/5 (20%) of men without urethritis (p = 
0.63, Fisher’s exact test). Therefore, STI-associated urethritis did not impact the establishment of 
compartmentalized lineages.  
 
INTRODUCTION 
Nearly two million new HIV-1 infections occur worldwide every year, predominately 
through sexual transmission (74). Therefore, understanding the genotypic and phenotypic 
properties of HIV-1 present in the male genital tract is vital for treatment and prevention 
strategies. It has been well-established that the probability of sexual transmission of HIV-1 
increases with an increasing viral load (50, 80, 83, 233), and there are several factors that can 
influence the concentration of viral RNA present in semen. For example, stage of disease (234), 
CD4+ T cell count (78), and the presence of inflammatory conditions (such as concurrent 
sexually transmitted infections [STI]) have all been demonstrated to increase the semen viral 
load (reviewed in (235)). 
 32 
 For semen-mediated transmission events, the transmitted/founder virus is most proximal 
to the male genital tract at the time of transmission. Thus, the origin of virus in the male genital 
tract is relevant to a fuller understanding of HIV-1 transmission. Often the virus present in semen 
is similar to virus found in the blood (an equilibrated population), but there is also evidence that 
the male genital tract is able to support independent replication of HIV-1. This is inferred from 
observations of genetically distinct, or compartmentalized, HIV-1 populations in semen, as 
compared to the virus found in the blood and other anatomical compartments  (82, 89, 90, 97, 98, 
236, 237). In addition, several studies (101, 103) have reported the presence of HIV-1 RNA in 
the semen of men on suppressive antiretroviral therapy, with undetectable blood plasma viral 
loads, implying that the male genital tract can influence viral replication independent of the 
periphery and harbor an independent viral reservoir. It is therefore important to elucidate the 
factors that promote the establishment and maintenance of compartmentalized viral lineages in 
the male genital tract.  
In the current study, we examined the effects of STI-associated urethritis on the 
establishment and maintenance of compartmentalized lineages in the male genital tract by 
comparing viral sequences in the blood to those in seminal plasma using deep sequencing 
technology with Primer ID (238, 239). We explored the possibility that STI-associated 
inflammation could act to recruit CD4+ T cells into the genital tract, thereby promoting a mixing 
of viral populations in the blood and semen with a concomitant reduction in apparent 
compartmentalization, or conversely the influx of cells could enhance the replication of locally 
produced virus and increase compartmentalization. We also examined the viral population 
dynamics between blood and semen over time to determine whether antibiotic treatment of the 
concurrent STI would impact HIV-1 compartmentalization. We detected no difference between 
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the proportions of men who had compartmentalized, semen-derived lineages, grouped by the 
presence or absence of urethritis. Furthermore, antibiotic treatment of the STI did not observably 
impact the population dynamics between the blood and the semen, at least in the short term. We 
conclude that STI-associated inflammation is not a driving factor behind the establishment or 
maintenance of compartmentalized lineages in the semen and that compartmentalized viral 
replication can occur independently of inflammatory conditions. 
 
RESULTS 
Participant characteristics and sequence generation 
Participants were part of a cohort of men based in Malawi that was established to 
examine the effect of STI-associated urethritis on seminal plasma HIV-1 viral load (240). In 
order to examine the relationship between urethritis associated with a concurrent sexually 
transmitted infection (STI) and the presence of compartmentalized virus in the genital tract, we 
selected a subset of men with (n = 19) and without (n = 5) STI-associated urethritis, with the 
sample size determined by availability of sufficient seminal plasma. All participants were 
chronically infected with subtype C HIV-1, and antiretroviral therapy (ART) naive, as ART was 
not available in Malawi at the time of the study.  
There was no difference in the blood viral load, semen viral load, or CD4+ T cell count 
between the two groups at baseline (Table 2.1). HIV-1 RNA was extracted from paired blood 
plasma and seminal plasma, and Illumina MiSeq deep sequencing with Primer ID was used to 
generate HIV-1 env V1/V3 amplicons. The deep sequencing output was collapsed into Template 
Consensus Sequences (TCS) for each Primer ID recovered to create a highly accurate sequence 
for each original RNA template sampled. An average of 62 TCSs were obtained from each 
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compartment (blood and semen) for each participant (range: 12-200), giving us 95% power to 
detect minor populations present in most samples at a 1.5-5% frequency.  
 
Compartmentalized, semen-derived lineages are observed in men with and without 
urethritis 
As we were primarily interested in identifying diverse compartmentalized lineages, 
which represent independent replication over a period of time, rather than compartmentalized 
lineages that consist primarily of clonal sequences, we initially collapsed sequences that were 
identical to within one nucleotide into a single haplotype. After identical sequences were 
collapsed, an equal number of blood-derived and semen-derived sequences were used to 
construct maximum likelihood phylogenetic trees for each participant, allowing us to compare 
the two populations at equivalent sampling depth. Compartmentalization was assessed using both 
the Slatkin-Maddison test (241), and the Structured Slatkin-Maddison test (Pond et al, in 
preparation, https://github.com/veg/hyphy-analyses/tree/master/SlatkinMaddison), which has 
been modified to reduce potentially spurious compartmentalization detection in trees with large 
numbers of sequences. When both tests resulted in a P value < 0.05, the tree was deemed 
compartmentalized. When one test indicated compartmentalization while the other did not, trees 
were inspected visually for the presence of diverse, semen-dominated lineages.  
Among the 24 men, we observed varying degrees of compartmentalization, ranging from 
near-complete separation of blood and semen-derived sequences, to minor compartmentalization 
in 6/24 (25%) participants. In men with urethritis, compartmentalization was detected in 6/19 
(31.5%) men, while viral populations were equilibrated between the blood and semen in 13/19 
(68%) men. In men without urethritis, we observed minor compartmentalization in 1/5 (20%) 
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individuals, and equilibrated viral populations in 4/5 (80%) individuals. Thus, both 
compartmentalized and equilibrated HIV-1 populations were found in men with and without 
urethritis (Figure 2.1 and Table 2.2) at statistically indistinguishable frequencies. This suggests 
that urethritis does not alter the establishment of compartmentalized lineages although the 
generalizability of this conclusion is limited by the number of samples studied. 
 
HIV-1 population dynamics between blood and semen remain largely stable after STI 
treatment 
To examine the effects of antibiotic treatment of the STI on HIV-1 population dynamics, 
we compared pre-treatment and post-treatment time points in 13 men (12 with urethritis, 1 
without urethritis). Samples were obtained an average of 12 days after antibiotic treatment had 
been initiated (range: 7-14 days). Maximum likelihood phylogenetic trees were built as described 
above, and the relationship between blood and semen-derived sequences (i.e., equilibrated or 
compartmentalized) was determined at each time point. In 12/13 men, the relationship did not 
change following STI treatment (Figure 1.2). In one individual, S101, semen and blood-derived 
lineages were equilibrated in the pre-STI treatment time point, but compartmentalized post-
treatment, as determined by both the Standard Slatkin-Maddison test and the Structured Slatkin-
Maddison test (p < 0.0001, Table 2.2).   
Next, we compared within-compartment viral diversity before and after STI treatment. 
To this end, we inferred maximum likelihood phylogenetic trees containing equal numbers of 
semen-derived sequences from the pre and post STI treatment time points for the 13 men 
described above. Both the Standard Slatkin-Maddison and the Structured Slatkin-Maddison tests 
were performed on the trees in order to determine whether the pre- and post-STI treatment semen 
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sequences constituted distinct clades. In 12 of 13 men, the semen populations before and after 
STI treatment were not significantly different from one another – i.e., populations that existed 
before STI treatment were still readily observable after STI treatment. Of particular interest were 
the individuals with compartmentalized, semen-derived lineages. In 2 of the 3 men with 
compartmentalized lineages at both time points, the lineage that was responsible for the 
compartmentalization was the same before and after STI treatment (Figure 2.2A and 2.2B). 
Thus, not only was the relationship between compartments unchanged, but the specific lineages 
themselves persisted. However, in one individual the compartmentalized, semen-derived lineage 
that was detected before STI treatment was not detected at the second time point but a new 
compartmentalized lineage was observed (Figure 2.2C). 
 
Clonal amplification of blood and semen-derived sequences is observed in men with and 
without urethritis 
As we were primarily interested in the presence of diverse, compartmentalized lineages, 
rather than compartmentalized lineages comprised of a clonally expanded population, we 
collapsed sequences that were identical to within one nucleotide into a single haplotype. In doing 
so, we observed that a large proportion of both blood and semen-derived V1/V3 sequences were 
identical or nearly identical. Such an observation could be made because of the PCR 
amplification step prior to sequencing where the original templates are repetitively sequenced, a 
phenomenon called PCR resampling; however, the use of Primer ID to tag each original 
templates before PCR avoids this problem allowing us to infer the presence of identical or near 
identical sequences within the viral population in vivo. For blood-derived sequences, a mean of 
only 41% and 48% of sequences were unique in men with and without urethritis, respectively (p 
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= 0.4237, Figure 2.3A). For semen-derived sequences, a mean of only 44% and 62% of 
sequences were unique in men with and without urethritis, respectively (p = 0.086, Figure 2.3C). 
The proportion of unique sequences observed in blood and semen remained stable before and 
after STI treatment in men with urethritis (Figure 2.3B and 2.3D).  This result indicates that a 
significant fraction of the population in each compartment was in a genetic bottleneck or had 
recently gone through a bottleneck.  
We considered the possibility that the short env V1/V3 amplicon (527 bases) would over-
estimate the percentage of sequences that were identical across the entirety of env. To evaluate 
this possibility, we performed single genome amplification (SGA) of full-length HIV-1 env 
genes (~2500 bases) from the blood and semen of four men (3 with urethritis and 1 without). We 
obtained an average of 30 full-length env sequences from each participant. In two of the four 
cases, we observed identical sequences across the entirety of env. When we trimmed the full-
length sequences and analyzed only the V1/V3 region used in our deep sequencing, we observed 
identical or nearly identical sequences in all four participants. Sequences that were identical in 
the V1/V3 region but not identical across the entire envelope only differed by a few nucleotides. 
Such differences are consistent with the low-level diversity generated from recent viral 
replication from a unique ancestor/bottleneck (Figure 2.4, and Figures 2.7 – 2.9). Thus, while 
examining only the V1/V3 region does increase the number of sequences that appear identical, 
the overall viral diversity of those variants is low and consistent with recent clonal expansion 
involving a bottleneck with subsequent viral replication to introduce modest diversity. In a 
control experiment we generated 8 env amplicons from virus produced from the cell line 8E5, 
which contains a single defective viral genome. When the 8 amplicons were sequenced we 
observed a single substitution mutation and a single frameshift mutation (data not shown). The 
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low-level diversity observed in the viral populations in vivo were in most cases greater than the 
level observed in the control amplification, consistent with ongoing viral replication after a 
recent bottleneck rather than just virus production from a clonally expanded cell. 
 
Semen-derived HIV-1 envelopes are T-cell tropic 
HIV-1 primarily infects CD4+ T cells, which have a high density of the CD4 protein on 
their cell surface that is typically required by the virus for efficient entry. However, viruses that 
have been replicating independently in anatomically distinct regions such as the central nervous 
system where CD4+ T cells are less abundant, can evolve the ability to enter cells expressing 
lower densities of CD4, such as macrophages. This has been observed for compartmentalized 
lineages derived from both the CNS (131) and, in one case, the male genital tract (70). In order 
to determine whether compartmentalized, semen-derived lineages from our cohort have the 
ability to enter cells expressing a low density of CD4, we produced pseudotyped virus that 
expressed participant-derived Env surface proteins, obtained through SGA. These viruses were 
used to infect Affinofile cells that had been induced to express either high or low densities of 
CD4. The amount of luciferase produced by the cells was quantified and used as a surrogate 
measure of infectivity. As shown in Figure 2.5, semen-derived HIV-1 env genes, from both 
compartmentalized and equilibrated lineages, encoded Env proteins that require a high density of 
CD4 for efficient cell entry, indicating that they were being selected for replication in T cells. 
 
Cytokine/chemokine dynamics during treatment of the STI 
To better understand the magnitude of the inflammation present within the genital tract 
during a concurrent sexually transmitted infection, we measured the concentrations of seven 
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inflammatory cytokines and chemokines present in the blood and semen before and after 
treatment of the STI. To differentiate between STI-induced inflammation and HIV-induced 
inflammation, we included samples from HIV+ individuals not experiencing urethritis. As shown 
in Figure 2.6A, there was a group of cytokines (TNF-a, IL-6, and IL-1b) whose concentrations 
were increased in the semen of men with urethritis at the pre-treatment time point, and 
subsequently decreased after STI treatment. A second group of cytokines/chemokines, including 
CXCL10, IL-10, IFN-g, and CCL2, were at similar concentrations in men with and without 
urethritis, as well as before and after STI treatment. A subset of four cytokines/chemokines 
(TNF-a, IL-10, CCL2 and CXCL10) were measured in blood as well (Figure 2.6B). There was 
no difference in the concentration of any of these analytes at any time point in men with or 
without urethritis, suggesting that STI-associated inflammation is limited to the genital tract and 
largely resolves with antibiotic treatment. 
 
DISCUSSION 
In this study, we used Primer ID deep sequencing to examine the prevalence of 
compartmentalized HIV-1 populations in the male genital tract in men with and without STI-
associated urethritis. Urethritis did not impact the prevalence of genital tract 
compartmentalization. In further support of this conclusion, we observed similar viral population 
dynamics between the blood and genital tract before and after STI treatment, while 
simultaneously observing a decrease in genital tract inflammation.  
There have been numerous studies (82, 90, 94, 96, 237, 242-244) that have examined the 
prevalence of male genital tract compartmentalization of HIV-1, sometimes with discordant 
results. Some of these studies (94, 98, 242) examined the phenomenon of compartmentalization 
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through the use of bulk amplification and/or cloning prior to sequencing; however these 
approaches have been shown to introduce sequencing artifacts, such as PCR-mediated 
recombination and sequence resampling (245-247). The use of deep sequencing with Primer ID 
in the current study corrects for PCR and sequencing errors through the creation of a template 
consensus sequence for each Primer ID-tagged cDNA (the template for PCR), while 
simultaneously allowing for the precise quantification of the total number of templates 
sequenced, i.e. the sample size of sampling of the viral sequence population (239). Thus, we can 
be confident that the viral variants we analyze are an accurate representation of the diversity 
found in vivo.   
We observed compartmentalization in 31.5% of men with urethritis, and 20% of men 
without urethritis; thus, given this number of participants we did not detect a difference in the 
extent of compartmentalization with and without and STI-associated urethritis. In the overall 
cohort, we observed compartmentalization in the genital tract of 29% of men. This prevalence of 
compartmentalized lineages in the genital tract is similar to what was observed in a previous 
study (97) that used a heteroduplex tracking assay to examine the relationship between blood and 
semen-derived env V3 populations in men with and without urethritis. In this earlier study, they 
observed discordant V3 populations between the blood and semen of 40% of men. Importantly, 
there was no difference in the V3 population dynamics between the blood and semen of men 
with urethritis, compared to men without urethritis. Later, Anderson and colleagues (236) 
utilized single genome amplification to examine the relationship between blood and semen-
derived HIV-1 envelopes in men without urethritis. Here, they reported a 31% prevalence of 
compartmentalization in the genital tract. They also observed clonal amplification in the semen 
of men without urethritis. Compartmentalized populations in the genital tract have also been 
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observed in the context of acute HIV-1 infection. In a recent study by Chaillon et al. (96), deep 
sequencing was used to examine HIV-1 populations in blood and semen in early infection. They 
observed compartmentalization in 2 of 6 participants at baseline (a median of 81 days after the 
estimated date of infection).  
The observation that inflammation does not alter the frequency with which we detect 
semen-specific HIV-1 lineages suggests that, when compartmentalized lineages are present, they 
are most likely produced by cells in anatomical areas that are not in direct contact with the 
periphery. In one extreme case of this type of isolation we previously observed the presence of a 
macrophage-tropic variant in semen (70). In the current study all of the viruses tested were T 
cell-tropic, requiring a high density of CD4 for efficient entry into cells. In addition, all were 
predicted to use CCR5 as a coreceptor based on genotypic predictions of the V3 loop sequence 
(data not shown). This result is important as a recent report by Ganor and colleagues (71) 
reported the presence of macrophage-tropic viral variants in urethral tissues, suggesting the 
possibility of a urethral reservoir. However, it appears such variants are not shed in the semen as 
macrophage-tropic variants are rarely observed in semen, and the majority of transmitted/founder 
variants require high densities of CD4 for cell entry.  
Compartmentalization in the male (96, 242) genital tract has largely been defined as a 
transient phenomenon. Here, we examined how antibiotic treatment of a concurrent sexually 
transmitted infection (primarily gonorrhea or trichomonas) impacted the relationship between 
blood- and semen-derived HIV-1 env V1/V3 sequences. We found that viral variants present 
before STI treatment remained detectable after STI treatment, and furthermore, that the 
relationship between blood and semen-derived sequences remained consistent throughout the 
course of STI co-infection. In only one participant out of 13 did we detect a change in the 
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relationship between blood and semen-derived sequences over time. In this instance, the depth of 
sampling pre-STI treatment was relatively poor, while the sampling post-STI treatment was 
much greater. Thus, it is quite possible that the relatively few sequences obtained pre-treatment 
obscured the presence of the compartmentalized lineage that we observed post-treatment. It is 
also important to note that while gonococcal infections are cleared rapidly from the urogenital 
tract after a single antibiotic treatment (248), the underlying immune activation can persist, as 
demonstrated by the fact that in men with an STI, HIV-1 viral loads in semen were still higher 
than in men without an STI, even after effective antibiotic treatment (240), although we were 
able to measure some diminution of inflammation with a change in some inflammatory markers. 
Therefore, while we do observe stable relationships between blood and semen-derived sequences 
before and after STI treatment, our conclusions are limited by the relatively short period of 
follow-up. It is worth noting that in one participant, virus in the semen was compartmentalized 
relative to the blood both before and after STI treatment but the compartmentalized lineage in the 
semen changed between the two time points. Both lineages, while minor, were complex in 
sequence composition and thus the latter one did not evolve over the short period of time 
between the two samplings. Thus, there must have been reduced production of one lineage and 
the appearance of a pre-existing lineage over a relatively short period of time. 
The identification of identical or nearly identical sequences in the blood in chronic 
untreated infection is relatively infrequent considering the error-prone nature of HIV-1 reverse 
transcription (249). However, we observed a striking number of identical sequences in the blood 
and semen of men with and without urethritis. In the absence of therapy, the viral load of viruses 
with similar sequences is much higher, suggesting either that the corresponding cellular 
expansion is much greater or that the virus comes from another source, i.e. replication, after 
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passing through a recent genetic bottleneck. This question becomes even more relevant using the 
shorter amplicon associated with deep sequencing as a significant fraction of the viral sequences 
cluster into lineages of identical sequences. In order to determine if the identical sequences from 
deep sequencing observed off therapy in these men were truly clonal, we compared sequences 
obtained from deep sequencing to those obtained as full length env genes using template end-
point dilution PCR (SGA). We found that the sequences that were identical in the deep 
sequencing data set were in a population of similar but not identical sequences when the larger 
region of the genome was analyzed (Figure 2.4, Figures 2.7 – 2.9). We conclude that these 
populations are present at their detected level due to ongoing viral replication. However, the high 
level of similarity in these sequences implies a recent genetic bottleneck prior to expansion by 
viral replication, although the nature of that bottleneck remains unknown and could still be due 
to clonal expansion of an infected cell amplified by a burst of local replication. It is possible that 
this phenomenon is mediated by an infected antigen-specific cell that undergoes amplification 
due to the presence of the STI. 
HIV-1 infection is associated with dysregulation of seminal cytokines (250, 251) as well 
as an increased semen: blood cytokine ratio (236, 250, 251). This pro-inflammatory environment 
has been suggested to increase viral replication as semen viral load often correlates with cytokine 
levels (77), as well as the fact that several cytokines, including TNF-a, directly act on the virus 
to increase replication (252) (reviewed in (253)). A similar phenomenon is observed in men with 
STIs such as gonorrhea or trichomonas (240).  We analyzed cytokine/chemokine levels in the 
blood and semen of men with and without STI-associated urethritis to determine if inflammation 
increased with the presence of a concurrent STI infection and whether such inflammation had 
resolved during the two-week period of follow-up. Among the seven cytokines/chemokines 
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analyzed (IL-6, TNF-a, IL-1b, IFN-g, CXCL10, IL-10 and CCL2) only TNF-a was significantly 
increased in the semen of men with STI-associated urethritis, compared to HIV-positive men 
without urethritis. However, levels of IL-6 and IL-1b were also increased in men with urethritis, 
though the difference was not statistically significant. Importantly, the levels of TNF-a, IL-6 and 
IL-1b all decreased to levels similar to that of men without urethritis after STI treatment. Thus, 
we observed that men with urethritis have an enhanced pro-inflammatory environment compared 
to HIV-positive men without urethritis, and that this difference is reduced following antibiotic 
treatment of the STI. As expected, cytokine levels in the blood were similar in men with and 
without STI-associated urethritis and remained unchanged following STI treatment. This result 
further supports our finding that inflammation due to STI-associated urethritis does not impact 
the formation of compartmentalized lineages in the male genital tract. It is however, important to 
note that our relatively small number of individuals without urethritis limits the statistical power 
of our conclusions, as well as the generalizability of our results.   
 
MATERIALS AND METHODS 
Ethics Statement and Source of Clinical Samples 
Blood and semen samples were collected as part of a study examining the effects of 
genital tract inflammation on HIV-1 semen viral load (240). The study was approved by the 
Institutional Review Board at the University of North Carolina at Chapel Hill. A subset of STI 
samples (12/19) were previously examined via a heteroduplex tracking assay (97), and 2/5 
control samples were previously examined via single genome amplification (SGA) (236). 
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Deep Sequencing with Primer ID 
Deep sequencing with Primer ID was performed as previously described (239). Briefly, 
viral RNA was extracted from seminal and blood plasma using the QIAamp Viral RNA 
Extraction Kit (Qiagen). Based on viral loads, up to 5,000 RNA copies (range: 196-5,000, mean: 
3,161) were used for cDNA synthesis. cDNA was synthesized using the env V1/V3 Primer ID 
primer (HXB2 positions 6585-7208): 5’-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNCAGTCCATTTTGCT
CTACTAATGTTACAATGTGC-3’ and SuperScript III Reverse Transcriptase (Invitrogen). The 
final cDNA reaction contained the following: 0.5 mM dNTP mix (KAPA) 0.25 µM V1-V3 
reverse primer, 5 mM DTT, 6 U RNaseOUT, and 30 U SuperScript III RT in a total volume of 
60 µl. Initially a mixture containing dNTPs, cDNA primer and RNA template was incubated at 
65°C for 5 minutes, followed by 4°C for 2 minutes. Then DTT, RNaseOUT and SuperScript III 
were added and the reactions were incubated for one hour at 50°C, followed by one hour at 
55°C. Samples were then heated to 70°C for 15 minutes to inactivate the SuperScript III prior to 
addition of RNase H (2 units) and a final incubation at 37°C for 20 minutes. cDNA was purified 
using Agencourt RNAclean XP beads (Beckman Coulter) at a volume ratio of 0.6:1 beads: 
cDNA. The beads were washed four times with 70% ethanol. Purified cDNA was eluted in 24 
µl molecular grade water (Corning), and the purification was repeated with a bead:cDNA ratio of 
0.6:1. The purified cDNA was again eluted in 24 µl molecular grade water and stored at -20°C. 
All (24 µl) of the cDNA was used for PCR amplification. KAPA 2G Robust HotStart 
Polymerase was used as the first-round PCR enzyme along with the following forward primer: 5- 
GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNTTATGGGATCAAAG
CCTAAAGCCATGTGTA-3’ corresponding to the HIV-1 env V1/V3 region. Following 
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amplification, PCR products were purified using AmpureXP beads (Beckman Coulter) at a ratio 
of 0.7:1 beads: DNA. Beads were washed four times using 70% ethanol, and the purified DNA 
was eluted in 50 µl of DNase-free water (Corning). The second round of PCR consisted of 2 µl 
of purified first-round PCR product along with the KAPA HiFi Robust Polymerase enzyme and 
served to incorporate MiSeq adaptors and index oligonucleotides that allowed for multiplexing 
of samples.  
 
MiSeq Library Preparation and Quality Control 
Amplicons were visualized on a 1.2% agarose gel. Gel extraction was performed using 
the MinElute Gel Extraction Kit (Qiagen) according to manufacturer’s instructions. Purified 
DNA was eluted in 10 µl of EB Buffer (Qiagen) and quantified using the Qubit dsDNA Broad 
Range Assay (Thermo Fisher). Samples were pooled in equimolar concentrations and the final 
library was purified using AmpureXP beads at a ratio of 0.7:1 beads: DNA. Libraries were 
submitted to the UNC High Throughput Sequencing Facility for generation of 2x300 base 
paired-end reads using the Illumina MiSeq platform.  
 
Phylogenetic and Compartmentalization Analyses  
Compartmentalization of viral populations was assessed using two tree-based methods: 
the Slatkin-Maddison (S-M) test (241) and the presence of a genetically diverse, semen-derived 
lineage. The S-M test was performed on phylogenetic trees that had equal numbers of semen and 
blood-derived V1/V3 sequences, after collapsing identical sequences in each compartment to 
focus on diverse populations rather than clonally amplified populations. The standard Slatkin-
Maddison test was modified to account for the structure of the tree, with the leaves of each node 
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being permutated sequentially before inferring migrations (S.L. Kosakovsky Pond et al, 
https://github.com/veg/hyphy-analyses/tree/master/SlatkinMaddison). Trees were considered 
compartmentalized if 10,000 permutations of the Standard Slatkin-Maddison test or 50,000 
permutations the Structured Slatkin-Maddison test yielded a p-value <0.05 and there was a 
semen-derived, genetically diverse lineage. Both S-M tests are implemented in the standard 
analysis “sm” in HyPhy v2.5 (254).  
 
Single Genome Amplification 
Single genome amplification (SGA, or template end-point dilution PCR) was performed 
as previously described (236). Briefly, viral RNA was extracted using a QIAamp viral RNA 
extraction kit (Qiagen). cDNA was synthesized using an oligo(dT) primer and SuperScript III RT 
(Invitrogen). Template cDNA was diluted such that <30% of reactions were positive in the 
subsequent PCR. Nested PCR was performed using Platinum Taq High Fidelity polymerase 
(Invitrogen) and the following primers: PCR-1: 5’-GGGTTTATTACAGGGACAGCAGAG-3’ 
(Vif1) and 5’- TAAGCCTCAATAAAGCTTGCCTTGAGTGC-3’ (OFM19), PCR-2: 5’- 
GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ (EnvA) and 5’- 
ACACAAGGCTACTTCCCTGGATTGGCAG-3’ (EnvN). SGA products were fully sequenced 
from both directions to confirm the presence of a single template. Amplicons with evidence of 




Construction of HIV-1 env clones 
Amplicons of the full-length HIV-1 env gene from the first round PCR with confirmed 
sequences were subjected to an additional round of PCR using the Phusion Hot-Start High 
Fidelity DNA polymerase (Invitrogen) and the primers cEnvA (5’-
CACCGGCTTAGGCATCTCCTATACCAGGAAGAA-3’) and EnvN (5’- 
CTGCCAATCAGGGAAGTAGCCTTGTGT-3’) following the manufacturer’s instructions. 
HIV-1 env amplicons were subsequently gel purified using the Qiagen QIAQuick Gel Extraction 
Kit. An aliquot of 50 ng of purified HIV-1 env DNA was used to clone into the pcDNA 
3.1D/V5-His-TOPO vector (Invitrogen) and MAX Efficiency Stlb2 competent cells (Life 
Technology) were transformed per the manufacturer’s instructions.  
 
Env-pseudotyped viruses 
Env-pseudotyped luciferase reporter viruses were generated by co-transfection of 810 ng 
of an env expression vector and 810 ng of pZM247Fv2Denv backbone (255) using 293T cells 
and the Fugene 6 reagent and protocol (Promega). Five hours after transfection, the medium was 
changed. Forty-eight hours after transfection, the medium was harvested, filtered through a 0.45 
µm filter, and aliquoted into 0.6 mL tubes. Aliquots were stored at -80°C until use.  
 
Single-cycle infection of 293-Affinofile cells 
The ability of HIV-1 Env proteins to mediate infection of cells expressing low densities of 
CD4 was assessed as previously described (256-258). Briefly, experiments were carried out in 
black, flat-bottomed, 96-well plates. A solution of 100 µl of 293-Affinofile cells at a density of 
1.8x105 cells/ml was added to the inner 60 wells of each 96-well plate. All 293-Affinofile cells 
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were induced to express high levels of CCR5 expression using Ponesterone A. CD4 expression 
was induced in half of the cells using Doxycycline. Twenty-four hours after CCR5 and/or CD4 
induction, cells were spinoculated (259) with previously titered Env-pseudotyped viruses (849 x g 
for 2 hours at 37°C). Following spinoculation, cells were incubated at 37°C for forty-eight hours. 
Cells were then washed twice with PBS and lysed with 1x Renilla luciferase assay lysis buffer 
diluted in distilled water. Following lysis, plates were kept at -80°C overnight. The following day, 
plates were thawed at room temperature and read using a luminometer. A 50 µl aliquot of Renilla 
assay reagent was injected into the luminometer per well, and relative light units (RLUs) were 
recorded over 5 seconds with a 2-second delay.  
 
Cytokine Evaluation 
Cytokine concentrations in blood plasma and seminal plasma were quantified using a 
LuminexÒ bead-based multiplex assay (R&D Systems). Specifically, TNF-a, IL-6, CXCL10, 
IL-10, CCL2, IL-1b, and IFN-g concentrations were determined. All assays were performed 
following the manufacturer’s instructions. 
 
Data availability 
The full-length env gene sequences have been deposited in GenBank under accession 
numbers MT227374-MT227495. The MiSeq sequences have been deposited in the Sequencing 






Table 2.1. Clinical characteristics of participants analyzed. 
aCells per microliter of blood, bDiagnosed sexually transmitted infection (STI) as described by 
Cohen et al, Lancet 1997. Gon, gonorrhea; Tri, trichomonas; Ulc, genital ulcers; NPI, no 
pathogen identified. ND, not done 

























(n = 19)        
S003 5.23 5.48  5.51 4.8 ND Gon., Ulc 
S018 5.59 4.70  5.40 4.96 476 Gon, Tri, Ulc 
S019 4.18 5.48  4.34 4.32 712 Gon 
S031 4.95 4.62  4.63 4.92 333 Gon, Ulc 
S053 6.11 6.08  5.88 5.38 318 Tri, Ulc 
S070 4.73 3.92  4.96 4.46 670 Gon 
S073 4.59 4.60  4.51 4.23 275 Gon 
S075 5.59 5.20  5.90 4.08 ND NPI 
S101 5.83 5.89  5.79 5.20 235 Gon 
S103 3.95 5.00  5.11 4.79 454 Gon 
S146 4.79 4.96  5.58 5.53 258 Ulc 
S172 4.80 5.18  4.28 4.62 344 Gon 
S029 5.23 4.71  ND ND 496 Gon 
S017 5.79 4.40  ND ND 178 NPI 
S039 5.56 5.04  ND ND ND Gon 
S047 5.77 4.92  ND ND 469 Gon 
S099 5.57 5.82  ND ND ND Gon, Tri 
S148 5.08 5.98  ND ND  Gon 
S067 4.90 5.04  ND ND  Gon 




       
C019 7.00 5.72  5.72 6.76 599 None 
C073 4.82 3.76  ND ND ND None 
C082 5.49 4.20  ND ND 305 None 
C111 4.84 5.95  ND ND 210 None 
C061 5.56 6.51  ND ND 262 None 
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SMa S-SMb Visual 
Urethritis 
(n = 19) 
 
        
S003 187 0.15 0.0009 Equil 25 0.788 0.392 Equil 
S018 120 0.327 0.186 Equil 24 0.926 0.819 Equil 
S019 48 0.076 0.004 Equil 22 0.335 0.03 Equil 
S031 200 0 0 Compart 306 0 0 Compart 
S053 29 0.461 0.027 Equil 23 0.396 0.111 Equil 
S070 15 0.946 0.539 Minor compart 12 0.262 0.017 
Minor 
Compart 
S073 24 0.882 0.734 Equil 8 0.428 0.428 Equil 
S075 43 0.263 0.003 Minor compart 42 0.515 0.06 
Minor 
Compart 
S101 13 0.653 0.15 Equil 103 0 0 Compart 
S103 62 0.904 0.902 Equil 10 0.322 0.098 Equil 
S146 71 0.251 0.004 Minor compart 45 0.36 0.033 
Minor 
Compart 
S172 32 0.805 0.277 Equil 24 0.96 0.89 Equil 
S029 47 0.713 0.17 Equil ND ND ND ND 
S017 32 0.003 0 Minor compart ND ND ND ND 
S039 19 0.825 0.61 Equil ND ND ND ND 
S047 25 0.916 0.383 Equil ND ND ND ND 
S099 200 0.002 0.0009 Compart ND ND ND ND 
S148 82 0.294 0.014 Equil ND ND ND ND 
S067 98 0.203 0.01 Equil ND ND ND ND 
         
No 
Urethritis 
(n = 5) 
 
        
C019 25 0.787 0.369 Equil 32 0.649 0.029 Equil 
C073 15 0.795 0.111 Equil ND ND ND ND 
C082 12 0.537 0.248 Equil ND ND ND ND 
C111 46 0.572 0.025 Equil ND ND ND ND 
C061 34 0.404 0.006 Minor Compart ND ND ND ND 
 
Table 2.2. Summary of statistical analyses of compartmentalization. 
aSM; Slatkin-Maddison, bS-SM; Structured Slatkin-Maddison, cVisual; Visual inspection of tree  
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Representative maximum likelihood env V1/V3 phylogenetic trees depicting 
compartmentalization between the blood and semen-derived lineages (A) and equilibration 
between blood and semen-derived lineages (B). Blood-derived sequences are shown in red, 





Figure 2.1. Semen-derived HIV-1 env V1/V3 sequences can be compartmentalized or 
equilibrated in men with and without STI-associated urethritis. 
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Maximum likelihood phylogenetic trees depicting blood-derived env V1/V3 sequences (red) and 
semen-derived env V1V3 sequences (blue). Sequences from before STI treatment are shown in 
filled circles, and sequences from after STI treatment are shown in open circles. In (A) and (B), 
the same compartmentalized lineage appears in the semen before and after STI treatment (circled 
nodes). In (C), a different semen-derived, compartmentalized lineage is observed in the pre and 
post STI-treatment time points.  
Figure 2.2. HIV-1 population dynamics between blood and semen remain unchanged after 
STI treatment. 
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An analysis of the percent of V1/V3 sequences that are not identical, derived from blood (A), or 
semen (C). The percent of unique sequences remains stable in overtime in both the blood (B) and 





Figure 2.3. Clonal amplification of identical sequences is observed in both blood and 
semen-derived viruses in men with and without urethritis. 
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SGA-derived full-length envelope sequences and the corresponding V1/V3 region only are 
shown on the left and right, respectively. Nucleotide changes relative to the master (top) 
sequence are indicated by colored vertical ticks. Boxed sequences represent those that are 
identical in the V1/V3 amplicon, and nearly identical over the full envelope amplicon. 
 
  
Figure 2.4. Highlighter plot of paired full-length env and env V1/V3 sequences. 
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 (A-C) Maximum likelihood trees of env V1/V3 blood (red) and semen (blue) derived sequences. 
The graphs below depicts the ability of SGA-derived envelopes from blood and semen to enter 
cells expressing low densities of CD4. Colored arrows on the trees depict the locations of the 
envelopes used in the graphs below. JR-CSF and Bal are T-tropic and M-tropic controls, 
respectively. Error bars represent the standard deviation. Data represent the average of three 





Figure 2.5. SGA-derived HIV-1 envelopes from the semen are T-cell tropic. 
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Cytokine/chemokine concentrations in semen (A) and blood (B) were measured before (denoted 
Blood1 and Semen1) and after STI treatment (denoted Blood2 and Semen2). The values were 
compared to a group of HIV+ men without a concurrent STI (labeled as “control”, and depicted 
by the grey bars). Bars show the mean +/- the standard deviation. A paired t test was used to 





Figure 2.6. Cytokine/chemokine analysis in semen and blood before and after antibiotic 
treatment of the STI. 
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SGA-derived full-length envelope sequences and the corresponding V1/V3 region only are 
shown on the left and right, respectively for participant S146. Boxed sequences represent those 






Figure 2.7. Highlighter plots comparing full-length env sequences and V1/V3 sequences for 
participant S146. 
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SGA-derived full-length envelope sequences and the corresponding V1/V3 region only are 










Figure 2.8. Highlighter plots comparing full-length env sequences and V1/V3 sequences for 
participant C061. 
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Figure 2.9. Highlighter plots comparing full-length env sequences and V1/V3 sequences for 
participant S101. 
SGA-derived full-length envelope sequences and the corresponding V1/V3 region only are 
shown on the left and right, respectively for participant S101. Boxed sequences represent those 
















Figure 2.10. Combined pre and post-STI treatment phylogenetic trees. 
Maximum likelihood env V1/V3 phylogenetic trees showing blood-derived sequences (red) and 
semen-derived sequences (blue) before and after STI treatment. Sequences from before STI 












Figure 2.11. Combined pre and post-STI treatment trees, continued. 
 Maximum likelihood env V1/V3 phylogenetic trees showing blood-derived sequences (red) and 
semen-derived sequences (blue) before and after STI treatment. Sequences from before STI 












Figure 2.12. Pre-STI treatment phylogenetic trees. 
Maximum likelihood env V1/V3 phylogenetic trees showing blood-derived sequences (red) and 












Figure 2.13. Phylogenetic trees for participants without STI-associated urethritis. 
Maximum likelihood env V1/V3 phylogenetic trees showing blood-derived sequences (red) and 
semen-derived sequences (blue) from individuals without STI-associated urethritis.  
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Using single genome amplification and droplet digital PCR, we sought to quantify HIV-1 
proviral burden and genetic composition in various regions of the brain and determine to what 
extent these viral variants are present in the cerebrospinal fluid. Additionally, we examined 
whether compartmentalized brain-derived populations are present in individuals with 
equilibrated blood and CSF populations.  
 
AUTHOR SUMMARY 
There is an incomplete understanding of HIV-1 in the central nervous system. HIV-1 can 
replicate independently within the central nervous system, as evidenced by the relatively 
frequent identification of viral populations in the cerebrospinal fluid (CSF) that are genetically 
distinct, or compartmentalized, from viral populations in the periphery. Importantly, the source 
of virions detected within the CSF, and the degree to which these viral populations represent the 
diversity found across the entire brain, has not been fully elucidated. There are important clinical 
sequelae associated with the presence of HIV-1 in the CNS, including HIV-associated 
neurocognitive disorders (HAND). Even with suppressive antiretroviral therapy, between 20 and 
 
2 The following individuals contributed to the experiments discussed in this chapter; ODC, SBJ, LPK and RS 
designed the experiments; LPK and SBJ obtained sequences from the blood and CSF; ODC obtained sequences 
from brain tissue; ODC and LPK performed entry assays; ODC, LPK, SBJ and RS analyzed the data.  
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50% of people living with HIV-1 will experience some form of neurocognitive difficulty 
demonstrable in neuropsychological tests. In order to begin to understand the mechanistic drivers 
of HAND, it is important that we address key questions concerning HIV-1 biology within the 
central nervous system. In the following chapter, I discuss the origins of HIV-1 in the CSF, as 
well as the distribution of HIV-1 DNA across various regions of the brain. Overall, the results 
demonstrate that CSF-derived viral populations generally reflect the overall diversity and entry 
phenotype of HIV-1 present within the brain, in individuals with compartmentalized CSF 
populations. In an initial analysis of a small number of individuals without compartmentalized 
CSF populations, blood, CSF, and brain-derived HIV-1 sequences cluster together suggesting 
that independent viral replication is not occurring at a detectable level. Together, these results 
advance our understanding of the biology of HIV-1 in the central nervous system.  
 
INTRODUCTION 
HIV-1 routinely invades the central nervous system, and can be detected in both the 
cerebrospinal fluid (CSF) (129, 260-263) as well as the brain (135, 139, 263). In addition, HIV-1 
can undergo sustained, independent replication within the CNS, leading to the emergence of viral 
populations that are genetically distinct, or compartmentalized, from virus circulating in the 
blood (260). There are numerous sequelae associated with the presence of HIV-1 in the central 
nervous system, including HIV-associated neurocognitive disorders, and encephalitis. In a subset 
of individuals on antiretroviral therapy, HIV-1 RNA continues to be detected in the CSF despite 
being undetectable in the blood (264, 265). This observation suggests that the CNS can serve as a 
viral reservoir, which has implications for the implementation of a cure. Therefore, it is 
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important that we understand the origins of HIV-1 in the CSF so that we may have a more 
complete picture of the relationship between CSF- and brain-derived viral variants.   
The majority of our knowledge of HIV-1 in the CNS stems from studies examining HIV-
1 RNA circulating in the cerebrospinal fluid as it is the most readily obtained component of the 
central nervous system that can be sampled in living people. A number of observations lend 
support to the idea that HIV-1 in the CSF is a reasonable surrogate for HIV-1 in the brain 
parenchyma. First, neurocognitive disorders are more commonly observed in individuals with 
detectable HIV-1 RNA in the CSF, suggesting a relationship between viral RNA in the CSF and 
ongoing neuronal damage (266). Additionally, when viral suppression is achieved in the CSF of 
these individuals, neurocognitive symptoms generally subside (267, 268). The second 
observation is the existence of CSF-derived viral populations that are genotypically and 
phenotypically distinct from HIV-1 populations observed in the periphery. For example, CSF- 
and plasma-derived variants can have different rates of decay, indicative of replication in 
different cell types with differing half-lives (131, 269). Genetically diverse, compartmentalized 
lineages observed in the CSF can efficiently enter cells, such as macrophages, that express low 
densities of CD4 on the cell surface (131). From this observation, we can infer that viruses have 
been replicating in an environment that has selected for the ability to use low densities of CD4, 
arguably due to a relative paucity of CD4+ T cells. The brain, rich in macrophages and microglia 
which express low densities of CD4 and relatively devoid of CD4+ T cells, is an example of an 
environment in which such selective pressure might exist. Taken together, these observations 
support the idea that virus present in the CSF, particularly when it is genetically distinct from the 
periphery, is derived from HIV-infected cells in the brain.  
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There are several outstanding questions regarding the relationship between HIV-1 present 
in the CSF and HIV-1 in the brain. While the observations discussed above would tend to 
suggest that virus circulating in the CSF is produced by HIV-infected cells in the brain, it is 
unclear to what extent the overall viral diversity in the brain is represented by virus in the CSF. It 
is possible that certain regions of the brain may be more likely to contribute virus to the CSF, 
while other populations may be more difficult to sample in this manner. Previous work has 
observed the presence of distinct viral populations in different areas of the brain, suggesting that 
virus present in one region may not completely reflect variants present throughout the brain (141, 
270). Additionally, specific regions of the brain may be differentially sampled by the CSF, as 
such, it is likely that not all viral populations within the brain are present in the CSF at any given 
time point. Finally, it remains to be seen whether compartmentalized HIV-1 in the brain can 
occur in the presence of equilibrated blood and CSF populations.  
In order to address these questions, we examine full-length HIV-1 env sequences 
obtained from the blood, cerebrospinal fluid, and various brain regions of five antiretroviral 
therapy-naïve individuals. Using phylogenetic methods and statistical tests we determine to what 
extent the CSF-derived and brain-derived populations are well-mixed. Additionally, we examine 
the burden of HIV-1 DNA in various regions of the brain and identify regions with higher 
densities of HIV-infected cells. Altogether our results demonstrate that while viral populations in 






Participants were part of the National NeuroAIDS Tissue Consortium (NNTC). Five 
individuals were selected on the basis of the availability of blood, cerebrospinal fluid (CSF), and 
brain samples from a subset of individuals that had been diagnosed with HIV-associated 
dementia (HAD) prior to death. All participants were infected with subtype B HIV-1. CD4 
counts ranged from 53 to 299 cells per µl of blood with a mean of 118 cells/µl at the time of 
sample collection. No participant was taking antiretroviral therapy, and HIV-1 RNA was 
detectable in both the blood and CSF with mean viral loads of 4.6x105 and 3.1x105 copies/mL, 
respectively (Table 3.1).  
 
Detectable, independent viral replication in the central nervous system is not a prerequisite 
for a diagnosis of HIV-associated dementia 
All five of the participants were diagnosed with HIV-associated dementia (HAD) prior to 
death. HAD is the most severe, and most debilitating form of all HIV-associated neurocognitive 
disorders. In order to examine whether independent viral replication within the central nervous 
system is a prerequisite for the development of HAD, we performed single genome amplification 
(SGA) of paired blood and cerebrospinal fluid (CSF) samples from these five participants. In 2 
of the 5 participants, the blood- and CSF-derived HIV-1 env sequences were intermingled 
throughout the tree (ie: the viral populations were equilibrated), suggesting that there was no 
sustained independent replication occurring in the CNS, at least as detected as virus shed into the 
CSF (Figure 3.1A). The other 3 participants had CSF-derived lineages that were genetically 
distinct from the blood-derived lineages (ie: the viral populations were compartmentalized), 
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which is indicative of sustained independent replication in the CNS (Figure 3.1B). While all of 
these participants had been diagnosed with HAD, they had variable HIV-1 viral loads in their 
CSF, and an analysis of their CSF- and blood-derived variants showed both equilibrated and 
compartmentalized populations. This observation suggests that HIV-1 replication in the CNS, 
defined as compartmentalized virus in the CSF, is not required to progress to a diagnosis of 
HAD, however the generalizability of this result is limited by the small sample size.  
 
There is an uneven burden of HIV-1 DNA across different regions of the brain 
The brain is a heterogeneous organ, with distinct regions that differ in cell density, cell 
type, immune response, and function (121, 124, 271). Given this, we examined whether the 
density of HIV-1-infected cells would also be unevenly distributed across different regions of the 
brain. To this end, we extracted total DNA from frozen tissue samples collected from the frontal 
lobe (both white and grey matter), occipital lobe, basal ganglia, cerebellum, leptomeninges, and 
choroid plexus from five participants at autopsy. Using primers and probes complementary to the 
5’ HIV-1 long terminal repeat, we quantified the amount of HIV-1 DNA present in each sample 
through droplet digital polymerase chain reaction (ddPCR) (272). Total cellular DNA was 
quantified using primers and probes specific for the RPP30 gene (273). The number of HIV-1 
copies per million cells (inferred from the amount of cellular DNA) varied substantially across 
all regions of the brain, ranging from nearly 100,000 copies per million cells in the occipital 
lobe, to less than 100 copies per million cells in the cerebellum (Figure 3.2A). For each region, 
the burden of HIV-1 DNA also varied between individuals, although those with higher HIV-1 
copy numbers in one region tended to have higher copy numbers across the entire brain. Next, 
we examined whether the average concentration of HIV-1 DNA in the brain correlated with the 
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HIV-1 viral RNA load in the cerebrospinal fluid (CSF). While the small sample size limits 
statistical power, individuals with higher average HIV-1 DNA burdens in the brain have higher 
CSF viral loads (Figure 3.2B). This suggests that the viral burden present in the CSF reflects that 
of the brain.  
 
Brain-derived sequences from ART-naïve individuals are significantly more intact than 
PBMC-derived sequences from individuals on ART 
Using a droplet digital PCR-based single genome amplification strategy (see Materials 
and Methods), we obtained an average of 24 full-length HIV-1 envelope sequences from each of 
five HIV-positive, ART-naïve individuals. Sequences were obtained from multiple regions of the 
brain for three of the five participants (Table 3.2). An average of 88% of brain-derived sequences 
were genetically intact, defined as being without premature stop codons or being hypermutated 
with APOBEC3-mediated G-to-A transitions. It has been previously demonstrated that >95% of 
HIV-1 DNA from individuals on ART is defective (196), however it has not been described to 
what extent defective viral genomes are observed in the absence of therapy. To this end, we 
compared the percent of hypermutated brain-derived sequences to that of PBMC-derived 
sequences in individuals on suppressive ART for an average of 5.2 years (Figure 3.3A). A 
significantly reduced number of sequences from untreated infection were hypermutated, as 
compared to sequences from treated infection (7% vs 46%, respectively, p = 0.0027). As a 
corollary to this, we also compared the percent of env sequences that were intact (i.e. without 
deletion) in individuals off-therapy compared to individuals on therapy (Figure 3.3B). Similar to 
our hypermutation analysis, there were significantly more intact proviral HIV-1 env sequences in 
ART-naïve individuals (88% vs 49%, respectively, p = 0.0028). It is worth noting that premature 
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stop codons in ART-naïve individuals primarily arose as the result of frameshifts, rather than 
hypermutation (data not shown). We conclude that in the absence of antiretroviral therapy, the 
percent of proviral genomes that are defective is greatly reduced. As such, we posit that the 
majority of proviral env sequences obtained from the brains of ART-naïve individuals represent 
replication-competent genomes because of the evidence of purifying selection.  
 
 The CSF represents the viral diversity present in some, but not all, regions of the brain 
The incidence of HIV-associated neurocognitive disorders increases with an increasing 
CNS viral load (274). Studies of HIV-1 in the CNS are generally carried out through an analysis 
of the virus present in the CSF as it is the most accessible component of the CNS. The CSF is a 
highly dynamic fluid that is completely replaced multiple times every day (155). Therefore, the 
information gained by examining the viral populations present in the CSF represents an 
instantaneous snapshot of what is occurring within the CNS. It is largely unknown how well such 
snapshots represent the full genetic diversity present within the CNS since it is not clear how 
efficiently virus is shed into the CSF from different regions of the brain. As noted above, we 
obtained full-length HIV-1 env sequences from multiple regions of the brain using single 
genome amplification. Neighbor-joining phylogenetic trees were constructed using CSF-derived 
and brain-derived sequences (Figure 3.4). The extent to which the brain-derived sequences 
cluster with the CSF-derived sequences varied between different regions of the brain. For 
example, in participant 7569 the basal ganglia-derived sequences form a distinct lineage that is 
separate from that of the CSF-derived sequences, and constitutes a compartmentalized lineage by 
both the Standard (241) and Structured Slatkin-Maddison tests (Figure 3.4A, Table 3.3). In 
contrast, HIV-1 env sequences derived from the frontal lobe, occipital lobe, and leptomeninges 
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are more interspersed with CSF-derived sequences (Figure 3.4 B-D). The results of the 
compartmentalization tests for all participants are shown in Table 3.3. In comparing the 
phylogenetic relationship between HIV-1 isolated from various regions of the brain to HIV-1 
isolated from the CSF, we conclude that not all viral populations present within the brain are 
sampled by and represented in the CSF at any given time.  
 
The relationship between brain- and CSF-derived HIV-1 is complex and varies between 
individuals  
Having determined that the viral diversity present in the CSF better represents what is 
observed in some regions of the brain but not others, we next sought to determine how well the 
CSF represents the HIV-1 diversity present in the entire brain. To do this, we constructed 
neighbor-joining phylogenetic trees containing all brain and CSF-derived sequences (Figure 3.5). 
We observed two patterns between these five individuals. For three of the five participants, brain 
and CSF-derived sequences were well mixed for the regions of the brain that were sampled 
(10129, 7480 and 30005). Furthermore, sequences derived from the different regions of the brain 
were also intermingled.  In the other two participants, brain-derived sequences were largely 
distinct from CSF-derived sequences (7569 and 6568). For these two participants, there was 
statistically significant compartmentalization between the brain- and CSF-derived sequences 
(Table 3.2). Having analyzed the relationship between sequences obtained from each region of 
the brain and sequences obtained from the CSF, we determined that the signal for 
compartmentalization across the entire brain was largely being driven by sequences derived from 
the basal ganglia (for participant 7569) and from the choroid plexus (for participant 6568). In 
addition, sequences derived from different regions of the brain clustered together, forming 
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distinct lineages. This observation could represent multiple entries of HIV-1 into the CNS, with 
each entry seeding different regions of the brain. Alternatively, the CNS may only be seeded 
once and virus replicating within a given region of the brain then carried to another region in the 
brain where it undergoes further independent replication.  
 
Blood-CSF compartmentalization predicts blood-brain compartmentalization 
Next, we sought to determine how well blood-CSF compartmentalization predicts the 
relationship between blood- and brain-derived sequences. Specifically, we examined whether 
there was evidence of occult brain infection not observed in the CSF of people with equilibrated 
viral populations in the blood and CSF. To this end, we constructed neighbor-joining 
phylogenetic trees containing blood, CSF and brain-derived sequences (Figures 3.6 – 3.10). We 
observed multiple patterns across the five participants. In the three individuals for whom viral 
populations in the blood and CSF were genetically distinct, the brain-derived sequences clustered 
with the CSF-derived sequences. All sequences obtained from the CNS in these three individuals 
had a common ancestor, suggesting a single introduction of HIV-1 into the CNS. Clonal 
amplification was also observed in the brain, though the frequency of clones varied between 
individuals.  
Individuals with equilibrated viral populations in the blood and CSF demonstrated a 
different relationship between brain, blood and CSF-derived sequences. Brain-derived sequences 
clustered with both blood- and CSF-derived sequences in both participants (10129 and 7480). 
This suggests that independent replication was not occurring at a substantial level in the central 
nervous system. From this lack of a distinct brain-derived lineage, we conclude that in the 
absence of blood-CSF compartmentalization, there is little evidence for occult infection of the 
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brain. Therefore, while HIV-1 present in the CSF does not always reflect the entire diversity of 
HIV-1 in the brain, it provides relevant insight into whether independent viral replication is 
occurring within the CNS as a whole. However, because of the low viral DNA load in the brain 
of these two participants this conclusion is based on a relatively small number of brain-derived 
sequences (n = 5) per participant. 
 
Compartmentalized, brain-derived HIV-1 envelopes efficiently enter cells expressing low 
densities of CD4 
In order to examine whether brain-derived HIV-1 envelopes were adapted to entering 
cells expressing low densities of CD4, we performed single-cycle entry assays using 293-
Affinofile cells and pseudotyped reporter viruses that express brain-, blood- and CSF-derived 
envelopes. JR-CSF and Bal envelopes were used as T cell-tropic and macrophage-tropic 
controls, respectively. Pseudotyped viruses containing compartmentalized, brain-derived HIV-1 
envelopes were able to efficiently enter cells expressing a low density of CD4, similar to what 
we observe with compartmentalized, CSF-derived envelopes (Figure 3.11). This result suggests 
that these CNS HIV-1 populations are adapted to replicating in cells that have a low density of 
CD4, such as macrophages and microglia. In one participant, 6568, we observed notable 
differences in the ability of envelopes from different regions of the brain to mediate entry into 
cells with low densities of CD4 (Figure 3.11B). Compared to the choroid plexus, Envs from the 
basal ganglia were 8-fold more efficient in using low densities of CD4 for entry. In contrast, 
brain-derived envelopes from participants in whom blood-, CSF-, and brain-derived populations 
were well-mixed were unable to enter cells expressing a low density of CD4, suggesting that 
these viruses are adapted to entering and replicating in CD4+ T cells (Figure 3.12). The one 
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potential exception was observed in the basal ganglia of participant 10129 (Figure 3.12B). In 
contrast to blood-, CSF-, and choroid plexus-derived envelopes which displayed less than 1% 
relative infectivity at low CD4, sequences from the basal ganglia were able to infect at low CD4 
densities 3% as efficiently relative to high CD4 expression. This suggests an intermediate entry 
phenotype, reflective of ongoing adaptation to replication in macrophages/microglia. However, 
given the poor sampling depth for this participant, further experiments are required in order to 
determine whether there are brain-derived viral populations with phenotypes not observed in the 
CSF. Overall, this preliminary study supports the idea that for individuals with CSF 
compartmentalization, the primary source of virions present in the CSF are produced by CNS-
resident macrophages and microglia. However, when CSF and blood populations are 
equilibrated, CD4+ T cells from the periphery are the major sources of virions found in the CSF.  
 
DISCUSSION 
HIV-associated neurocognitive disorders remain a significant factor affecting the quality 
of life for individuals living with HIV-1, even in the era of antiretroviral therapy. There are still 
77,000 deaths worldwide each year from HIV-1 (74) with perhaps 25% of these people suffering 
from HIV-associated dementia (161, 162, 275).  In addition, virus replicating in the brain has the 
potential to create a distinct type of reservoir that could persist while on therapy.  In order to 
make progress assessing these issues, a more thorough understanding of the relationship between 
HIV-1 in the brain and HIV-1 in the CSF is needed to allow us a clearer view of pathogenic 
processes based on the accessible sampling of CSF. In this study, we examined the genotypic 
and phenotypic properties of HIV-1 in autopsy samples from the brain. We describe the 
phylogenetic relationship between blood, CSF, and brain-derived HIV-1 env sequences in five 
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participants who had been diagnosed with HIV-associated dementia prior to death. Our results 
demonstrate that phylogenetically distinct HIV-1 sequences can be observed in discrete regions 
of the brain within a single individual. Moreover, while not all of these sequences are 
represented in the CSF at a single point in time, the overall genetic diversity of HIV-1 within the 
brain is reflected in the CSF.   
Independent HIV-1 replication within the CNS increases the likelihood that an individual 
will experience some form of HIV-associated neurocognitive disorders. This is perhaps best 
demonstrated in examples of CSF escape, in which individuals have significantly higher viral 
loads in the CSF compared to the blood (264, 265). The discordant viral loads between the CSF 
and the blood often indicate a CNS-specific source of the virus, that is independent from that of 
the periphery. An array of neurocognitive symptoms have been associated with CSF escape, and 
studies have shown that once CSF viral loads decline, symptoms often subside (276). In our 
examination of the relationship between blood- and CSF-derived sequences from individuals 
with HIV-associated dementia, we observed compartmentalized CSF lineages in 3 of 5 
individuals, and equilibrated populations in 2 of 5 individuals. Furthermore, the CSF viral loads 
of equilibrated individuals were substantially lower than those of individuals with 
compartmentalized CSF populations. Together, these results suggest that the development of 
HIV-associated dementia is not completely dependent upon independent viral replication within 
the CNS, and that simply the presence of HIV-1 within the CNS is enough to drive the pathology 
associated with HIV-associated dementia, and is in agreement with previous work (132). 
However, this conclusion is limited by the fact that we only examined CSF and blood-derived 
lineages at one peri-mortem time point. Additional sampling at other time points may reveal that 
all individuals with HIV-associated dementia had compartmentalized populations in the CNS at 
 78 
one time. It is possible, however, that the apparent disconnect between independent HIV-1 
replication and the development of HIV-associated dementia is due to an incorrect diagnosis, or 
one that is complicated by other comorbidities. We must also consider the possibility that our 
sampling depth was not sufficient to detect low-level replication that might contribute to 
neuronal damage and the development of HAD.  
In order to discuss HIV-1 in the CNS, it is important to understand the types of HIV-1 
permissive cells that exist within the CSF and the parenchyma. The cerebrospinal fluid is 
routinely patrolled by memory CD4+ T cells (117, 277, 278). In stark contrast to this, T cells are 
rarely found in the parenchyma of healthy individuals. Indeed, uncontrolled T cell migration into 
the parenchyma can lead to encephalitis. In the absence of encephalitis, the predominate HIV-1-
permissive CD4+ cells found in the parenchyma include perivascular macrophages and microglia 
(279, 280). There is an ongoing debate in the field as whether or not astrocytes (which lack the 
CD4 receptor necessary for viral entry) can be infected (281, 282). However, the most 
convincing work in this area suggests that HIV-1 DNA found in these cells is the result of 
phagocytosis of an infected, permissive cell. Microglia are the resident immune cells of the 
brain. Similar to the distribution of immune cells throughout the periphery, there is an uneven 
distribution of microglia in different regions of the brain (127). Higher densities of microglia 
have been observed in the basal ganglia and the hippocampus, whereas lower densities of 
microglia are found in the cerebellum (124). Our data demonstrating differences in the frequency 
of HIV-1 infected cells in different regions of the brain are consistent with the varying density of 
permissive cells in the different regions analyzed. Specifically, we note the second-highest 
concentration of HIV-1 DNA per million total cells in the basal ganglia (about 50,000 infected 
cells per million) and the lowest concentration in the cerebellum (about 86 infected cells per 
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million, Figure 3.2).  If this correlation holds with larger sample sizes it would suggest that 
microglia play a larger role in sustaining HIV-1 infection in the brain compared to perivascular 
macrophages; alternatively the number of microglia may determine the strength of the 
inflammatory signal that brings in inflammatory microglia. 
It has been well-established that in the presence of antiretroviral therapy, the majority of 
HIV-1 DNA is defective (190, 196). In individuals with detectable viremia, the percent of intact 
proviral DNA is considerably higher (196, 283). The participants in this study were not on ART 
at the time of sample collection, and HIV-1 RNA was detectable in both the blood and CSF. As 
such, we expected a larger proportion of HIV-1 DNA sequences obtained from these individuals 
to represent intact genomes. While we only analyzed full-length HIV-1 env sequences, we 
observed that over 80% of brain-derived HIV-1 DNA env sequences were intact. This was in 
contrast to just over 50% of PBMC-derived env sequences from individuals on long-term, 
suppressive ART.  
There have been very few studies that have examined the relationship between CSF- and 
brain-derived HIV-1 sequences. Understanding this relationship is important, as the viral load in 
the CSF is used diagnostically to monitor viral suppression within the CNS. Studies using non-
human primate models of SIV infection have observed that CSF-derived sequences incompletely 
represent the full diversity of SIV found in various regions of the brain, and that most CSF-
derived sequences shared the highest genetic similarity to sequences obtained from the meninges 
(284). In our most thoroughly sampled individual, we obtained HIV-1 env sequences from four 
regions of the brain and compared them individually to CSF-derived sequences (Figure 3.4). In 
agreement with the SIV studies, HIV-1 sequences from the leptomeninges and CSF were 
intermingled, suggesting a free flow of virus between these two compartments. In contrast, 
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sequences from the basal ganglia and occipital lobe formed distinct clusters, and were not readily 
observed in CSF-derived sequences. This observation is in contrast with a study in which 
cultured virus from the brain and CSF of untreated, HIV-positive individuals were compared 
(156). Here, the authors observed no distinct brain-specific sequences, and concluded that CSF-
derived virus adequately captured the diversity of sequences observed in the parenchyma. It is 
important to note that prolonged culturing of virus prior to sequencing can give rise to mutations 
and/or select for faster growing viruses which can distort the viral populations present in vivo. 
Through the use of a ddPCR-based single genome amplification strategy used in the present 
study, we can be confident that the sequences we obtain represent viral populations found in 
vivo. Across all five participants analyzed, brain and CSF-derived sequences were 
compartmentalized in two individuals (7569 and 6568) and well-mixed in three individuals 
(10129, 7480, and 30005). Taken together, our results demonstrate that the relationship between 
brain- and CSF-derived sequences is complex, with multiple patterns emerging between 
individuals. Ultimately, virus in the CSF must represent both the amount of virus produced at 
each site in the brain and the extent to which CSF captures the virus that is produced at each site. 
Similar to regional differences in HIV-1 DNA burden, HIV-1 sequence diversity has also 
been found to vary between regions of the brain (135, 139, 285, 286). There are multiple 
potential explanations for this observation. One possible explanation might be that different 
regions of the brain are seeded at different times by virus imported from the periphery, which 
subsequently underwent a bottleneck followed by sustained, independent replication. Our data 
suggest that in the three participants with compartmentalized viral populations in the brain 
relative to the blood, there is a single common ancestor for all brain-derived variants, suggesting 
a single introduction of HIV-1 into the central nervous system. A single introduction of HIV-1 
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into the CNS could give rise to region-specific HIV-1 variants if the initially infecting variant 
subsequently diversified and the early variants were deposited into other regions of the brain via 
the CSF. Region-specific lineages might also arise as the initially seeded viral variants adapted to 
differing local immune pressures. Additionally, the differences in the density of HIV-permissive 
cells in the various regions of the brain might also account for regional differences in diversity. 
Areas of the brain that are densely populated with microglia and perivascular macrophages, such 
as the basal ganglia, might allow for more robust replication and de novo infection whereas 
regions with low densities of target cells may only experience slow, focal infection in these 
regions, thereby restricting the diversification of the virus in these areas. Finally, though our data 
suggest that there is a single introduction of HIV-1 into the CNS that gives rise to these regional 
infections, it is also possible that the regional diversity is a result of multiple introductions of 
HIV-1 into different regions of the CNS over time. Additional sampling of variants circulating in 
the blood at multiple time points would be required in order to determine if the CNS is seeded 
multiple times.  
Another goal of this work was to determine whether distinct brain-derived HIV-1 
lineages are present in individuals with equilibrated blood and CSF compartments. While our 
sample size is small, with only two participants meeting this criteria, viral populations derived 
from the brain intermingle with both blood and CSF populations in both cases. It will be 
important for future studies to more thoroughly examine the question of whether 
compartmentalized lineages can be found in the brain when CSF and blood populations are 
equilibrated, but in this preliminary analysis of the question, we find no evidence of such a  
phenomenon. A lack of occult brain infections further solidifies the utility of monitoring CSF-
derived populations as a proxy for viral replication within the brain. In our cohort of five 
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participants, we have observed that when blood and CSF populations are compartmentalized, 
brain-derived sequence diversity is generally, but not completely, represented in the CSF. In 
individuals with equilibrated blood and CSF populations, brain-derived sequences are also 
equilibrated. As such, compartmentalization in the CSF can be used as a marker for replication 
within the CNS and a lack of compartmentalization largely corresponds with a lack of sustained, 
independent replication in the brain. However, these results must be confirmed with a larger 
population in order to more definitively determine the presence or absence of compartmentalized 
populations in the brain that are not sampled by the CSF.  
It has been postulated that the type of infected cell in the CNS may be different in people 
with equilibrated viral populations as compared to those with compartmentalized populations 
(287). Multiple genetic differences between CNS and blood-derived HIV-1, including V3 loop 
length and charge (134), differences in N-linked glycosylation patterns (135), and sensitivity to 
soluble CD4 antibodies (134, 288) have led to the notion that compartmentalized replication in 
the CNS is associated with an expanded cellular tropism that includes the ability to infect cells 
that express low densities of CD4, such as macrophages and microglia. In a preliminary analysis, 
we observed that the entry phenotypes of brain-derived envelopes were equivalent to their 
matched CSF-derived envelopes. That is, for participants without evidence of independent 
replication in the CNS (ie: equilibrated viral populations in the blood and CSF), all envelopes 
tested regardless of origin required high densities of CD4 for entry, indicative of replication in 
CD4+ T cells. In contrast, for participants with CNS compartmentalization, both CSF- and brain-
derived envelopes were able to efficiently enter cells with low densities of CD4. As this was a 
preliminary study, the number of brain-derived envelopes tested was small, limiting the 
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generalizability of our results. It will be important to conduct additional experiments in order to 
fully characterize the phenotypic properties of CSF- and brain-derived envelopes.  
In conclusion, we have characterized the genotypic and phenotypic properties of HIV-1 
present in the brain, as compared to blood- and CSF-derived populations. Our results 
demonstrate that the CSF captures most, but not all, of the genetic diversity present in the brain 
when CSF and blood populations are compartmentalized. In addition, we do not observe distinct 
brain-derived sequences when CSF and blood populations are equilibrated. Our study is not 
without limitations. The small sample size and varied number of brain regions analyzed per 
participant limit statistical power. Additionally, we cannot preclude the possibility of blood 
contamination of brain tissue samples. However, as we were able to observe brain-derived 
sequences that were distinct from the blood in multiple participants, overt blood contamination 
does not appear to be a widespread problem. Taken together, these results suggest that viral 
diversity in the CSF as compared to blood is a good indicator of the presence of independent 
viral replication within the CNS as a whole.  
  
MATERIALS AND METHODS 
Source of samples  
Blood, cerebrospinal fluid, and brain tissue samples were obtained from the National 
NeuroAIDS Tissue Consortium (NNTC). Relevant de-identified clinical information was also 
obtained from the NNTC.  
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RNA extraction from blood and CSF 
Prior to RNA extraction, blood plasma and CSF supernatants were centrifuged at 22,000 
RPM for two hours at 4°C to pellet the virus. Following ultracentrifugation, all but 140 µl of 
supernatant were removed. Virus pellets were resuspended in the remaining 140 µl of 
supernatant, and RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) according 
to the manufacturer’s instructions.  
 
DNA extraction from brain tissue 
DNA was extracted from brain tissue using the Monarch â Genomic DNA Purification 
Kit (New England Biolabs). DNA extraction was carried out according to the manufacturer’s 
instructions, with the following modifications. Approximately 25 mg of tissue was used for each 
DNA extraction. Tissue sections were lysed in 200 µl of Tissue Lysis Buffer, containing 3 µl of 
Proteinase K for up to three hours at 56°C. Following lysis, samples were centrifuged at 12,000 x 
g for 3 minutes to pellet any residual debris. After centrifugation, the supernatant was transferred 
to a fresh 1.5 mL tube. Purified DNA was eluted in 100 µl of DEPC-treated water, warmed to 
56°C by centrifugation at 13,000 x g for one minute.  
 
Droplet digital polymerase chain reaction (ddPCR) 
The concentration of HIV-1 DNA copies in each sample was determined using the 
following primers and probes spanning the packaging signal between the end of the 5’ long 
terminal repeat and the start of gag (HXB2 coordinates 684 – 810) (272). LTRgagF: 5’-
TCTCGACGCAGGACTCG-3’, LTRgagR: 5’- TACTGACGCTCTCGCACC- 3’, and 
LTRgagProbe: 5’/56-FAM/CTCTCTCCT/ZEN/TCTAGCCTC/31ABkFQ/-3’. Cell 
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concentration was determined using the following RPP30 primers and probes: RPP30-F: 5’- 
GATTTGGACCTGCGAGCG-3’, RPP30-R: 5’-GCGGCTGTCTCCACAAGT-3’, RPP30-
Probe: 5’-/56-FAM/CTGACCTGA/ZEN/AGGCTCT/31ABkFQ/-3’ (273). LTRgag ddPCR 
reactions contained the following: 10 µl ddPCR Supermix for Probes (no dUTP) (Bio-Rad), 1 µl 
each primer (LTRgagF and LTRgagR) at a concentration of 20 µM, 0.35 µl of LTRgag probe at 
a concentration of 20 µM, 6.65 µl DEPC-treated water (Thermo Fisher Scientific), and 3 µl of 
undiluted DNA for a total volume of 22 µl. RPP30 ddPCR reactions contained the following: 10 
µl ddPCR Supermix for Probes (no dUTP) (Bio-Rad), 1 µl each primer (RPP30-F and RPP30-R) 
at a concentration of 20 µM, 0.35 µl of RPP30 probe at a concentration of 20 µM, 8.65 µl 
DEPC-treated water (Thermo Fisher Scientific), and 1 µl of DNA diluted 1:100. The DNA 
volume specified for each type of reaction (LTRgag or RPP30) was replaced with DEPC-treated 
water for the negative controls. 8E5 DNA was used as a positive control. Samples were run in 
duplicate and the values averaged.  
Droplets were generated using the QX200 Automated Droplet Generator (Bio-Rad), in a 
final volume of 40 µl. After droplet generation, plates were sealed with a pierceable foil seal and 
immediately subjected to the following PCR conditions on a C1000 Touch Thermal Cycler with 
96-Deep Well Reaction Module (Bio-Rad): 95°C for 10 minutes, then 45 cycles of 95°C for 30 
seconds followed by 60°C for 1 minute, a final extension of 98°C for 10 minutes and a 4°C hold. 
Following thermal cycling, plates were read on the QX200 Droplet Reader (Bio-Rad) with the 
following set-up: Experiment = Rare Event Detection, Mix = ddPCR Supermix for Probes (no 
dUTP), Target 1 = FAM, Target 2 = VIC.  
Analysis of ddPCR data was done using QuantaSoft (Bio-Rad). Thresholds for the 
detection of each target were set using the negative controls. The same threshold was used for all 
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reactions of a particular target in a given run. The concentration of HIV-1 copies per µl of 
sample was calculated as follows: Quantasoft LTRgag concentration x (total volume of PCR 
reaction / volume of DNA added). The concentration of cells per µl of sample was calculated as 
follows: Quantasoft RPP30 concentration x (total volume of PCR reaction / volume of DNA 
added) x dilution factor x 0.5. 
 
Single genome amplification 
For RNA templates (from the blood and CSF), purified viral RNA was reverse 
transcribed using an oligo(dt) primer and SuperScript III Reverse Transcriptase (Invitrogen). 
Following reverse transcription, cDNA was diluted such that < 30% of the subsequent PCR 
reactions were positive. Single genome amplification was performed using nested PCR. First-
round PCR primers were as follows: F5010: 5’- TGCCAAGAAAAGCAAAGATCATTAG- 3’ 
and LTR DN1: 5’- GACTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG- 3’. Second-
round PCR primers were as follows: B5957 UP1: 5’- 
GATCAAGCTTTAGGCATCTCCTATGGCAGGAAGAAG-3’, and LTR DN1. Reaction set-up 
and thermal cycler conditions for both PCR-1 and PCR-2 are described below.  
Single genome amplification of DNA templates was done following ddPCR 
quantification of HIV-1 copy number. HIV-1 DNA was added such that <30% of PCR reactions 
were positive. First-round PCR primers were as follows: Vif1: 5’- 
GGGTTTATTACAGGGACAGCAGAG-3’, (HXB2 coordinates 4900 - 4923) and OFM19: 5’- 
GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’, (HXB2 coordinates 9632 - 9604). Each 
reaction contained the following reagents at their final concentrations: 2mM MgSO4, 0.2mM 
dNTP mix, 0.2µM each primer and 5U of Platinum Taq DNA Polymerase High Fidelity 
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(Thermo Fisher Scientific). First-round thermal cycler conditions were as follows: an initial 
denaturation of 2 min at 94°C, followed by 35 cycles of 15 s at 94°C for denaturation, 30 s at 
55°C for annealing, and 4 min at 68°C for extension followed by a final extension of 10 min at 
68°C. Second-round PCR primers were as follows: EnvA: 5’-
GGCTTAGGCATCTCCTATACCAGGAAGAA-3’, (HXB2 coordinates 5954 – 5982) and 
EnvN: 5’- CTGCCAATCAGGGAAGTAGCCTTGTGT-3’, (HXB2 coordinates 9171 – 9145). 
Reactions were set up as outlined above and contained 1 µl of first-round PCR product. Second-
round thermal cycler conditions were as follows: an initial denaturation of 2 min at 94°C, 
followed by 45 cycles of 15 s at 94°C for denaturation, 30 s at 55°C for annealing, and 4 min at 
68°C for extension followed by a final extension of 10 min at 68°C. PCR products were 
visualized on a 1.2 % agarose gel.  
 
Construction of HIV-1 env clones 
Amplicons of the full-length HIV-1 env gene from the first round PCR with confirmed 
sequences were subjected to an additional round of PCR using the Phusion Hot-Start High 
Fidelity DNA polymerase (Invitrogen) and the primers cEnvA (5’-
CACCGGCTTAGGCATCTCCTATACCAGGAAGAA-3’) and EnvN (5’- 
CTGCCAATCAGGGAAGTAGCCTTGTGT-3’) following the manufacturer’s instructions. 
HIV-1 env amplicons were subsequently gel purified using the Qiagen QIAQuick Gel Extraction 
Kit. An aliquot of 50 ng of purified HIV-1 env DNA was used to clone into the pcDNA 
3.1D/V5-His-TOPO vector (Invitrogen) and MAX Efficiency Stlb2 competent cells (Life 
Technology) were transformed per the manufacturer’s instructions.  
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Generation of Env-pseudotyped viruses 
Env-pseudotyped luciferase reporter viruses were generated by co-transfection of 1µg of 
an env expression vector and 1µg of pNL4-3.LucR-E-HIV-1 (136) backbone using 293T cells 
and the Fugene 6 / Fugene HD reagent according to the manufacturer’s instructions (Promega). 
Twenty-four hours after transfection, the medium was changed. Forty-eight hours after 
transfection, the medium was harvested, filtered through a 0.45 µm filter (Millipore), and 
aliquoted into 0.6 mL tubes. Aliquots were stored at -80°C until use.   
 
Single-cycle infection of 293-Affinofile cells 
The ability of HIV-1 Env proteins to mediate infection of cells expressing low densities 
of CD4 was assessed as previously described (256-258). Briefly, experiments were carried out in 
black, flat-bottomed, 96-well plates. A solution of 100 µl of 293-Affinofile cells at a density of 
1.8x105 cells/ml was added to the inner 60 wells of each 96-well plate. All 293-Affinofile cells 
were induced to express high levels of CCR5 expression using Ponesterone A (Invitrogen). CD4 
expression was induced in half of the cells using Doxycycline (Invitrogen). Twenty-four hours 
after CCR5 and/or CD4 induction, cells were spinoculated (259) with previously titered Env-
pseudotyped viruses (849 x g for 2 hours at 37°C). Following spinoculation, cells were incubated 
at 37°C for forty-eight hours. Cells were then washed twice with PBS and lysed with 1x 
luciferase assay lysis buffer (Promega) diluted in distilled water. Following lysis, plates were 
kept at -80°C prior to reading. Plates were thawed at room temperature and read using a 
luminometer. A 50 µl aliquot of luciferase assay reagent was injected into the luminometer per 
well, and relative light units (RLUs) were recorded over 2 seconds.  
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Phylogenetic and statistical analyses of compartmentalization 
Amplicons were screened for the presence of multiple peaks using Sequencher (Gene 
Codes Corporation). Amplicons with multiple peaks were not used in subsequent analysis. 
Contigs were assembled and consensus sequences were inspected for premature stop codons. 
Sequences that lacked the a stop codon or contained premature stop codons were not used in 
subsequent analyses. Neighbor-joining phylogenetic trees were constructed using MUSCLE 
(multiple sequence comparison by log-expectation) (289). All sequences obtained from each 
anatomical location (blood, CSF, and brain) were used in tests for compartmentalization. Both 
the standard (241) and the structured Slatkin-Maddison test were used to evaluate trees for the 
presence of compartmentalized lineages. The structured Slatkin-Maddison test was modified to 
account for the structure of the tree by permutating the leaves of each node sequentially before 
inferring migrations (S.L. Kosakovsky Pond et al, https://github.com/veg/hyphy-
analyses/tree/master/SlatkinMaddison). Both tests were implemented in the standard analysis 
“sm” in Hyphy v2.5 (254). Trees were considered compartmentalized if 50,000 permutations of 





aHIVE; HIV encephalitis.  
 
Table 3.1. Summary of clinical characteristics of NNTC participants.   
 Last Viral Load 
(copies/mL) 
Last CD4 Count 
(cells/uL) 
Reported Pathologya 











      
7569 >7.5x105 >7.5x105 49 HIVE, Microglial 
nodule encephalitis, 
HIV myelitis, vacuolar 
myelopathy 
      
10129 >7.5x105 328 53 Cryptococcus, HIVE 
      





      
7480 4.0x104 2.7x103 299 Atherosclerosis of the 
brain 
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7569 Basal Ganglia 25 0 92 
 Frontal Lobe (White) 8 0 87.5 
 Leptomeninges 19 0 79 
 Occipital Lobe 9 0 100 
 Total Brain 61 (sum) 0 (average) 90 (average) 
     
6568 Basal Ganglia 8 12.5 75 
 Choroid Plexus 24 0 92 
 Occipital Lobe 2 0 100 
 Total Brain 34 (sum) 4 (average) 89 (average) 
     
30005 Frontal Lobe 9 0 100 
     
10129 Choroid Plexus 7 29 57 
 Basal Ganglia 2 0 100 
 Total Brain 9 (sum) 14 (average) 79 (average) 
     
7480 Leptomeninges 6 17 83 
     
Average  24 7 88 
 
 
Table 3.2. Summary of brain-derived HIV-1 env sequences obtained for each participant. 
This table describes the analysis of the number of brain-derived HIV-1 env sequences that are 





  Standard SM p value vs Structured SM p value vs 













 Choroid Plexus 0.005 0 1 0.004 
 Occipital 0.071 0.223 1 1 
 Total Brain 0.002 0 1 0.4 
      
7569 Basal Ganglia 0 0 0 0.01 
 Frontal Lobe 0.001 0.035 0.235 0.176 
 Leptomeninges 0 0.001 0.032 0.282 
 Occipital 0.001 0.007 0.248 0.257 
 Total Brain 0 0 0 0.033 
      
10129 Choroid Plexus 1 0.427 1 0.427 
 Basal Ganglia 1 1 1 1 
 Total Brain 0.051 0.113 1 0.852 
      
30005 Frontal Lobe 0 0.01 0.048 0.889 
      
7480 Leptomeninges 0.043 0.186 1 0.572 
 
 








Figure 3.1. Relationship between blood- and cerebrospinal fluid-derived HIV-1. 
A) Neighbor-joining trees for participants 10129 and 7480. Blood-derived sequences (red) and 
CSF-derived sequences (blue) are interspersed throughout the tree. B) Neighbor-joining trees for 
participants 7569, 6568 and 30005. CSF-derived sequences (blue) form a separate lineage from 
the blood-derived sequences (red), depicted by the circle. The genetic distance between the 







Figure 3.2. Burden of HIV-1 DNA varies across different regions of the brain and 
correlates with CSF viral load. 
A) HIV-1 copy number per million cells, as determined by ddPCR, is shown for each participant 
and region of the brain analyzed. Participants with compartmentalized HIV-1 in the 
cerebrospinal fluid compared to the blood are shown in filled circles. Participants with 
equilibrated HIV-1 populations in the blood and CSF are shown in open circles. B) HIV-1 viral 
load in the CSF, quantified as RNA copies/mL, is plotted against the average number of HIV-1 
DNA copies per million cells in the brain (all regions). Open circles denote participants whose 
blood and CSF are equilibrated. Closed circles: CSF is compartmentalized compared to blood.   
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Figure 3.3. HIV-1 DNA from untreated infection is significantly more genetically intact 
compared to HIV-1 DNA obtained after extended antiretroviral therapy. 
A) The percent of hypermutated sequences obtained from the brain of individuals with untreated 
HIV-1 infection is compared to that of HIV-1 DNA sequences obtained from peripheral blood 
mononuclear cells (PBMC) from people on ART. Bars show the mean +/- the standard deviation. 
A Mann-Whitney test was used to compare the two groups as the data were not normally 
distributed. B) env sequences were defined as intact if they lacked hypermutation, and premature 
stop codons. Bars show the mean +/- the standard deviation. An unpaired t test was used to 






Figure 3.4. Distinct phylogenetic relationships between brain-derived and CSF-derived 
HIV in different regions of the brain. 
A-D) Neighbor-joining phylogenetic trees depicting full-length HIV-1 env sequences rooted to 
an outgroup. CSF sequences are shown in blue, brain-derived sequences are color-coded to 
match the diagram in the corner of each tree. The location of each region of the brain analyzed is 
shown in the corner of each tree. Genetic distance between sequences is shown by the scale bar 




Figure 3.5. The relationship between brain- and CSF-derived HIV-1 is complex and varies 
between individuals. 
Neighbor-joining phylogenetic trees containing brain- and CSF-derived HIV-1 env sequences. In 
3 participants (10129, 7480 and 30005), the brain and CSF sequences are intermingled. In 2 
participants (7569 and 6568) brain-derived sequences from different regions cluster together and 






Figure 3.6. Phylogenetic analysis of HIV-1 env sequences from participant 7569. 
Neighbor-joining tree containing full-length HIV-1 env sequences derived from the blood (red), 
CSF (blue), and four regions of the brain (basal ganglia; orange, frontal lobe; purple, occipital 
lobe; black, and leptomeninges; green). Genetic distance between sequences is shown by the 
scale bar at the bottom. Clonally amplified sequences are indicated by the vertical bar. For a 







Figure 3.7. Phylogenetic relationship between HIV-1 env sequences from participant 6568.  
Neighbor-joining tree containing full-length HIV-1 env sequences derived from the blood (red), 
CSF (blue) and three regions of the brain (basal ganglia; orange, choroid plexus; pink, and 
occipital lobe; black). Clonally amplified sequences are denoted by the vertical bars. The genetic 






Figure 3.8. Phylogenetic relationship between HIV-1 env sequences from participant 30005. 
Neighbor-joining tree containing full-length HIV-1 env sequences derived from the blood (red), 
CSF (blue) and frontal lobe (purple). The CSF and blood-derived sequences are 
compartmentalized while the brain and CSF-derived sequences are equilibrated. Two identical 






Figure 3.9. Phylogenetic relationship between HIV-1 env sequences from participant 10129. 
 Neighbor-joining tree containing full-length HIV-1 env sequences from the blood (red), CSF 
(blue) and two regions of the brain (basal ganglia; orange, choroid plexus; pink). No clonal 
amplification was observed in this participant, and brain, CSF, and blood-derived sequences 
were interspersed throughout the tree. The genetic distance between sequences is shown by the 






Figure 3.10. Phylogenetic relationship between HIV-1 env sequences from participant 7480. 
Neighbor-joining tree containing full-length HIV-1 env sequences from the blood (red), CSF 
(blue) and leptomeninges (green). Sequences from all three compartments were interspersed 
throughout the entire tree. The genetic distance between sequences is shown by the scale bar at 





Figure 3.11. Entry phenotypes of brain-, CSF-, and blood-derived HIV-1 envs from 
individuals with compartmentalized CNS populations. 
A-C) Single-cycle infectivity assays using pseudotyped HIV-1 envs and 293-Affinofile cells. A) 
phenotype data for participant 7569. Envelopes used for phenotyping experiments are indicated 
by stars on the phylogenetic tree. Lepto; leptomeninges, BG; basal ganglia, FW; frontal lobe 
white matter, Occ; occipital lobe. B) Entry phenotype data for participant 6568. CP; choroid 
plexus, BG; basal ganglia. C) Entry phenotype data for participant 30005. FL; frontal lobe. JR-





Figure 3.12. Entry phenotypes for brain-, CSF-, and blood-derived HIV-1 envs from 
participants with equilibrated CNS populations. 
A-B) Single-cycle infectivity assays using pseudotyped HIV-1 envs and 293-Affinofiles cells. 
Envelopes used in the phenotyping experiment are indicated by stars in the phylogenetic tree.  A) 
Entry phenotype data for participant 7480. Bars are color-coded to match the leaf labels on the 
tree. B) Entry phenotype data for participant 10129. JR-CSF and Bal are T cell-tropic and 
macrophage-tropic controls, respectively.  
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CHAPTER IV. AN ANALYSIS OF THE COMPOSITION AND 
FORMATION OF THE HIV-1 DNA RESERVOIR3
 
OBJECTIVE 
The goal of this study was to examine the composition and formation of the HIV-1 DNA 
reservoir. To this end, we performed ddPCR-based single genome amplification of 3’ half 
genomes derived from peripheral blood mononuclear cells collected after participants had been 
on suppressive antiretroviral therapy for a mean of 5.2 years (range: 4.1 - 6.1 years). These HIV-
1 DNA reservoir sequences were phylogenetically dated by analyzing their relationship to 
longitudinally collected pre-ART RNA sequences. In addition, we sought to compare the timing 




Current HIV-1 cure strategies are insufficient due in part to the size of the latent 
reservoir. Understanding the mechanisms that govern the formation of the long-lived HIV-1 
reservoir will enable the strategic design of interventions aimed at blocking its formation and 
consequently lowering the barrier to a cure. In this study, we examined the formation of the long-
 
3 The data described in this chapter were generated by the following individuals. The study was designed and 
supervised by R. Swanstrom and C. Williamson. Data collection was overseen by M.-R. Abrahams, S.B. Joseph, and 
N. Garrett. Pre-ART RNA sequences were obtained by L. Tyers and D. Doolabh. Reservoir sequences were 
obtained by N. Archin, S.B. Joseph, M. Moeser, S. Zhou and O.D. Council. Phylogenetic analyses were performed 
by S.K. Pond, C. Anthony, M. Moeser, and O.D. Council. DNA reservoir sequences were obtained and analyzed by 
O.D. Council.  
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lived HIV-1 DNA reservoir in ten women from the CAPRISA-002 acute infection cohort. Using 
pre-ART RNA sequences obtained longitudinally throughout the entire history of untreated 
infection, we were able to phylogenetically date when sequences entered the long-lived reservoir. 
In addition, we compare the timing of reservoir formation between the replication-competent and 
total HIV-1 DNA reservoirs. While the majority of HIV-1 DNA sequences analyzed contain 
defects such as hypermutation and deletions, both the replication-competent and largely 
defective reservoirs are seeded at similar times. In the overall cohort, we observed that 54% of 
HIV-1 DNA reservoir sequences are most closely related to viral variants circulating in the year 
before ART initiation. This study extends previous work by comparing the timing of the 
formation of the replication-competent and total HIV-1 DNA reservoirs in the same set of 
participants. Our finding that defective and intact reservoirs are seeded at similar times suggests 
a common mechanism driving the formation of the majority of the long-lived reservoir.  
 
INTRODUCTION 
The long-lived latent reservoir is the main barrier to an HIV-1 cure. With an estimated 
half-life of 44 months under suppressive antiretroviral therapy (ART), specific interventions are 
required in order to eliminate latently infected cells (194). Furthermore, cells that are latently 
infected with HIV-1 do not produce viral proteins and are therefore not susceptible to cytotoxic 
T lymphocyte-mediated clearance. The absence of viral protein production also means these cells 
are not eliminated as the result of viral cytopathic effects. Cure strategies aimed at eliminating 
latently infected cells have been difficult to implement, given the lack of a reliable marker of 
latent infection (290-293). Rather than attempting to target the latent reservoir after it has 
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formed, another strategy is to block its formation. In order for such a strategy to be effective, it is 
vital that we understand the mechanisms by which cells enter the long-lived reservoir. 
Our understanding of the formation of the latent reservoir has largely been informed by 
studies of non-human primates infected with simian immunodeficiency virus (SIV), as well as a 
few studies of antiretroviral therapy (ART) initiation during acute HIV-1 infection (218, 219). 
This work has culminated in the notion that the latent reservoir forms continuously throughout 
untreated infection. Recent work has shown that the reservoir that remains after years of 
suppressive ART is drastically different in composition compared to the reservoir present before 
ART or after brief periods of ART (294). Such observations raise the possibility of multiple 
mechanisms of reservoir formation and/or different stabilities of portions of the reservoir that are 
formed during early infection compared to those formed near the time ART is initiated.  
One manner in which we can begin to elucidate the driving mechanisms behind the 
formation of the long-lived reservoir is to examine phylogenetic relationships between reservoir 
sequences and viral genomes present at different times prior to ART. Work by Brodin and 
colleagues (222) determined that 60% of HIV-1 DNA reservoir sequences present after at least 
three years on ART were most similar to HIV-1 RNA populations that were circulating in the 
year before the start of therapy. In order to reconcile these data with the widely-accepted notion 
that the reservoir is formed continuously, it was proposed that the pre-ART reservoir turns over 
at a constant rate and that the initiation of antiretroviral therapy halts or drastically reduces this 
turnover. We sought to extend this observation by comparing the timing of the formation of both 
the long-lived replication-competent viral and proviral DNA (defective) reservoirs.  
Using viral evolution prior to therapy, we were able to date when each reservoir sequence 
was seeded into the reservoir. Reservoir sequences were generated after individuals had been on 
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suppressive therapy for a mean of 5 years. The rate at which the reservoir decays is fastest in the 
first year of therapy, and reaches a plateau after approximately four years at which point the 
slope of the decay rate is not statistically significantly different than zero (295, 296). Given the 
fact that the reservoir sequences we examined were obtained after a mean of five years of 
antiretroviral therapy, we assert that these sequences are part of the stable, long-lived reservoir. 
Our results indicate that the majority of the reservoir (both replication-competent and defective) 
is seeded in the year prior to ART initiation. Furthermore, we detect no difference in when 
replication-competent and defective genomes are seeded. These results support the idea that 
ART initiation triggers biological changes which stabilize the latent reservoir that is present at 
the time ART is started.   
 
RESULTS 
Participant characteristics  
In this study, we examined pre-ART HIV-1 RNA, on-ART DNA, and quantitative viral 
outgrowth assay-derived (QVOA) sequences from ten women from the Center for the AIDS 
Programme of Research in South Africa Acute Infection Cohort 2 (CAPRISA-002). This cohort 
was established in 2004 as part of an effort to characterize how viral set point and CD4+ T cell 
responses influence disease progression in heterosexually transmitted subtype C HIV-1 infection 
(297). Participants were ART naive for an average of 4.3 years (range: 2.6 to 7.3). At regular 
intervals throughout untreated infection, plasma was obtained and viral RNA was sequenced 
using Illumina MiSeq deep sequencing with Primer ID (221). An average of 8.6 pre-ART time 
points were sampled (range: 6 to 14), corresponding to two samples per year. Prior to ART 
initiation, the average CD4+ T cell count was 288 cells/µl (range: 74 to 436, Table 4.1). 
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Suppressive ART treatment was initiated according to in-country guidelines at the time. After an 
average of 5.2 years on suppressive antiretroviral therapy (range: 4.1 – 6.1 years), peripheral 
blood mononuclear cells (PBMCs) were obtained in order to examine the long-lived reservoir 
(Figure 4.1).  
 
Overview of HIV-1 DNA sequences obtained 
Total genomic DNA was extracted from between 5 and 20 million PBMCs per 
participant. HIV-1 copies per million cells was estimated using droplet digital polymerase chain 
reaction (ddPCR). On average, there were 200 HIV-1 DNA copies per million cells (range: 44 to 
515), which is in agreement with previous estimates of HIV-1 DNA burden in treated individuals 
(294). This estimate was used to inform DNA dilutions such that a single HIV-1 copy was 
present in each subsequent PCR reaction. A nested PCR strategy was used to obtain 3’ half 
genome amplicons approximately 5kb in length (HXB2 coordinates: 4678 – 9603), spanning vif 
through nef, and including the majority of the 3’long terminal repeat. An average of 14 3’ half 
genome sequences were obtained per participant (range: 6 to 20). A modest number of clonal 
sequences were observed, with an average of 15% of half genomes belonging to clones (range: 0 
to 31%). Following removal of clonal sequences, the remaining sequences were divided into 
regions corresponding to pre-ART MiSeq sequences; three of these regions were located in env 
(denoted as c1c2, c2c3, and c4c5) and one in nef. These four regions were individually screened 
for the presence of hypermutations using the Quality Control tool from Los Alamos National 
Laboratories (https://www.hiv.lanl.gov/content/sequence/QC/index.html). When all four regions 
were free of hypermutation, the sequence was used in our analysis of the timing of reservoir 
formation. The number of half genomes whose corresponding MiSeq regions were devoid of 
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hypermutation and thus able to be used in our phylogenetic dating analysis ranged from four to 
twelve, with an average of eight sequences per participant (Table 4.2).  
 
The majority of the HIV-1 DNA reservoir is defective 
After removing clonal sequences, we analyzed each DNA reservoir sequence for the 
presence of common defects such as hypermutations or large internal deletions. For 9 of 10 
participants, we had at least one matched quantitative viral outgrowth assay (QVOA)-derived 
sequence to use as a participant-specific reference when screening for hypermutations and 
deletions. For the one participant for whom we did not have any corresponding QVOA-derived 
sequences (CAP380), we used a QVOA-derived consensus sequence, obtained by generating a 
consensus sequence from all participants with QVOA-derived virus, as the reference. As shown 
in Figure 4.2A, the majority of DNA sequences contained at least one type of defect, with 
hypermutations being the most common followed by sequences with both hypermutations and 
large internal deletions. An average of 48.2% of half genomes were inferred to be intact, as they 
had intact env genes and did not possess either internal deletions or hypermutations. It is worth 
noting that in one participant, CAP222, 10 out of 11 half genomes (91%) were inferred to be 
intact. 
Given the fact that it has been reported that only 2% of proviral genomes are intact, we 
sought to understand why our estimate was substantially greater. Using data from Bruner et al., 
2016 (196), we categorized the breakdown of various defects observed in the 3’ half of the 
genome alone. As shown in Figure 4.2B, when analyzing only the 3’ half of the genome, 46% of 
proviruses (n = 151) are devoid of obvious defects including hypermutation, deletions and 
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inversions.  Thus, when we compare our half genomes to those studied by Bruner et al., we see 
an equivalent proportion of intact sequences.  
 
In-depth analysis of hypermutation reveals regional hotspots and linked hypermutations 
Apolipoprotein B mRNA editing enzyme catalytic peptide-like 3G (APOBEC3G)-
mediated hypermutations occur during the process of reverse transcription. During this process, 
single-stranded cytidines are deaminated during negative strand synthesis, resulting in an 
accumulation of G-to-A mutations during synthesis of the plus strand DNA from a deaminated 
template.  Given the specificity of APOBEC3G for single-stranded DNA, it has been 
hypothesized that the number of G-to-A mutations would increase in frequency as one moves 
from the 5’ end of the genome towards the 3’ end, and furthermore, that this gradient is the direct 
result of the amount of time the minus strand DNA is single stranded during reverse transcription 
(298). In order to examine this phenomenon in the context of DNA sequences present in the 
long-lived reservoir, we examined the location, frequency and proportion of subgenomic 
sequences exhibiting hypermutations. In our first analysis, we used a QVOA-derived consensus 
sequence to determine what fraction of DNA reservoir genomes had G-to-A mutations present at 
each position along the 3’ half of the genome (Figure 4.3A). Consistent with previously 
published data (196), as well as our own analysis about the fraction of proviral genomes bearing 
hypermutations, there were a number of positions at which 100% of DNA-derived genomes 
harbored a G-to-A mutation. Furthermore, there was an increased frequency of mutations in env 
and nef, relative to vif. This observation is consistent with the notion that the frequency of 
hypermutations increases in a 5’ to 3’ direction. When we broke our analysis down by gene and 
determined the percent of each participant’s sequences that were hypermutated in a given gene, 
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overall the percent of sequences that were hypermutated did not increase consistently moving 
towards the 3’ end (Figure 4.3B). However, in 7 out of 10 participants, the percent of 
hypermutated vif sequences was lower than env or nef sequences, demonstrating that in a 
majority of participants analyzed, there was a higher frequency of hypermutation in genomic 
regions located at the 3’ end of the genome.  
In a final analysis, we wanted to determine whether hypermutations were linked across a 
genome. To this end, we plotted each unique proviral DNA sequence (n = 183) and determined 
whether or not hypermutation was present in each of the following regions: vif, gp120, gp41 and 
nef (Figure 4.3C). Of the 183 total sequences, 64 (35%) were not hypermutated in any region. Of 
the 119 sequences with at least one hypermutated region, 99 (83%) were hypermutated in both 
vif and either gp120 or gp41. Hypermutation was present in all four regions in 27 of the 183 
sequences (15%). Interestingly, there were no sequences in which hypermutation was only 
present in gp41 or nef. From this analysis, we conclude that the probability a given sequence will 
be hypermutated is largely dependent upon whether or not hypermutation is present in vif.   
 
Lack of correlation between total HIV-1 DNA reservoir size and other clinical data 
The size of the total HIV-1 DNA reservoir was estimated using ddPCR, and is expressed 
as HIV-1 DNA copies per million cells. If the reservoir forms continuously starting in early 
infection until ART is initiated, it is reasonable to expect the size of the reservoir to correspond 
with the number of years an individual has been HIV+ but ART naive. In our cohort of ten 
women, we did not observe a correlation between the size of the DNA reservoir and the length of 
time an individual was ART naïve (Figure 4.4A). Similarly, women who had been on ART for 
longer periods of time prior to their reservoir blood draw did not have reduced reservoir sizes 
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(Figure 4.4B). This suggests that the DNA reservoir does not decay at an easily detectable rate 
after viral suppression is achieved.  
As others have previously described, the majority of the HIV-1 DNA reservoir is 
defective and therefore not capable of producing replication-competent virus upon ART 
interruption (196). For this reason, it has been suggested that focusing on the size of the 
replication-competent portion of the latent reservoir might better reflect progress towards an 
HIV-1 cure.  One such metric, derived from the quantitative viral outgrowth assay, is termed 
infectious units per million CD4+ T cells, or IUPM. As shown in Figure 4.4C, while there is no 
statistically significant correlation between the DNA-derived estimate of the total reservoir size 
and the size of the replication-competent reservoir, it is true that in general individuals with 
larger total reservoirs have higher IUPMs. In an effort to determine if the proportion of defective 
proviruses correlated with the size of the replication-competent reservoir, we examined the 
relationship between the percent of each participant’s HIV-1 DNA genomes that were 
hypermutated and their IUPM estimate. There was no correlation between the percent of 
hypermutated HIV-1 DNA genomes and the IUPM estimate (Figure 4.4D). Given that the 
estimate of total reservoir size did not correlate with IUPM, it is not surprising that there was no 
correlation between hypermutated genomes and replication-competent proviruses.  
 
A phylogenetic approach to inferring when HIV-1 DNA reservoir sequences are seeded 
HIV-1, like most RNA viruses, lacks a proofreading mechanism. As such, the high error 
rate of reverse transcriptase and RNA polymerase II (249) gives rise to a highly diverse viral 
quasispecies within an infected individual over the course of untreated infection (299-301). This 
accumulation of mutations over time means that viruses circulating at different time points will 
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cluster distinctly on a phylogenetic tree. Given this, we were able to use viral evolution prior to 
ART initiation to determine when sequences present in the long-lived reservoir were seeded 
based on their placement within a phylogenetic tree. Importantly, not every gene has the same 
rate of mutation. More conserved regions, such as gag accumulate mutations at a reduced rate 
(302). Therefore, such regions are less informative to our dating strategy, as there is less genetic 
distance between variants sampled at different time points. Given this, we focused our 
phylogenetic analyses on regions of the genome that had higher rates of mutation, namely 
regions in env and nef. Maximum-likelihood phylogenetic trees containing pre-ART RNA 
sequences and on-ART reservoir sequences (both QVOA and DNA-derived) are shown in Figure 
4.5. For each region, pre-ART sequences from each time point form distinct clusters. QVOA-
derived (shown in pink) and DNA-derived reservoir sequences (shown in black) cluster together 
on the trees and the majority of the reservoir sequences cluster with pre-ART sequences that 
were circulating in the year prior to ART initiation.  
 
The DNA and replication-competent reservoirs are seeded at similar times 
Given the multiple biological differences between replication-competent and defective 
HIV-1 proviruses, we wondered whether there were differences in when these two portions of 
the long-lived latent reservoir were seeded. In order to examine this question, we sequenced 
QVOA and DNA-derived reservoir viruses from five women in the CAPRISA-002 acute 
infection cohort. In general, the number of QVOA and DNA-derived sequences obtained was 
similar, although for CAP257 there were four times as many QVOA-derived sequences than 
DNA-derived sequences. All reservoir sequences were phylogenetically dated, as described in 
the methods. The results of this dating analysis are shown in Figure 4.6. When we compared the 
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proportion of QVOA and DNA-derived reservoir viruses that date to the year before ART was 
initiated, there was no difference (Fisher’s exact test, Table 4.3). Furthermore, we observed that 
this agreement between QVOA and DNA-derived estimates of the timing of reservoir formation 
remained even when the majority of the reservoir was not seeded in the year prior to ART 
(Figure 5, CAP302). In this participant, only 17% of the replication-competent reservoir was 
seeded in the year prior to ART, compared to 40% of the DNA reservoir (Fisher’s exact test, p = 
0.59). In conclusion, in a subset of five participants for whom we had adequate sampling of both 
the replication-competent and DNA reservoirs, there was no observable difference in when these 
two reservoirs were seeded.  
 
Sampling depth does not significantly alter the proportion of reservoir sequences dating to 
the year prior to ART.   
Although we have determined that our amplification strategy does not appear to be biased 
towards the amplification of intact genomes, there is still the chance that random sampling may 
have influenced the proportion of reservoir sequences that cluster with pre-ART RNA sequences 
circulating in the year before ART initiation. In order to examine this possibility, we increased 
our sampling depth three-fold in three participants. For two of these participants (CAP257 and 
CAP288), our initial analysis had determined that the majority of the DNA reservoir (88% and 
75%, respectively) was seeded in the year before ART. In the third participant, CAP277, only 
13% of DNA reservoir sequences analyzed clustered to the year before ART. Increasing our 
sampling depth, we observed no statistically significant difference in the percent of reservoir 
sequences that dated to the year before ART in any of the three participants (Figure 4.7). 
However, for CAP277, we did observe that with an increased sampling depth, a minority of 
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reservoir sequences dated to primary infection, which we had not observed in our initial 
sampling. This supports the idea that the reservoir can and does form throughout untreated 
infection. However, our overall results indicate that this portion of the reservoir decays rapidly.  
 
The majority of the DNA reservoir is seeded in the year before ART initiation 
Recent data have suggested that while the vast majority of the DNA reservoir may not 
contribute to viral recrudescence following ART cessation, these defective proviruses are 
capable of producing viral proteins that can contribute to the persistent immune activation 
associated with multiple HIV-1 co-morbidities (199, 201). Given this, it is important to develop 
strategies that limit the formation of both the replication-competent and DNA reservoirs. 
Understanding when the DNA reservoir forms would aid in the development of strategies to limit 
its formation. To this end, we performed phylogenetic dating of the DNA reservoir in ten women 
from the CAPRISA-002 cohort. Across all participants, the majority (54%) of the long-lived 
DNA reservoir is seeded in the year prior to ART (Figure 4.8). When we examine the 
composition of each participant’s DNA reservoir, multiple patterns emerge. In 3 of 10 
participants, the DNA reservoir only contains sequences that date to the one or two years 
immediately preceding ART (CAP336, CAP316, and CAP288). In another pair of participants 
(CAP257 and CAP333), while the majority of sequences date to the year prior to ART, 
sequences from earlier in infection are also present in the reservoir. Two participants (CAP244 
and CAP222) have reservoirs containing sequences that span the entire history of untreated 
infection. Finally, in one participant, 0% of DNA reservoir sequences date to the year prior to 
ART, although it should be noted that this participant had the least sampling depth (n = 4 
sequences), as well as the shortest duration of untreated infection (2.6 years).  Given these 
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results, we conclude that while the majority of the DNA reservoir forms as the result of changes 
in T cell biology that occur around the time of ART initiation, there are other mechanisms that 
allow for sequences to be archived throughout untreated infection, though at much lower rates.  
 
DISCUSSION 
The long-lived latent reservoir is the main barrier to an HIV-1 cure. In this study, we 
examined viral sequence diversity to infer when the proviral DNA reservoir was seeded and to 
further our understanding of how the total DNA reservoir relates to the replication-competent 
portion of the reservoir. Our results indicate that even though the majority of the proviral DNA 
reservoir is comprised of defective genomes, the dynamics and timing of the formation of the 
total DNA reservoir mirrors that of the replication-competent reservoir. This study significantly 
enhances our understanding of the mechanism driving formation of the long-lived reservoir, as 
our data suggest that it is cell-driven, rather than virus-driven. This distinction is important, as it 
implies that strategies aimed at controlling memory T cell formation around the time of ART 
initiation would significantly reduce the size of the reservoir.  
Independent of when during the course of infection antiretroviral therapy is started, it has 
been established that the majority of HIV-1 DNA is defective (196). Defects primarily originate 
as the result of genomic insults that occur during the process of reverse transcription. In 
agreement with previously published studies, we observed that the majority of proviral 3’ half 
genomes obtained from women who initiated ART during chronic infection were defective. 
Furthermore, the relative frequencies of the various types of defects observed were consistent 
with what has been reported in the literature. Although our analysis was primarily focused on 
half genome amplicons, we did analyze near full-length proviral genomes and confirmed that 
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both the frequency and type of defects observed are in agreement with what has previously been 
observed (data not shown). Verifying that the majority of proviral genomes obtained through our 
amplification strategy are defective is important as it confirms that in designing primers, we did 
not inadvertently bias our results towards an analysis of the small portion of the reservoir that is 
genetically intact. We can therefore be confident that the HIV-1 DNA sequences we obtained 
and the subsequent analyses performed are representative of the total DNA reservoir.   
APOBEC3G-mediated hypermutation is one of the main inducers of lethal premature 
stop codons, contributing to the inability of the majority of proviral genomes to produce virions. 
We observed that on average, 56% of proviral half genomes were hypermutated. Interestingly, 
there was a high degree of variability from participant to participant, with one notable individual 
(CAP222), having only one hypermutated sequence out of eleven (9%). This person-to-person 
variation could have multiple explanations. It has been established that there are multiple genetic 
variants of APOBEC and that single nucleotide polymorphisms within the gene, most notably 
H186R, have been associated with higher HIV-1 viral load, faster CD4+ T cell decline, and a 
faster time to AIDS-defining illness (303-306). Furthermore, T cell subsets are differentially able 
to upregulate APOBEC mRNA expression and protein synthesis in response to cytokine stimulus 
(307). Taken together, previous work has shown there to be a precedent for such variation in 
APOBEC-mediated HIV-1 hypermutation.  
The observation that hypermutation appears to be linked across the genome, and that the 
frequency of hypermutated genes increases in a 5’ to 3’ direction supports established 
mechanisms of APOBEC-mediated hypermutation. The catalytic deamination has been described 
to be processive (308). Once an APOBEC target sequence is located and the enzyme binds, it 
continues to scan along the same ssDNA substrate in a 3’ to 5’ manner through a combination of 
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jumping and sliding mechanisms until another target sequence is found (308, 309). The 
processive nature of the enzymatic activity of APOBEC explains the observation that we rarely 
see a single hypermutated region in a given genome. Indeed, even a single molecule of A3G can 
deaminate a genome to such a degree as to lethally mutate a provirus (310). The slight but 
consistent increase that we observed in hypermutated genes located at the 3’ end of the genome, 
relative to more upstream genes, also supports the notion that the probability of APOBEC-
mediated deamination is correlated with the amount of time the negative sense cDNA remains 
single stranded during reverse transcription (298).  
There has been considerable debate in the field as to which methods of quantifying the 
latent reservoir best correlate with the size of the replication-competent competent reservoir and 
predict the time to viral rebound following ART cessation. Consistent with some previous 
reports (213) and contrary to others (296, 311), we observed no statistically significant 
correlation between total HIV-1 DNA copies per million cells and IUPM, though there was a 
trend towards a positive correlation. The lack of a statistically significant correlation between 
HIV-1 DNA burden and the size of the inducible, replication-competent reservoir may be a 
function of the relatively small sample size. It is also notable that 6 out of 10 participants in our 
cohort had IUPM estimates near the lower limit of quantification (194) which could have 
obscured the relationship.  Another possible explanation for this result might be the result of 
differential decay rates of intact versus defective proviruses. Using a ddPCR-based assay that 
differentiates between defective and intact HIV-1 DNA, Peluso and colleagues determined that 
intact proviruses decay at a significantly faster rate in the first seven years of antiretroviral 
therapy, compared to defective proviruses (312).  
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While it has been demonstrated that the latent reservoir can begin to form during acute 
infection (220), much of what we know about reservoir formation has come from studies of non-
human primates infected with simian immunodeficiency virus (SIV) (219, 313, 314). Given the 
multiple genetic differences between SIV and HIV-1 (19, 315, 316), it is vital that we 
corroborate observations made with SIV by examining analogous processes in HIV-1. Although 
CD4+ T cells harboring HIV-1 genomes have been identified in early infection, this observation 
alone does not indicate that such reservoir sequences persist long-term. If the long-lived reservoir 
started forming early and formed continuously throughout untreated infection, we would expect 
to see the size of the reservoir increase with an increasing amount of time an individual was 
ART-naïve. Furthermore, we would expect reservoir sequences to be genetically similar to 
variants circulating at multiple time points prior to the start of ART. Instead, we observe no 
correlation between the size of the total HIV-1 DNA reservoir and the time an individual was 
ART naïve (Figure 4A). In addition, the vast majority of reservoir HIV-1 DNA sequences cluster 
with variants that were circulating in the year prior to ART initiation. Neither of these 
observations is consistent with a long-lived reservoir that is continually formed.  
Since the seminal work of Ho et. al. (195) and Bruner et. al. (196), in which it was 
determined that the vast majority of the latent reservoir is comprised of defective genomes, there 
has been a significant amount of work put in to developing technologies to separate the 
replication-competent reservoir from the defective reservoir (206, 312, 317-319). Recently, it 
was shown that defective HIV-1 DNA genomes can produce viral proteins that can be 
recognized by the immune system (199, 201), potentially explaining a mechanism for the 
ongoing inflammation observed in HIV-positive, ART-suppressed individuals (197, 198, 320, 
321). This observation provided one of the first clues that defective HIV-1 genomes could exert a 
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deleterious effect on human health, regardless of their inability to produce replication-competent 
virus. Similarly, in comparing the formation of the replication-competent and proviral DNA 
reservoirs and finding no difference between them, we add another way in which examining the 
total reservoir expands our understanding of HIV-1 biology. The observation that the DNA 
reservoir is seeded at similar times as the replication-competent portion of the reservoir has both 
technical and biological significance. Technically, it is much more challenging to carry out 
studies of the replication-competent reservoir. Furthermore, recent work has shown that not all of 
the replication-competent reservoir can be induced following a single round of mitogen 
stimulation, as is commonly used in traditional outgrowth assays (195, 230), thus limiting the 
information we can gain from such assays and precluding our ability to study this portion of the 
reservoir in its entirety. However, the current study demonstrates ways in which the total DNA 
reservoir, regardless of its ability to produce virus, informs our understanding of the portion of 
the reservoir that is responsible for viral recrudescence upon ART cessation. Biologically, the 
observation that the defective HIV-1 DNA and replication-competent portions of the reservoir 
form at the same time sheds light on the manner in which the latent reservoir is formed. It has 
previously been suggested that the genetic intactness of given provirus influences the likelihood 
that an infected cell would contribute to the long-lived reservoir, by affecting the half-life of the 
infected cell (232, 312). Although this may be true at a low frequency, our data suggest that for 
the majority of the reservoir, it is the biology of the infected T cell, and the physiological 
environment present at the time of infection, that influences whether or not a cell will enter the 
reservoir. This distinction is important, as it means that strategies that limit the transition of 
CD4+ cells to a long-lived memory phenotype (322) around the time ART is initiated may help 
to limit the size of the reservoir, thereby lowering the barrier to cure.  
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Our analysis of the timing of the formation of the HIV-1 DNA reservoir has revealed 
multiple patterns of reservoir formation, but one common theme. While the composition of each 
participant’s reservoir is varied, across the entire cohort the majority of DNA-derived reservoir 
sequences phylogenetically cluster with variants that were circulating in the year before ART 
was initiated. Since we observed DNA-derived reservoir sequences that dated to early infection 
in a few participants (CAP244 and CAP222), our results do not rule out the possibility of a 
portion of the long-lived reservoir being seeded in early infection. However, it is clear that in the 
majority of participants, the reservoir is not seeded and eliminated at a constant rate in 
individuals on long-term, suppressive antiretroviral therapy. An alternative explanation for our 
results could be that the pre-ART reservoir is formed and decays at a constant frequency, but that 
physiological changes that occur when ART is initiated stabilizes the portion of the reservoir that 
was seeded proximal to the start of ART, thereby changing the rate at which the long-lived 
portion of the reservoir decays. Changes in reservoir composition (294) and decay rate (223) 
have been previously documented.  
Altogether, this study has demonstrated that the long-lived portion of the largely 
defective HIV-1 DNA reservoir is formed at similar times to the replication-competent portion of 
the reservoir. This study is not without weaknesses. The sampling depth of the HIV-1 DNA 
reservoir varied substantially from participant to participant. In some cases, only a few reservoir 
sequences were available for analysis of the timing of reservoir formation. In general, this was 
the result of a large number of clonal sequences (that represent single introductions into the 
reservoir) or hypermutated sequences that were not able to be accurately dated, and were 
therefore not used in subsequent analyses. Nonetheless, increasing our sampling depth in all 
participants would strengthen our findings. Additionally, sampling multiple time points after 
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ART initiation could help determine how the composition of the reservoir changes over time, 
which would provide additional insight into the mechanism(s) of its formation. The insights 
gained from this and subsequent studies will inform strategies to reduce the size of the reservoir 
through interventions aimed at blocking its formation.  
 
MATERIALS AND METHODS 
Ethics statement and source of clinical samples 
Participants were part of the CAPRISA-002 acute infection cohort based in KwaZulu-
Natal, South Africa. Women were identified in acute infection and subsequently gave blood 
samples every 3 to 6 months. ART was initiated based on in-country guidelines. Following ART 
initiation, women remained in the cohort an additional five years. For this study, we identified 
ten women who had been ART-naïve for a minimum of 2.6 years and on ART for a minimum of 
4.1 years. Peripheral blood mononuclear cells were collected by Ficoll gradient following a 200 
mL blood draw. Cryopreserved cells were used for analysis of the long-lived reservoir as 
described below. The use of previously obtained and stored samples for new analyses was done 
under a protocol approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu Natal (BE178/150) and the Human Research Ethics Committee of the University of 
Cape Town (588/2015) in South Africa, and the University of North Carolina at Chapel Hill.   
 
Sequencing HIV-1 RNA populations in the blood pre-ART  
Sequencing of pre-ART HIV-1 RNA populations was done as previously described 
(221). Briefly, viral RNA was extracted from blood plasma using the QIAamp Viral RNA Mini 
Kit (Qiagen). Complementary DNA (cDNA) was generated by reverse transcription of the viral 
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RNA using SuperScript III/IV Reverse Transcriptase (Invitrogen). Multiple primers, each with a 
Primer ID (238, 239), were used for each sample in separate cDNA synthesis reactions. This 
allowed for  the simultaneous amplification and sequencing of multiple genomic regions 
downstream. cDNA products were purified twice using Agencourt RNAClean XP magnetic 
beads (Beckman Coulter). PCR amplification was performed using the KAPA2G Fast Multiplex 
Mix (Kapa Biosystems). Equimolar amounts of gene-specific forward primers that included a 
common binding sequence to the 5’ end of the cDNA primer and an excess of a universal reverse 
primer were used. A second PCR step was performed using the Expand High Fidelity PCR 
System (Roche) which served to incorporate the Illumina MiSeq version 2 indexes and adaptors. 
PCR products were purified using SPRIselect beads (Beckman Coulter) at a 0.6:1 volume ratio 
of beads to PCR product following each PCR step. The final purified libraries were prepared by 
pooling amplicons at equimolar ratios following quantification using the Qubit double-stranded 
DNA high sensitivity assay. Following a final purification using SPRIselect beads, Illumina 
MiSeq 2 x 300 base paired-end sequencing was performed.  
 
DNA extraction 
Total DNA was extracted from peripheral blood mononuclear cells using the DNeasy 
Blood and Tissue Kit (Qiagen), following the manufacturer’s instructions with the following 
modifications. DNA was eluted from the column using 200 µl of DEPC-treated water (Thermo 
Fisher Scientific) instead of elution buffer. Following a one minute centrifugation at 6000 x g, 
the eluate was re-applied to the membrane, allowed to incubate for one minute at room 
temperature, and re-eluted. DNA was stored at -20°C until use.  
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Quantitative viral outgrowth assay (QVOA) 
Resting CD4+ T cells were isolated from peripheral blood mononuclear cells via negative 
selection with CD25 depletion in order to isolate cells that were CD69-, HLA-DR-, and CD25low 
(Custom Kit, STEMCELL). Isolated resting CD4+ T cells were then analyzed by flow cytometry 
(LSRII Fortessa) for expression of CD69 (phycoerythrin, BD), CD25 (anaphase-promoting 
complex, BD), CD8 (fluorescein isothiocyanate, BD), CD4 (peridinin chlorophyll protein 
complex-Cy5.5, BD), and viability (Aqua LIVE/DEAD, Thermo Fisher Scientific) to confirm 
cell purity.  
Quantitative viral outgrowth assays were performed as previously described (323). 
Briefly, resting cells were cultured at a density of 100,000 cells per well with purified 
phytohemagglutinin (PHA) (1.5 µg/ml; Remel-PHA, Thermo Fisher Scientific), Interleukin-2 
(60 U/ml), and irradiated peripheral blood mononuclear cells from an HIV-seronegative donor. 
After 15 and 19 days in culture, supernatants were tested for HIV-1 p24 capsid protein 
production via enzyme-linked immunosorbent assay. Supernatants positive for p24 were stored 
at -80°C until further use.  
 
Droplet digital PCR 
The concentration of HIV-1 DNA copies in each sample was determined as previously 
described in Chapter Three. Briefly, ddPCR primers and probes complementary to the region 
between the 5’ LTR and gag were used to quantify HIV-1 copy number. Cell equivalents were 
determined using primers and probes complementary to the RPP30 gene. Droplets were 
generated using the QX200 Automated Droplet Generator (Bio-Rad) and thermal cycling was 
carried out using a C1000 Touch Thermal Cycler with 96-Deep Well Reaction Module (Bio-
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Rad). Reactions were carried out in duplicate with positive and no-template controls included in 
every run.  
 
Near full-length HIV-1 amplification (QVOA) 
Supernatant from p24+ quantitative viral outgrowth assay wells was reverse transcribed 
using oligo(dt) and SuperScript III Reverse Transcriptase (Invitrogen). Overlapping 5’ and 3’ 
half genomes were amplified in separate PCR reactions using PacBio barcoded primers. PCR 
products were examined on a 0.8 % agarose gel. Positive wells were gel purified, pooled, and the 
SMRTbell Template Prep Kit (Pacific Biosciences) was used to add adaptors to the barcoded 
amplicons.  
 
Half genome HIV-1 amplification (HIV-1 DNA) 
A nested PCR approach was used to generate 3’ half genome amplicons. First round PCR 
primers were as follows: U5-623F: 5’-AAATCTCTAGCAGTGGCGCCCGAACAG-3’ and U5-
601R: 5’- TGAGGGATCTCTAGTTACCAGAGTC-3’. The first round primers were used in 
conjunction with 5U of Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher 
Scientific). HIV-1 DNA was added such that each reaction contained one copy of HIV-1 DNA, 
based on ddPCR estimates. A no template control was included in each run. First round thermal 
cycler conditions were as follows: an initial denaturation of 2 min at 92°C, followed by 10 cycles 
of 10 s at 92°C for denaturation, 30 s at 60°C for annealing, 10 min at 68°C for extension, then 
20 cycles of 10 s at 92°C for denaturation, 30 s at 55°C for annealing, 10 min at 68°C for 
extension, followed by a final extension of 10 minutes at 68°C, and a 4°C hold. The resulting 
amplicon corresponds to HXB2 coordinates 623 – 9686. 
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The second round PCR primers, for amplification of the 3’ half of the genome, are as 
follows: 4653F: 5’-CCCTACAATCCCCAAAGTCAAGGAG-3’ (HXB2 coordinates 4653 – 
4677) and OFM19: 5’- GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’ (HXB2 coordinates 
9604 – 9632). To facilitate multiplexing, PacBio barcodes were added to the 5’ end of both the 
forward and reverse second round primers. Each reaction consisted of 34.8 µl of DEPC-treated 
water (Thermo Fisher Scientific), 5 µl of 10X High Fidelity Buffer, 2 µl of 50 µM MgSO4, and 5 
U of Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific), and 2µl of first 
round PCR product. Barcoded forward and reverse primers were mixed for a final concentration 
of 0.2 µM each, and 5 µl of this mix was added individually to each PCR reaction. Second round 
thermal cycling conditions were as follows: 2 min at 94°C for the initial denaturation, then 10 
cycles of 15 s at 94°C for denaturation, 30 s at 55°C for annealing, and 8 min at 68°C for 
extension, then 25 cycles of 15 s at 94°C for denaturation, 30 s at 55°C for annealing, and 8 min 
at 68°C for extension with an additional 20 s of extension time added each cycle; a final 7 min at 
68°C for extension, followed by a hold at 4°C. Second round PCR products were screened for 
positives on a 0.8 % agarose gel stained with SYBRÒ Safe DNA Gel Stain (Thermo Fisher 
Scientific), and visualized with a UV gel imager.  
 
Sequencing of reservoir populations 
Both QVOA-derived and DNA-derived reservoir amplicons were sequenced using single 
molecule real-time (SMRT) sequencing. To prepare amplicons for sequencing, barcoded 
amplicons were pooled and gel purified using the MinElute Gel Extraction Kit (Qiagen). The 
SMRTbell Template Prep Kit (Pacific Biosciences) was used to add adaptors to pooled, barcoded 
amplicons. The libraries were sequenced using the Pacific Biosciences Sequel II system with a 
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movie time of 10 hours for data collection. Sequences were grouped by barcode, and high-
quality reads were processed using the PacBio Long Amplicon Analysis package.  
 
Illumina MiSeq data processing 
Raw sequencing reads were processed using in-house pipelines written in R and Python, 
which have previously been described in detail (239). Sequence data was filtered by quality 
score, overlapping paired-end reads were merged, and the Primer ID processing method was 
carried out using the MotifBinner2 program (https://github.com/HIVDiversity/MotifBinner2; 
DOI: 10.5281/zenodo.3372204). Resultant Primer ID consensus sequences were processed with 
an in-house pipeline (https://github.com/HIVDiversity/NGS_processing_pipeline; DOI: 
10.5281/zenodo.3372202) which further refines the results by removing nontarget gene 
sequences as well as sequences with degenerate bases or deletions larger than 50 nucleotides.  
 
Phylogenetic and statistical analyses 
Alignments containing pre-ART RNA sequences, as well as both QVOA and DNA-
derived reservoir sequences were generated using multiple sequence comparison by log-
expectation (MUSCLE) (289). Hypervariable loops in env were manually removed. Trimmed 
sequences were then processed through a pipeline that generated in-frame codon alignments for 
each subgenomic region (https://github.com/veg/ogv-dating; DOI: 10.5281/zenodo.3370141). 
Sequences that contained frameshifts were aligned to in-frame sequences using the Smith-
Waterman algorithm in the BioExt package (https://github.com/veg/BioExt). In-frame sequences 
were once more aligned using MUSCLE, to generate in-frame, codon-aligned sequences that 
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lacked frameshifts. Approximately-maximum-likelihood trees were constructed using FastTree2 
with more rigorous search options (324).  
Dating of reservoir sequences was performed using three methods from each genomic 
region, as previously described (221). To begin, phylogenetic trees were rooted to maximize the 
relationship between its root-to-tip distances and the time linear regression coefficient. The first 
method of estimating when a sequence entered the reservoir, called the “patristic distance” 
computes the path lengths between a reservoir sequence and every other pre-ART RNA 
sequence located on the tree. The minimum distance (d) is determined, and the reservoir 
sequence is determined to have originated from the time point from which the simple majority of 
pre-ART sequences within 2d originate. In the second “clade support” method, the analysis 
begins at the reservoir sequence and traverses the tree towards the root until a well-supported 
clade (with bootstrap support ³ 90%) that contains pre-ART RNA sequences is identified. The 
date of the reservoir sequence is calculated to be the time point from which most pre-ART 
sequences in the well-supported clade originate. The last method used to date reservoir 
sequences was phylogenetic placement (325, 326). In this method, approximately-maximum-
likelihood trees containing pre-ART sequences only were analyzed and the position where 
reservoir sequences were most likely to be found was identified.  Patristic distance and clade 
support estimates with tree support values < 0.4 were excluded from subsequent analyses. Final 
dating estimates for reservoir sequence entry were determined using the weighted median of the 







Table 4.1. Clinical data for the ten women from the CAPRISA-002 cohort. 
The number of pre-ART time points refers to the number of time points at which HIV-1 RNA 
was sequenced by Illumina MiSeq with Primer ID. CD4 count on ART reflects the participant’s 
CD4 count nearest to the time point at which blood was collected for reservoir analyses (after an 

































CAP336 2.7 5 6 74 424 EFV/3TC/TDF 
 
CAP288 4.0 5.3 7 318 692 EFV/FTC/TDF 
 
CAP302 3.2 5.2 7 307 622 EFV/3TC/AZT 
EFV/FTC/TDF 
 
CAP316 4.1 4.1 9 436 888 3TC/AZT/LPV/r 
EFV/FTC/TDF 
 
CAP333 3.7 5.0 7 218 524 EFV/3TC/TDF 
EFV/FTC/TDF 
 
CAP222 6.1 5.6 10 305 803 EFV/FTC/TDF 
 
CAP244 7.3 5.2 14 318 666 EFV/3TC/TDF 
 
CAP277 5.0 5.1 11 322 926 EFV/3TC/TDF 
 
CAP380 2.6 5.1 6 407 959 EFV/FTC/TDF 
 












% Clonal Half 
Genomes  
No. of Half 
Genomes used 
for Dating 
CAP257 515 16 0 8 
CAP336 203 14 29 7 
CAP288 44 20 20 12 
CAP302 114 16 13 10 
CAP316 322 16 31 9 
CAP333 106 6 0 5 
CAP222 49 11 0 11 
CAP244 432 12 0 8 
CAP277 154 17 29 8 
CAP380 65 8 25 4 
Average 200 14 15 8 
 
Table 4.2. Overview of HIV-1 DNA reservoir sequences analyzed. 
The number of HIV-1 copies per million total cells was determined via droplet digital PCR 
(ddPCR) using primers/probes corresponding to HIV-1 LTR/gag and RRP30 primers and probes 
to quantify the number of total cells in the sample. Half genomes were used for phylogenetic 
dating if all four regions of interest (env c1c2, c2c3, c4c5 and nef) were not hypermutated, as 
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CAP316  10 1  8 1 1 
CAP336  10 1  7 0 1 
CAP288  7 0  9 3 0.26 
CAP302  1 5  4 6 0.59 
 
Table 4.3. The proportion of QVOA and DNA-derived sequences that date to the year prior 
to ART is not statistically different. 
Late refers to reservoir viruses that date to the year before ART was initiated. Not-late refers to 
reservoir viruses that date to any time point other than the year prior to ART initiation. A 









Figure 4.1. Participant viral loads and sampling strategy. 
HIV-1 viral loads before and after ART initiation are shown for each of the ten CAPRISA 
participants analyzed. The dashed line indicates the limit of detection for the viral load assay. 
Colored arrows above the graph indicate time points at which HIV-1 RNA was sequenced before 
ART initiation. After an average of 5.2 years on ART, HIV-1 DNA and QVOA-derived virus 








Figure 4.2. The majority of 3’ HIV-1 DNA half genomes are defective. 
A) Pie charts depicting the fraction of each participants half genomes that contained deletions, 
hypermutations, deletions and hypermutations, or were devoid of defects (inferred intact). The 
percent shown in the center of the graphs represents the percent of intact sequences. The number 
of unique half genome sequences analyzed for each participant is shown below the graphs. B) 
Data from Bruner et al., Nature Medicine, 2016 were used to generate a breakdown of the 
various defects observed in the 3’half of the genome. The percent in the center of the graph 






Figure 4.3. Regional hypermutation “hotspots” are present, and hypermutation is often 
linked across a genome. 
A) The fraction of half genomes with a G-to-A mutation at the indicated position is shown for 9 
of the 10 participants (CAP380 is not included). The relative positions of the genes of interest are 
shown below. B) Half genome sequences were partitioned into vif, Env gp120, Env gp41, and 
nef coding regions using the Los Alamos National Laboratories Gene Cutter Tool. The percent of 
genomes in each region that are hypermutated is shown. ND = not done. C) All unique genomes 
obtained for each of the 10 participants are shown on separate lines. Shaded regions indicate 
hypermutation was present in the indicated region. The majority of genomes that are 
hypermutated are hypermutated in >1 region, with vif and gp120 being the regions most likely to 
be hypermutated.  
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Figure 4.4. No correlation between the size of the HIV-1 DNA reservoir and other estimates 
of reservoir size. 
A) The number of HIV-1 DNA copies per million cells was estimated based on ddPCR data. 
There is no correlation between the number of HIV-1 DNA copies per million cells and the 
amount of time a participant was HIV+ but antiretroviral therapy naïve. B) No correlation 
between the size of the DNA reservoir and the number of years an individual had been on 
antiretroviral therapy. C) Infectious units per million CD4+ T cells (IUPM) was estimated by 
determining the number of p24+ cells in a quantitative viral outgrowth assay after treatment with 
latency reversing agents.   
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Figure 4.5. Representative phylogenetic trees used to infer when reservoir sequences 
entered the long-lived reservoir. 
Pre-ART RNA sequences are shown in colors ranging from red (the first year of infection) to 
blue (the year prior to ART initiation), which correspond to the time relative to the start of ART 
at which the sample was obtained. QVOA-derived reservoir sequences are shown in pink; DNA-
derived reservoir sequences are shown in black. Pre-ART sequences from each time point form 
distinct clusters, allowing for the dating of reservoir sequences. In the trees shown, the majority 
of both the QVOA and DNA-derived reservoir sequences cluster with pre-ART sequences that 







Figure 4.6. The long-lived replication competent and DNA reservoirs are seeded at similar 
times. 
Pie charts depicting the breakdown of each participant’s QVOA and DNA-derived reservoirs in 
terms of when the sequences were seeded into the long-lived reservoir. The number of sequences 
analyzed is shown beneath each graph. The percent of reservoir sequences that were seeded in 
the year prior to ART initiation is shown in the center of each graph. A Fisher’s exact test was 
used to determine whether the percent of QVOA-derived sequences that were seeded in the year 
prior to ART initiation was different than the percent of DNA-derived sequences seeded in the 







Figure 4.7. Sampling depth does not significantly alter the proportion of reservoir 
sequences dating to the year prior to ART. 
A-C) Pie charts depicting when HIV-1 DNA reservoir sequences were seeded. Increasing the 
sampling depth by approximately three-fold in each case did not significantly alter the percent of 
sequences that were seeded in the year prior to ART initiation (Fisher’s exact test).   
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Figure 4.8. The majority of the long-lived HIV-1 DNA reservoir is seeded in the year prior 
to ART initiation. 
Pie charts depict when each DNA reservoir sequence entered the long-lived reservoir. The 
percent of sequences dating to the year prior to ART initiation is shown in the center of each 
graph. Across all participants, an average of 54 % of DNA reservoir sequences date to the year 
prior to ART initiation.  
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CHAPTER V. CONCLUSIONS AND FUTURE DIRECTIONS
 
In this dissertation, I have leveraged HIV-1 genetic diversity as a tool to explore 
fundamental questions about HIV-1 biology. Key concepts that are important to the design and 
implementation of an HIV-1 cure, such as compartmentalization and the mechanisms underlying 
formation of the latent reservoir, have been explored. In Chapters Two and Three, I examined 
HIV-1 compartmentalization in the male genital tract and central nervous system, respectively, 
using highly sensitive techniques such as deep sequencing with Primer ID and single genome 
amplification followed by phylogenetic and statistical analyses. In Chapter Four, I analyzed the 
composition and formation of the long-lived HIV-1 DNA reservoir through the use of next 
generation sequencing. These studies advance our understanding of two key biological processes 
that underlie HIV-1 persistence.  
In Chapter Two, I examined the hypothesis that inflammation due to STI-associated 
urethritis influences the establishment and maintenance of compartmentalized populations in the 
male genital tract. The results demonstrated that compartmentalized populations were detected at 
similar frequencies in men with and without urethritis. This study furthers the field by examining 
the impact of STI-associated inflammation on not only the establishment of compartmentalized 
lineages, but also the persistence of such lineages as the relationship between blood- and semen-
derived HIV-1 populations was examined both before and after antibiotic treatment of the STI. 
By examining seminal plasma-derived cytokine concentrations before and after antibiotic 
treatment of the STI, I showed that inflammation within the male genital tract was reduced 
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following antibiotic treatment. Importantly, the presence and subsequent reduction of 
inflammation did not alter the relationship between blood- and semen-derived viral populations. 
Overall, these results suggest that local inflammation does not influence the establishment or 
maintenance of compartmentalized lineages in discrete anatomical compartments.  
Ultimately, the factors that promote independent viral replication within the male genital 
tract remain unresolved. In order to continue to shed light on this, it will be important to 
determine the origins of HIV-1 shed in semen, and furthermore, to dissect the roles of both cell-
free and cell-associated HIV-1 in transmission events. A recent study a using a non-human 
primate model of SIV infection attempted to identify the tissue source of compartmentalized SIV 
shed in semen (93). The authors noted that the similarity between semen-derived and tissue-
derived SIV varied, and that in most cases, there was no single genital tissue that 
overwhelmingly contributed to SIV found in the semen. Beyond phylogenetic analyses, 
examining the entry phenotype of viruses derived from the male genital tract can give clues 
about the environment in which the virus has been replicating. In Chapter Two, I showed that 
none of the compartmentalized, semen-derived HIV-1 envelope proteins were able to efficiently 
mediate entry into cells expressing low densities of CD4. This suggests that these viruses have 
been replicating in T cells, which have high densities of CD4 on the surface, rather than 
macrophages, which have low densities of CD4. Previously, we described the identification of a 
macrophage-tropic, semen-derived HIV-1 variant (70). The ability to use low densities of CD4 
for viral entry requires viral replication in the face of selective pressure. This is most often 
observed in regions where CD4+ T cells are limiting, such as the central nervous system. In the 
absence of inflammation, both CD4+ T cells and macrophages are frequently observed in the 
genital tract, however macrophages are the predominant immune cell found in the urethra and 
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testes (327). Given this, it is conceivable that HIV-1 might become sequestered within those 
tissues thereby introducing the selective pressure necessary to drive the evolution of 
macrophage-tropism. Recent work has described the presence of HIV-infected urethral 
macrophages in individuals on suppressive ART (71). Interestingly, while infected macrophages 
are readily observed in this study, the authors note an apparent lack of infected T cells. This 
observation is notable for several reasons. First, our understanding of the evolution towards a 
low-CD4-using phenotype suggests that these viruses can infect both T cells and macrophages. 
In other words, the ability to infect CD4+ T cells is not lost when a virus gains the ability to 
infect macrophages. That the authors here noted a complete absence of infected CD4+ T cells 
appears contradictory to this notion. Secondly, macrophage-tropic variants are rarely observed in 
the semen. It could be that such variants are produced in areas of the male genital tract that do 
not directly contribute to the semen, or that they are present at such low frequency that they are 
below the limit of detection. Whether they are present in semen or not, it seems macrophage-
tropic variants are unlikely to play a role in transmission as transmitted/founder variants almost 
exclusively require high densities of CD4 for cell entry (299, 328, 329).  
In much the same way that HIV-1 in semen is often used to make inferences about virus 
replication in the genital tract, HIV-1 in the cerebrospinal fluid has been used to monitor the 
presence of virus in the central nervous system. While there are many distinct advantages to 
using CSF-derived virus, including the ability to obtain multiple samples over time, an important 
caveat is our limited understanding of the origins of HIV-1 in the CSF. As such, it is important to 
evaluate the relationship between CSF- and brain-derived virus so that we can gain a better 
understanding of the degree to which virus present in the CSF reflects replication within the 
brain. HIV-1 isolated from CSF can have origins in either the periphery or the brain. For 
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example, and infected T cell may enter the CSF through the choroid plexus, thereby introducing 
the virus to this compartment. In other circumstances, infected cells residing within the brain can 
produce virus which drains into the CSF and is subsequently observed there. While each origin is 
the result of separate biological phenomena, the resulting inflammation and neuronal damage is 
often the same. As discussed above, the cellular composition of the brain is distinct from that of 
the CSF and the periphery. Under homeostatic conditions, T cells are not present in substantial 
numbers within the brain, however, macrophages and microglia are abundant and permissive to 
HIV-1 infection, though viral evolution is required in order for these cells to be efficiently 
infected. Given this, examination of the ability of CSF-derived HIV-1 Env proteins to mediate 
entry into cells with low densities of CD4 can shed light on the origin of HIV-1 in the CSF. 
However, a more direct approach requires examining the genetic similarity between CSF- and 
brain-derived HIV-1.  
In Chapter Three, I examined full-length HIV-1 env sequences obtained from the blood, 
cerebrospinal fluid, and brain regions of five individuals with untreated HIV-1 infection. Two of 
the five individuals had equilibrated viral populations in the blood and CSF, suggesting that the 
virus present in the CSF had recently been imported from the blood and has its origins in the 
periphery, rather than the brain. The remaining three individuals had diverse, compartmentalized 
CSF-derived viral populations, reflective of prolonged, independent replication within the CNS. 
When brain-derived sequences were compared to CSF- and blood-derived sequences, multiple 
patterns emerged that could be categorized based on the previously established relationship 
between blood and CSF populations for each individual. For those with equilibrated blood/CSF 
populations, brain-derived sequences were also well-mixed and did not constitute a separate 
lineage. This result suggests that when blood and CSF populations are equilibrated, the amount 
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of viral replication occurring within the brain is either non-existent or below the limit of 
detection. If these results are confirmed with follow-up studies examining a larger group of 
individuals, it would be an important indicator of the value of CSF-derived insights into viral 
replication in the central nervous system, specifically as it relates to the frequency of occult 
infections of the brain that are not sampled by the CSF.  
The relationship between brain- and CSF-derived populations when viral populations in 
the CSF are compartmentalized relative to the blood is more complicated. For two of the three 
CSF-compartmentalized individuals, I examined HIV-1 sequences derived from multiple regions 
of the brain. In both participants, brain-derived sequences clustered together in a region-specific 
manner and were separate from CSF-derived sequences. Other groups have reported regional 
differences in HIV-1 diversity within the brain (139, 141) however, to my knowledge, this is the 
first study to examine brain, blood, and CSF-derived sequences from the same participants 
without extensive culturing prior to sequencing. Importantly, while CSF- and brain-derived 
sequences clustered independently in these individuals, the genetic distance between the 
sequences was relatively small. Thus, while CSF-derived HIV-1 may not entirely recapitulate the 
full diversity of HIV-1 in the brain, it does reflect the major populations present and as such, is a 
useful indicator of viral replication in the brain. Further strengthening the argument that insights 
gleaned from studies of CSF-derived virus reflect the presence/absence of viral replication in the 
brain is my observation that the entry phenotype of CSF- and brain-derived viruses match. For 
individuals with equilibrated blood and CSF populations, the most likely source of CSF-derived 
virus comes from infected CD4+ T cells that have trafficked in from the periphery. In support of 
this notion is the observation that equilibrated CSF populations almost exclusively require high 
densities of CD4 in order to enter a cell, suggesting replication in T cells, rather than 
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macrophages (131). In contrast, compartmentalized viral populations in the CSF can often enter 
cells expressing low densities of CD4, suggesting adaptation to replication in cells such as 
macrophages and microglia (131). I found that the entry phenotype of brain-derived sequences 
matched that of CSF-derived sequences in all individuals. Those that had equilibrated blood and 
CSF populations had CNS-derived virus (obtained from both the CSF and brain) that required 
high densities of CD4 for entry. In contrast, individuals with compartmentalized CSF 
populations had CNS-derived virus (brain and CSF) that was able to efficiently enter cells 
expressing low densities of CD4. These results suggest that compartmentalized CSF populations 
are the result of infected macrophages/microglia within the brain producing virus that is sampled 
by the CSF.  
The latter part of my dissertation focused on a second biological process critical to HIV-1 
persistence – the establishment of the latent reservoir. In Chapter Four, I phylogenetically dated 
the timing of the formation of the long-lived HIV-1 DNA reservoir in ten women on long-term, 
suppressive antiretroviral therapy. By comparing reservoir DNA sequences to pre-ART RNA 
sequences, I was able to use viral evolution to determine when the long-lived DNA reservoir was 
seeded. This work extends previous work by our lab (221) and others (222, 223) in that it 
compares the formation of the HIV-1 DNA reservoir to the replication-competent reservoir in the 
same set of participants. In doing so, I have been able to show that both the mostly defective 
DNA reservoir and the replication-competent reservoir are largely comprised of viral variants 
circulating in the year before ART initiation, pointing to a common mechanism of seeding. This 
observation also suggests that the primary mechanism of reservoir formation is cell-driven, 
rather than virus-driven. One of the most likely explanations for the apparent skewing of the 
reservoir towards variants circulating just before ART is the idea that the initiation of 
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antiretroviral therapy triggers physiological changes which drive the transition of a large number 
of T cells to a long-lived, memory phenotype. If these results are supported by larger studies, 
particularly those that include individuals treated during acute infection, it would provide a 
rationale for the development of strategies aimed at blocking the formation of a large pool of 
memory CD4+ T cells when ART is initiated, thereby reducing the size of the reservoir and 
ultimately lowering the barrier to a cure.  
While these results suggest that the formation of the long-lived reservoir is skewed to the 
year before ART initiation, we do observe reservoir sequences that date throughout untreated 
infection. The recovery of reservoir sequences that date to primary infection suggests that the 
reservoir can and does form throughout untreated infection, although this mechanism of 
formation appears to account for a smaller portion of the reservoir than has previously been 
appreciated. Notably, two participants discussed in Chapter Four (CAP244 and CAP222) have 
reservoirs that contain sequences spanning the entire history of untreated infection while others 
(CAP336, CAP316 and CAP288) only contain sequences dating to the one or two years 
preceding ART. Therefore, while a common theme has emerged across the cohort, it is also clear 
that there are individual patterns of reservoir formation. In the future, it will be important to 
dissect these differences in order to better understand and prevent reservoir formation.  
The work presented in this dissertation illuminates several avenues of future research. 
The degree to which one can use genetic diversity as a tool to explore various questions about 
HIV-1 biology, and the insights that can be gained from such work, is predicated on currently 
available sequencing technologies. For example, as next generation sequencing platforms have 
become more widely available, new insights have been gained from the re-examination of 
questions previously addressed using methods such as the heteroduplex tracking assay. In a 
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similar manner, I can envision ways in which future technological advances will enable a closer 
examination of the biological phenomena I have discussed.  
One of the unanswered questions most relevant to the prevention of HIV-1 transmission 
is the issue of HIV-1 shedding during suppressive antiretroviral therapy. Discordant detection of 
HIV-1 in the semen when viral load is undetectable in the blood poses challenges to the 
prevention of transmission. Several important questions need to be addressed in order to 
understand the role intermittent viral shedding has on transmission potential. First, identifying 
the source of HIV-1 RNA shed in semen will inform strategies to prevent it. By comparing HIV-
1 RNA sequences in the semen to viral DNA sequences from PBMCs and non-sperm cells, we 
could determine whether the virus observed in the semen is being produced locally in the male 
genital tract, or imported from the blood. Multiple groups have observed an increase in viral 
shedding during inflammatory events, such as reactivation of other latent viral infections or de 
novo infection by a bacterial STI (81, 82, 108) suggesting a local source of shed virus produced 
by tissue-resident immune cells re-activated by viral or bacterial antigens. The second major 
unanswered question is whether viral RNA detected in semen is infectious. To answer this 
question, a combination of techniques interrogating both the RNA and the DNA in non-sperm 
cells will be informative. Novel assays such as the intact proviral DNA assay (IPDA) (317) can 
readily quantify the amount of intact HIV-1 DNA present in a sample without prolonged 
culturing as required by standard methods of studying the reservoir such as the quantitative viral 
outgrowth assay. It is possible that the genetic material detected in the semen of men on 
suppressive ART is not replication-competent. By using semen-derived viral RNA as a source of 
virus with which to expose animal models of HIV-1 infection, such as humanized mice, we 
could define the upper bounds of the potential for shed virus to initiate infection. However, given 
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that is impossible to completely prove that HIV-1 shed during ART is not infectious, the results 
of these future studies, and the practices and policies they inform, will have to be carefully 
considered.  
The work describing the origins of HIV-1 in the cerebrospinal fluid raises several points 
of future investigation. First, the exact type of brain-derived cell that is infected remains 
unknown. The data presented in this dissertation supports the idea that independent viral 
replication in the CNS occurs primarily in cells with low densities of CD4, such as macrophages. 
However, both perivascular macrophages and microglia are present in the brain. In order to more 
precisely determine the type(s) of infected cells within the brain, microscopy techniques such as 
DNAscope in situ hybridization could determine what cell surface proteins are expressed on cells 
containing HIV-1 DNA (330). This work would be aided by a novel microglia-specific cell 
marker that has recently been reported, transmembrane protein 119 (TMEM119) (331). 
Historically, microglia have been difficult to differentiate from macrophages due to the fact that 
they both express receptors such as CD45 and CD11b, albeit in differing ratios (332). A 
complementary approach to examining the cell-type specificity of HIV-1 infected cells in the 
brain would be to perform fluorescence activated cell sorting on cells isolated from brain tissue. 
Cell subsets, including CD4+ T cells, macrophages, microglia and astrocytes could then be 
interrogated for the presence of HIV-1 DNA through techniques such as ddPCR. In this manner, 
proviral DNA concentrations could be quantified and compared between cell subsets. 
Additionally, with techniques such as the IPDA discussed above, the relative intactness of 
proviral DNA observed in each subset could be examined. Identifying the cell types in the brain 
most often infected with HIV-1 is an important step in the design of therapeutics aimed at 
reducing or eliminating them.  
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To further characterize the source of HIV-1 observed in the cerebrospinal fluid, 
comparisons could be made between CSF cell pellet-derived HIV-1 DNA and CSF supernatant-
derived HIV-1 RNA. If compartmentalized viral populations in the CSF are primarily the result 
of infected cells in the brain producing virions which are sampled by the CSF, I would 
hypothesize that the sequence of the CSF-derived viral RNA would more closely resemble brain-
derived viral DNA, rather than viral DNA derived from CSF cell pellets. For equilibrated blood 
and CSF viral populations, our results suggest that the primary source of HIV-1 RNA in the CSF 
are infected CD4+ T cells that have migrated from the periphery into the CSF. If this is correct, 
there would be a high degree of genetic similarity between viral RNA derived from the CSF 
supernatant and viral DNA derived from CSF cell pellets. Such a result would strengthen the 
conclusion that equilibrated viral populations in the CSF are derived from infected CD4+ T cells 
that originate in the periphery.  
So far, we have only examined the origins of HIV-1 in the CSF of individuals with 
chronic, untreated HIV-1. The phenomenon of CSF escape (detectable HIV-1 RNA in the CSF 
despite low or undetectable plasma RNA in the presence of ART) suggests that the CNS is a 
potential viral reservoir. Indeed, a recent study demonstrated the presence of HIV-1 DNA and 
RNA in brain tissues of ART-treated individuals (333). Given this, it will be important for future 
studies to examine the extent to which the brain harbors genetically distinct populations in the 
presence of suppressive antiretroviral therapy. Due to the complexity of the question, and the 
numerous factors that must be controlled in order for interpretable data to be obtained (route of 
exposure, magnitude of viral inoculum, timing of ART initiation, ART adherence), such studies 
would probably be best suited for animal models of HIV/SIV infection such as humanized mice 
or non-human primates. These studies would help identify potential mechanisms driving the 
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phenomenon of CSF escape. It is possible that a number of mechanisms contribute to the 
phenomenon, such as latently infected T cells migrating into the CSF in response to an antigen 
and subsequently producing virions due to TCR-mediated activation. Alternatively, latently 
infected cells in the brain could reactivate. Ultimately, elucidating the potential mechanisms 
responsible for on-ART CSF viremia will inform strategies to combat the phenomenon.  
Finally, there are still a number of unknowns surrounding the mechanisms of reservoir 
formation. Thus far, the work we have done to understand the establishment of the long-lived 
reservoir has been in the context of a single on-ART time point. There is evidence to suggest that 
the stability of the reservoir varies. A faster rate of decay is observed in the initial years of ART 
treatment, after which point the decay rate slows. Additionally, it has been suggested that the 
decay rates of intact and defective genomes differ (312). While our analysis of a single on-ART 
time point would seem to suggest that the decay rates of the intact and defective reservoirs are 
similar after five years on therapy, it is important to evaluate this question in the context of 
multiple on-ART time points. Specifically, differences in reservoir decay rates may be observed 
in the initial one to two years following ART initiation that were not appreciated with the 
analysis of a time point taken after five years of therapy. It has been suggested that the increasing 
stability of the reservoir observed after 5-7 years of therapy might be due to the initial decay of 
latently infected cells with intrinsically shorter half-lives, followed by a much slower decay of 
cells with longer half-lives (312). Our analysis of the total HIV-1 DNA reservoir examined the 
reservoir in total PBMCs, rather than specific T cell subsets. In the future, dating the formation 
of the reservoirs within each T cell subset could shed light on this matter.  
Given the fact that the majority of HIV-infected cells reside in tissues, it is also important 
that future work specifically examine tissue-based reservoirs. I would hypothesize, based on data 
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demonstrating well-mixed tissue and blood-derived viral populations (106), that we would 
observe the same skewing of reservoir formation in tissues as we observed in the blood. Using 
the ddPCR-based single genome amplification strategy described in this dissertation, we have the 
methodology in place to readily address this question.  
Another line of inquiry stemming from this work concerns the portion of the reservoir 
that dates to primary infection. While our results of both the replication-competent and the total 
HIV-1 DNA reservoir suggest that the majority of the long-lived reservoir is formed near the 
time of ART initiation, we observed reservoir sequences dating to earlier pre-ART time points in 
multiple participants (CAP244, CAP302 and CAP222). This result implies that at some 
frequency, sequences are being archived into the reservoir throughout untreated infection. There 
are multiple mechanisms by which this might occur. In a similar manner in which the loss of 
HIV-1 antigen after ART initiation may drive the formation of a large portion of the reservoir, 
early variants may be seeded by clearance of other antigens such as influenza, for example. In 
this scenario, HIV-infected, flu-specific cells might transition to a memory phenotype at a low 
frequency. Given the dysregulated IL-7/IL-7 receptor signaling that is observed in individuals 
with untreated HIV-1 infection, the transition from effector to memory T cell is often impaired 
(334). As such, the number of HIV-infected cells that enter the reservoir during untreated 
infection may be smaller, thereby explaining the reduced frequency with which we observed 
reservoir sequences that date to primary infection (322). In order to examine this question, future 
experiments could perform deep sampling of the long-lived HIV-1 DNA reservoir. In this 
manner, minor variants will be sampled at a greater frequency allowing us to determine whether 
the early-forming reservoir forms episodically or continuously. Episodic formation of the early-
forming reservoir could suggest antigen-driven reservoir formation, as discussed above. On the 
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other hand, continuous formation of the early reservoir could indicate low-frequency, stochastic 
entrance into the reservoir.  
The incredible diversity of HIV-1 presents challenges to vaccine and cure research. 
However, it is this same diversity which has enabled much of our understanding of fundamental 
facets of HIV-1 biology, as I have described in this dissertation. While current methodologies are 
sufficient to pursue many of the future direction discussed above, technical challenges remain. 
For example, identifying the rare, HIV-infected cells in the blood or tissues of individuals on 
ART remains difficult. Novel strategies to enrich for HIV-infected cells in the presence of large 
quantities of genomic DNA will aid future endeavors. With increasing technological advances, 
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